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1. Introduction and literature background 
 
1.1. Significance and appearance of systemic inflammation 
Systemic inflammation is a generalized pathological process, which can be clinically 
manifested in various forms, including sickness syndrome, systemic inflammatory response 
syndrome (SIRS), sepsis, severe sepsis, septic shock, and multiple organ dysfunction syndrome 
[1]. The inflammatory response is a series of complex pathophysiological events that can result 
from infections, as well as from non-infectious causes, such as trauma, burns, and pancreatitis 
[2]. 
The exact definitions and clinical criteria of sepsis and related diseases have changed 
over the past three decades [3-5]. In 1991, a Consensus Conference was held with the goal of 
agreeing on definitions for the abovementioned terms. Such standardization of terminology was 
necessary to eliminate confusion in communication for clinicians and basic researchers 
concerning the phenomena related to systemic inflammation. For example, the term sepsis was 
generally used as a clinical response arising from infection. However, similar, or even identical, 
clinical responses can also arise in the absence of infection. As result of the consensus in 1991, 
the phrase SIRS was proposed to describe this inflammatory process, independent of its cause. 
In cases, when SIRS results from a confirmed (or suspected) infectious process, it is termed 
sepsis, since then it represents the systemic inflammatory response to the infection. Definition 
of SIRS includes two or more of the following conditions: (1) body temperature (Tb) > 38°C or 
< 36°C; (2) heart rate > 90 beats per minute; (3) respiratory rate > 20 breaths per minute or 
PaCO2 < 32 mm Hg; and (4) white blood cell count > 12000/mm3, < 4000/mm3, or > 10% 
immature bands [3]. In 2001, the definitions and criteria were revised, while the list of signs 
and symptoms of sepsis was expanded to better reflect the clinical response to infection, no new 
definitions for sepsis were introduced [4]. In line with the actuality of the topic, in 2015, some 
concepts have been changed. For instance, sepsis was defined as life-threatening organ 
dysfunction caused by an improperly regulated host response to infection. Septic shock was 
determined as a subset of sepsis in which particularly profound circulatory, cellular, and 
metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. 
Also, SIRS and severe sepsis were eliminated from the terms related to septic diseases [5]. 
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According to a recent study, sepsis constitutes a global burden for health care, with an 
estimated 48.9 million incident cases and 11 million sepsis-related deaths worldwide in a year 
[6], moreover, it has an incidence rate of ~30% in patients admitted to the intensive care unit 
[7]. It is important to mention, that sepsis can lead to death not only acutely, but it also increases 
the risk of death for five to eight years after the septic event [8, 9]. In the United States, the 
incidence of hospitalizations with sepsis increased by ~50% between 2003 and 2009 [10], with 
estimated annual costs exceeding $17 billion nationally due in part to the extended 
hospitalization of septic patients [11]. However, a more recent study describes, that the 
incidence of sepsis and sepsis-related mortality has remained stable in the United States 
between 2009-2014 [12]. 
 
1.2. Alterations of Tb in systemic inflammation 
As a systemic inflammation response, sepsis is often accompanied by changes of deep 
Tb, which can be manifested as either fever or hypothermia in experimental animals, as well as 
in human patients [1]. 
The importance of alterations in Tb in inflammation was recognized a long time ago. 
Elevation of Tb is also reflected in the word ‘inflammation’ itself, as it originates from the Latin 
inflammare (to set on fire). The presence of fever was already noted in the time of Hippocrates 
in disease states [13]. Heat (calor) is also one of the four cardinal signs of inflammation, along 
with redness, swelling, and pain, which were originally described by Celsus in the 1st century 
A.D. [14]. As an answer of the host’s defense reactions to danger, the inflammatory response 
is usually accompanied by changes in vital functions in fever, including increased activity of 
white blood cells, heart rate, and respiratory rate. Fever helps inhibiting growth of many 
microorganisms, at the same time achiness, fatigue and sleepiness conserve energy that is 
needed to fight the infection and elevate Tb; moreover, loss of appetite minimizes blood glucose, 
which is a preferred fuel for many microorganisms [15]. However, in severe forms of sepsis the 
maintenance of fever is challenging for the host, therefore, the conservation of energy resources 
by reduced metabolism and hypothermia is the preferred response. 
Based mainly on experimental data from animal studies it was proposed that fever and 
hypothermia can both develop as two definite adaptive mechanisms in sickness syndrome. 
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Fever typically occurs at the onset of an infection, representing an active fight against the 
pathogen, while hypothermia is usually associated with progressed stage or severity of the 
disease and it aims to secure the vital systems of the host [16, 17]. On the one hand, the two 
adaptive strategies can develop consecutively (e.g., early phase fever followed by late phase 
hypothermia) as the severity of the disease progresses; on the other hand, hypothermia can be 
also one of the earliest developing events in animal models of endotoxin shock [18]. Moreover, 
septic patients admitted to intensive care unit develop hypothermia more frequently in the early 
than in the late stages of their stay [19]. Therapeutic (i.e., induced) hypothermia has been also 
shown to improve the outcome of sepsis both in human and animal studies [20, 21], however a 
positive association was found between mortality rate and spontaneously occurring 
hypothermia in several studies reporting that the mortality rate of hypothermic patients with 
sepsis is twice as high as that of febrile septic patients [22-24]. A recent meta-analysis on this 
topic also supported these findings, showing that fever predicts lower, while hypothermia 
higher mortality rates compared with normal Tb, based on data from over 10,000 septic patients 
[25]. It has to be noted that the prognostic value of hypothermia in sepsis does not automatically 
mean a negative effect of Tb itself. Instead, the association between hypothermia and mortality 
can simply reflect the higher prevalence of hypothermia in severe cases of sepsis [26]. 
In accordance with the frequent thermoregulatory disorders that accompany systemic 
inflammation, many clinical scoring systems include the change of Tb. Among them, SIRS 
criteria are used for diagnosis [3, 4], while other scores are calculated to assess the prognosis 
of the critically ill patients, such as the Simplified Acute Physiology Score [27], the Acute 
Physiology and Chronic Health Evaluation [28], and the Predisposition, Insult, Response, 
Organ Dysfunction system [29]. A common disadvantage of these scoring systems is that 
reduced and elevated Tbs are considered to be equal levels of concern [30], which contradicts 
the current view in the field that fever is associated with lower, and hypothermia with higher 
severity of a disease [16, 17]. 
Despite the different pathological background of fever and hypothermia in systemic 
inflammation, both the increase and the decrease of Tb are evaluated as significant signs in the 
clinical practice. Thus, because of its frequent occurrence and high mortality rates, as of today, 
systemic inflammation represents a highly important field in basic research as well as in clinical 
practice. 
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1.3. Neurohumoral factors in the pathophysiology of systemic inflammation 
When the inflammation is triggered by an infectious insult, the inflammatory cascade is 
often initiated by an endotoxin, and then several signals activate the immune response. The 
most important mediators of systemic inflammation have been reviewed in details recently [1, 
31]. 
As a summary, many immune system cells hold receptors for common macromolecules 
present on invading organisms. For instance, CD14, a human protein expressed mainly by 
macrophages as part of the immune system, detects and binds lipopolysaccharide [(LPS), the 
major component of the outer membrane of Gram-negative bacteria] and activates Toll-like 
receptor 4, which triggers an intracellular multi-step process activating immune responses [32]. 
In this immune response cytokines are released, including tumor necrosis factor (TNF)-α [33], 
interleukin (IL)-1β, IL-6, and other mediators, cumulatively referred to as the “inflammatory 
soup” [34-36] and either attract other immune cells to the site of the inflammation, or act on 
other peripheral tissues to release further chemical mediators of inflammation. 
Among these mediators are the prostaglandins (PGs), which have a crucial role in 
mediating many aspects of systemic inflammation. PGs are derivatives of arachidonic acid, 
which is converted to PGH2 by cyclooxygenase (COX) enzyme, which has two isoforms, COX-
1 and COX-2. Various additional enzymes convert PGH2 to end-products: other PGs (PGE2 and 
PGD2), prostacyclins or leukotrienes. PGE2 acts on four different EP receptors, which are 
expressed in different parts of the central nervous system (CNS) [15, 37]. 
In studies conducted on rodents, it has been shown that in response to low-dose of LPS 
fever develops mainly through the activation of COX-2 [38] and that PGE2 acts through EP3 
receptors as the major mechanism in the development of the febrile response [39]. In contrast 
with fever, when a high dose of LPS is injected to rats hypothermia develops, which is triggered 
mainly by the activation of the COX-1 enzyme [38]. Receptorial and intracellular signaling 
cascades activated by the endogenous mediators are complex and involve lipid, peptide, 
gaseous, and other - as of today unidentified - messengers [40]. 
As common and prominent biochemical part of the inflammatory response, reactive 
oxygen species (ROS) are also produced. While production of ROS by different cells and 
tissues challenged with bacterial pyrogens is well documented [41], a little is known about 
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causal roles of ROS in regulating Tb responses during inflammation and infection, mainly due 
to the lack of effective tools for such investigations. Bilirubin, as a lipophilic molecule is 
generally considered as potentially toxic waste that needs to be excreted. However, some 
studies highlighted bilirubin as a powerful antioxidant that efficiently scavengers lipoperoxid 
radicals generated in either artificial or cellular membranes, and emphasizes its cytoprotective 
role [42, 43]. Hence, bilirubin might be used as a selective tool to inactivate water insoluble, 
lipid-generated ROS. 
In addition to ROS, studies have brought attention to the role that the transient receptor 
potential vanilloid-1 (TRPV1) channel expressed on sensory neural fibers may play a role in 
different inflammatory processes (Fig. 1) [44-46]. 
 
 
Figure 1. The three distinct effects of the activation of capsaicin-sensitive sensory nerve endings. CGRP, calcitonin gene-
regulating polypeptide; GAL, galanin; PACAP, pituitary adenylate cyclase-activating polypeptide; SP, substance P; SST, 
somatostatin; TRPV1, transient receptor potential vanilloid-1; VIP, vasoactive intestinal polypeptide [44]. 
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TRPV1 is activated by diverse stimuli, including several ingredients of the 
inflammatory soup [47]. Studies using either knockout (KO) (Trpv1-/-) mice, a pharmacological 
blockade with capsazepine (TRPV1 antagonist) or desensitization with resiniferatoxin (TRPV1 
agonist) have shown that TRPV1 plays an anti-inflammatory role in LPS-induced SIRS by, 
among other mechanisms, limiting the production of TNF-α, possibly via sensory nerves [48, 
49]. However, most studies were conducted in young rodents. Because SIRS is considered a 
disease of the aged due to its markedly higher incidence in the older population, it is also 
important to clarify whether TRPV1 channels play a similarly prominent anti-inflammatory 
role in young and older populations. 
Performing experiments to elucidate the role of TRPV1 in systemic inflammation also 
implies the use of genetically modified (Trpv1-/-) mice, but according to the literature, studies 
in genetically modified animals have failed to reveal a clear thermoregulatory phenotype in 
those mice [47]. Therefore, it is essential to first clarify the thermoregulatory phenotype of the 
Trpv1-/- mice under normal conditions and so we could determine whether these mice are 
suitable for the study of the role of TRPV1 in systemic inflammation. 
The activation of TRPV1 channels on neural endings (i.e., on capsaicin-sensitive 
afferent nerve fibers) also results in the release of an excess of inflammatory substances such 
as pituitary adenylate cyclase-activating polypeptide (PACAP)38, calcitonin gene-related 
peptide, and substance P (SP) (Fig. 1). 
PACAP38 deserves special attention, because the complex role of this, relatively newly 
discovered, peptide has been well established in various inflammatory processes [50-52]. 
Moreover, the peptide and its receptors are broadly expressed in main thermoregulatory areas 
of the brain, including the preoptic area (POA) of the hypothalamus [53-56], which is an 
important site in the development of the fever response. In physiological studies, injection of 
PACAP38 into the CNS caused an increase of Tb in rodents, which was brought about by 
elevation of non-shivering thermogenesis and increased locomotor activity [57, 58], but it has 
remained unclear whether PACAP38 can lead to simultaneous activation of autonomic 
thermoeffectors, which would be in accordance with a fever-like response. To fill this gap and 
to study whether the release of PACAP38 from TRPV1-expressing neurons can be regarded as 
a mediator of systemic inflammation, as a part of our investigation we aimed to characterize 
the thermoregulatory effects of PACAP38 on deep Tb. 
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Since the neurokinin-1 (NK1) receptor, formerly known as SP receptor, also plays an 
important role in mediation of local and systemic inflammatory processes, SP signaling has 
been presumed as mediator of fever. When rodents were treated with peptide SP (antagonist) 
analogs, the fever response to LPS was blocked [59, 60], similar attenuation of the LPS-induced 
fever was observed in rats after administration of the NK1 receptor blockers [61, 62]. These 
studies strongly support that SP signaling contributes to the development of LPS-induced fever, 
but it has remained largely unknown which mediators of the febrile process are influenced by 
SP or its receptors. Alternative approaches, such as the use of KO mice, may help to better 
clarify which step(s) of the classical molecular mechanisms of fever are influenced by the NK1 
receptor. 
 
1.4. Animal models to study systemic inflammation 
SIRS can be either triggered by non-infectious insults, or it can be associated with an 
infection, when it is called sepsis. To study the etiology of sepsis in the laboratory, different 
animal models have developed.  
Cecal ligation and puncture (CLP), a murine model of bacterial peritonitis has been used 
extensively to investigate the clinical settings of polymicrobial sepsis and septic shock [63]. 
Systemic administration of high or low dose of LPS in mice and rats is often used to induce 
SIRS aseptically. In the CLP and high-dose LPS models, shock and death can occur, largely as 
the result of the “cytokine storm,” a definite production of proinflammatory cytokines [35]. 
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2. Aims of the study 
 
The ultimate aim of the study was to discover new mechanisms, which may play a part 
in the mediation of systemic inflammation. Since systemic inflammation is often accompanied 
by alterations in deep Tb, in most experiments we used a thermophysiological approach to 
explore the contribution of the different investigated mediators to inflammation.  
To better understand the pathophysiological background of the inflammatory processes, 
in our study we wanted to investigate the role(s) of endogenous substances (which are 
physiologically produced in the body) and receptorial mechanisms related to the development 
of systemic inflammation. 
Therefore, because of their established roles in inflammatory processes, in different 
animal models: 
- we focused a part of our study on the role of bilirubin in systemic inflammation; 
- we attempted to characterize the role of the TRPV1 channel in thermoregulation 
under physiological conditions and in systemic inflammation; 
- we wanted to elucidate the importance of the TRPV1 channel in aseptic and 
microbial sepsis; 
- we studied the influence of PACAP on thermoregulatory processes; 
- and we analyzed the role of the NK1 receptor in inflammatory mechanisms. 
 
Here we provide a summary of the most important aims and findings, while the detailed 
description of the original studies can be found in the papers that served as the basis of the 
present work [64-68] (for full texts, see Appendices I-V.). 
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3. Materials and methods 
 
3.1. Experimental animals and their housing 
Over the past decades, the rat has become the primary animal model to study 
thermoregulatory manifestations of systemic inflammation, but with rapid development of 
genetic manipulations and new species-specific tools (recombinant antibodies and other 
proteins), the mouse is also becoming a common species to investigate the mechanisms of fever 
and hypothermia [16]. 
In our experiments we used adult male Wistar rats, as well as normobilirubinemic 
(heterozygous, asymptomatic; J/+) and hyperbilirubinemic (homozygous, jaundiced; J/J) Gunn 
rats. Other studies were conducted in mice of both sexes with the Trpv1 gene either present 
(Trpv1+/+) or missing (Trpv1-/-); or with the Tacr1 gene (i.e., the gene encoding the NK1 
receptor) homozygously either present (Tacr1+/+) or absent (Tacr1-/-); or with the Pacap gene 
homozygously either present (Pacap+/+) or absent (Pacap-/-). 
The animals were housed under standard conditions: kept in temperature-controlled 
rooms on a 12 h light/dark cycle, where standard rodent chow and tap water were available ad 
libitum. The animals were housed in groups until they were subjected to surgery, after which 
they were caged singly. They were extensively handled and habituated to staying in wire-mesh 
conical confiners, which were later used in the experiments. All procedures were conducted 
under protocols approved by the Institutional Animal Care and Use Committees. 
 
3.2. Surgical preparation  
Surgeries were performed under ketamine-xylazine [55.6 and 5.5 mg/kg 
intraperitoneally (i.p.), respectively] anesthesia on rats, and under ketamine-xylazine (81.7 and 
9.3 mg/kg i.p., respectively) anesthesia on mice; in some centers also in combination with 
acepromazine (1.1 and 1.2 mg/kg for rats and mice, respectively); for both species, antibiotic 
protection [gentamycin, 6 mg/kg, intramuscularly or enrofloxacin, 1.1 mg/kg, subcutaneously 
(s.c.)] was provided, except for animals subjected to CLP. For pain management, ketoprofen or 
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carprofen (5 mg/kg, s.c.) was administered at the end of surgery and on the next day. The 
experiments were performed 4-7 days after the surgeries. 
3.2.1. Intravenous (i.v.), i.p. catheterization and intracerebroventricular (i.c.v.) 
cannulation 
In order to administer substances to rats and mice in a non-stressful manner, the animals 
were preimplanted with an i.v. or i.p. catheter or with an i.c.v. cannula.  
For implanting an i.v. catheter, a small longitudinal incision was made on the ventral 
surface of the neck, left to the trachea. The left jugular vein was exposed, freed from its 
surrounding connective tissue, and ligated. A silicone catheter (ID 0.5 mm, OD 0.9 mm) filled 
with heparinized saline (50 U/ml) was passed into the superior vena cava through the jugular 
vein and secured in place with ligatures. The free end of the catheter was knotted, tunneled 
under the skin to the nape, and exteriorized. The wound on the ventral surface of the neck was 
sutured. The catheters were flushed with heparinized saline every other day. 
For the i.p. administration of drugs, a polyethylene (PE) catheter filled with pyrogen-
free saline was inserted into the peritoneal cavity, and the internal end of the catheter was 
attached with a suture to the abdominal wall. The free end of the catheter was knotted, tunneled 
under the skin to the nape, and exteriorized. The catheter was flushed with saline every other 
day. 
For i.c.v. drug administration, a 22 ga steel guide cannula (Plastics One) was implanted 
into the right lateral brain ventricle. The head of the animal was fixed in a stereotaxic apparatus; 
the scalp was incised over the sagittal suture; the periosteum was excised; the bone surface was 
cleaned; and two supporting microscrews were driven into the skull. A hole was drilled 1.0/0.5 
mm (rat/mouse, respectively) posterior to bregma and 1.5/1.0 mm (rat/mouse, respectively) 
right of the sagittal suture. The guide cannula was inserted into the lateral ventricle 3.8/2.0 mm 
(rat/mouse, respectively) below the skull surface. The cannula was fixed to the supporting 
microscrews with acrylic cement. After the experiments were concluded, a correct placement 
of each i.c.v. cannula was confirmed by anesthetizing the animal, infusing 5 μl of an aqueous 
solution of methylene blue (6 mg/ml) through the cannula, removing the brain, and then 
examining coronal sections macroscopically for the presence of the dye in the ventricular 
16 
 
system. Animals without the dye in the lateral cerebral ventricle were excluded from the final 
statistical analysis. 
3.2.2. Implantation of temperature-measuring device 
To record abdominal temperature (Tab, a measure of deep Tb) and gross locomotor 
activity in freely-moving mice, a miniature telemetry transmitter (G2 E-Mitter series; Mini 
Mitter) was implanted. The device was inserted into the peritoneal cavity via midline 
laparotomy and fixed to the lateral abdominal wall with a suture. The surgical wound was 
sutured in layers. Mice were then placed on top of the receivers (see section 3.3.3., for details) 
in their home cages.  
3.2.3. CLP procedure 
For CLP, the cecum was pulled out of the abdominal cavity, filled with the intestinal 
content (by gently squeezing the content from the ascending colon) and ligated with silk just 
distal to the ileocecal junction. The cecal wall was punctured through at the antimesenteric side 
with a needle. The survival rate and Tb were monitored for 108 h, at the end of experiments, 
any survivors were euthanized. 
 
3.3. Experimental setups 
We used three different experimental setups to measure the various thermophysiological 
parameters of rats and mice under physiological conditions and in forms of systemic 
inflammation. All experiments, were conducted under thermoneutral conditions, unless 
specified otherwise. 
3.3.1. Thermocouple setup 
The animals were placed in a confiner and equipped with two copper-constantan 
thermocouple (Omega Engineering) to measure colonic temperature (Tc) and tail skin 
temperature (Tsk). The colonic thermocouple was inserted 10 or 3 cm deep beyond the anal 
sphincter in rats and mice, respectively, and fixed to the tail with a loop of adhesive tape. The 
skin thermocouple was positioned on the lateral surface of the tail and insulated from the 
environment with tape. To record Tb and Tsk data, the thermocouple was plugged into a data 
logger (Cole-Parmer) connected to a computer. The animal in its confiner was then placed in 
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an environmental chamber (Forma Scientific) set to a neutral ambient temperature (Ta) specific 
for the setup. The implanted catheter or cannula was extended with a length of PE-50 tubing 
filled with saline, which was passed through a wall port and connected to a syringe filled with 
the drug of interest or saline. 
3.3.2. Respirometry setup 
Each animal in its confiner was transferred to a Plexiglas chamber of the four-chamber 
open-circuit calorimeter integrated system (Oxymax Equal Flow, Columbus Instruments, 
Columbus, OH, USA). The chamber was sealed, submerged into a temperature-controlled water 
bath, and continuously ventilated with room air. The fractional concentration of oxygen was 
measured in the air entering and exiting the chamber, and the rate of oxygen consumption (VO2) 
was calculated according to the manufacturer’s instructions using the Oxymax Windows 
software. In another setup, animals in their confiners were placed inside a sealed cylindrical 
Plexiglas chamber (Sable Systems). The Plexiglas chambers were kept in a climatic chamber 
and continuously ventilated. The rate of VO2 was calculated by comparing the oxygen fraction 
in the air exiting the chamber occupied by an animal to the oxygen fraction in the air exiting an 
empty chamber. 
3.3.3. Telemetry setup 
In this setup, mice were studied inside their home cages. Telemetry receivers (model 
ER-4000; Mini Mitter) were positioned in a temperature-controlled room or in a climatic 
chamber, and the home cages of mice preimplanted with a telemetry transmitter were placed on 
top of the receivers in order to measure Tab and locomotor activity in freely moving animals. 
 
3.4. Drugs and drug administration 
LPS from Escherichia coli 0111:B4 was purchased from Sigma-Aldrich. A stock 
suspension of LPS (5 mg/ml) in pyrogen-free saline was stored at -20oC. To induce SIRS in 
experimental animals, LPS was injected in a bolus (10 or 1,000 µg/kg i.v. for rats; 0.12 or 40 
mg/kg i.p. for mice) through the extension of the i.v. or i.p. catheter. Variables of interest were 
monitored up to 7 hours after the injection. Controls received saline. 
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AMG 517, which is a highly potent and selective TRPV1 antagonist, was used to block 
TRPV1 receptors pharmacologically. Aliquots of an ethanolic solution of AMG 517 (3 mg/ml) 
were stored at -80°C. AMG 517 (210 μg/kg s.c.) or its vehicle was administered as a bolus, 1 h 
before the administration of the pyrogen agent or saline. 
PACAP38 was synthesized at the University of Szeged as described in details elsewhere 
[69]. Lyophilized aliquots of PACAP38 were stored at 4°C. On the day of the experiment, a 
working solution was prepared and PACAP38 was delivered at final doses of 100 μg/kg i.v. 
and at 10 and 100 μg/kg i.c.v. for rats. Control animals were infused with saline. 
SP was purchased from Tocris Bioscience, Bristol, UK. Aliquots of an ethanolic stock 
solution of SP were stored at -80°C. On the day of the experiment, the stock solution was diluted 
with saline and infused into the lateral ventricle, at a total dose of 100 μg/kg. Controls were 
infused with the vehicle (10% ethanol in saline).  
 
3.5. In vitro experiments 
Levels of total bilirubin and markers of renal dysfunction and hepatocyte damage were 
determined in blood samples collected by cardiac puncture from rats 24 h after LPS injection. 
The blood was immediately transferred to EDTA-containing Vacutainer tubes. The plasma was 
separated by centrifugation, aliquoted, and stored at -80°C until biological assays were 
performed. 
Immunohystochemistry for the labeling of c-fos-expressing neurons in the Pacap-/- and 
Pacap+/+ mice was performed as described in details elsewhere [70]. In brief, the cell counts 
positive for c-Fos were determined in five serial sections, each interspaced by 60 μm in the 
median preoptic nucleus (MnPO) and medial preoptic area (MPO) according to Paxinos and 
Franklin atlas [71]. Cell counting was carried out on non-edited digital images and quantitation 
was performed in a double-blind setup. 
In order to determine LPS-induced changes in COX-2, 40 minutes after LPS infusion 
each mouse was perfused, lung, liver and brain tissue samples were collected and snap frozen 
in liquid nitrogen for RT-qPCR and Western blot. All tissue samples were stored at -80°C. 
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3.6. Statistical analysis 
Blood levels of bilirubin and biochemical markers of renal and hepatic dysfunction, and 
numbers of the c-Fos-positive cells were compared with Student’s t test. 
Thermophysiological parameters and COX-2 expression were compared by two- or 
three-way ANOVA followed by Fisher’s LSD post hoc tests or by Student’s t test, as 
appropriate. 
Survival data were analyzed by the χ2 test for individual time points and by the logrank 
test for the entire observation period. The Cox proportional hazard survival regression model 
was used to determine hazard ratios of death. 
For statistical analysis, Sigmaplot 11.0 or Statistica AXA 8.0 software was used. The 
effects were considered significant when P<0.05. All data are reported as mean ± standard error. 
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4. Results 
 
4.1. The role of bilirubin in systemic inflammation 
4.1.1. LPS-induced fever and hypothermia in Gunn rats 
At 30°C, rats respond to the low dose of LPS with a polyphasic fever, and to the high 
dose with hypothermia followed by fever [16]. In our study with Gunn rats [66], the i.v. 
injection of saline did not affect the Tc in either genotype of rats (Fig. 2A). To the low dose (10 
µg/kg) of LPS, both J/J and J/+ rats responded with a triphasic fever with peaks at ~50, 130, 
and 280 min post-injection (Fig. 2B), however there were no significant differences in the Tb 
dynamics between the genotypes. To the high dose (1,000 µg/kg) of LPS, J/+ rats responded 
with early hypothermia (nadir of -0.5°C at ~90 min; P=0.034 vs. saline) followed by fever (peak 
of 0.9°C at ~360 min; P<0.001 vs. saline) (Fig. 2C). A different Tb response of J/J rats was 
observed to the high dose of LPS, the early hypothermic response (nadir of -1.2°C at ~90 min, 
P<0.001 vs. saline) was remarkably exaggerated (P≤0.004 for 40-180 min vs. J/+ rats), and the 
subsequent fever response (peak of 0.3°C, P=0.039 vs. saline) was significantly attenuated 
(P<0.05 for 240-420 min vs. J/+ rats). 
4.1.2. Plasma bilirubin level in Gunn rats 
As LPS administration may cause liver failure with hyperbilirubinemia, we examined 
blood bilirubin levels in J/J and J/+ rats under basal conditions and in LPS-induced systemic 
inflammation [66]. As expected, the total plasma bilirubin level in saline-treated J/J rats was 
significantly higher (by 2 orders of magnitude) than that in J/+ rats, moreover the low dose of 
LPS did not affect the total bilirubin level in either genotype. However, in response to the 
injection of the high dose of LPS, the total bilirubin level elevated in both J/+ and J/J rats 
(P<0.001 vs. saline, for both genotypes), while in J/J rats it has still remained higher than in J/+ 
controls (figure not shown). 
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Figure 2. Deep (colonic) Tb responses of J/J and J/+ rats to the low (10 µg/kg, i.v.) and high (1,000 µg/kg, i.v.) doses of LPS. 
(A) Administration of the vehicle (saline) does not affect Tb in rats. (B) The low dose of LPS causes polyphasic fevers in J/J 
and J/+ rats, without any significant differences between the genotypes. (C) In J/+ rats, the high dose of LPS induces early 
hypothermia followed by late fever. In J/J rats, the hypothermic response is exaggerated, and the subsequent febrile response 
is attenuated, as compared to the J/+ controls. Time periods corresponding to significant intergenotype differences in the 
response to LPS are marked as *P<0.05 or **P<0.01. From Pakai et al. [66]. 
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4.1.3. Renal dysfunction and hepatic damage in Gunn rats after LPS administration 
Next, we studied biomarkers of kidney and liver damage [66]. As markers of renal 
function, neither blood urea nitrogen (BUN) nor creatinine levels differed significantly between 
saline-treated J/J and J/+ rats. While administration of the low dose of LPS did not raise the 
renal dysfunction markers, the high dose increased both BUN and creatinine in J/J (P≤0.001 for 
both BUN and creatinine) and J/+ rats (P=0.010 for BUN; P<0.001 for creatinine) without any 
significant differences between the genotypes (Fig. 3). 
 
Figure 3. Biochemical markers of renal dysfunction in J/J and J/+ rats. (A) Plasma BUN levels do not differ between saline-
treated J/J and J/+ rats and after administration of the low dose of LPS. The high dose of LPS raises BUN in both genotypes, 
without any intergenotype difference. (B) Plasma creatinine levels do not differ between saline-treated J/J and J/+ rats and 
after administration of the low dose of LPS. The high dose of LPS raises plasma creatinine in both genotypes, without any 
intergenotype difference. Significant differences in the response to LPS compared to saline are marked as ##P<0.01 or 
###P<0.001. Number of animals in the corresponding groups are indicated in the figure. From Pakai et al. [66]. 
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Plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), and 
gamma-glutamyl transferase (GGT) were used to assess hepatocyte damage [72]. Activities of 
all 3 enzymes were within the normal range in J/J and J/+ rats after the injection of saline or the 
low dose of LPS. When LPS was administered at the high dose, rats showed marked rises in 
ALT (P=0.019 for J/+; P=0.015 for J/J; Fig. 4A), AST (P=0.021 for J/+; P=0.041 for J/J; Fig. 
4B), and GGT (P<0.001 for both genotypes; Fig. 4C). In J/J rats, the surge was blunted for GGT 
(P=0.042) and tended to be reduced for ALT (P=0.208) and AST (P=0.179), as compared to 
J/+ rats. 
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Figure 4. Biochemical markers of hepatocyte damage in J/J and J/+ rats. (A) Plasma ALT levels do not differ between saline-
treated J/J and J/+ rats and remain unchanged after the administration of the low dose of LPS (10 µg/kg, iv). In response to 
the high dose of LPS (1,000 µg/kg, iv), plasma ALT surges in both genotypes, but this surge tends to be blunted in J/J rats (as 
compared to the J/+ controls). (B) Plasma AST levels do not differ between J/J and J/+ rats after administration of saline or 
LPS at the low dose. In response to the high dose of LPS, AST surges in both genotypes, but the surge tends to be blunted in 
J/J rats). (C) Plasma GGT levels are near the detection threshold in J/J and J/+ rats after administration of saline or the low 
dose of LPS. Plasma GGT rises in both genotypes in response to the high dose of LPS, but the rise is significantly reduced in 
J/J rats. A significant (P<0.05) intergenotype difference in the response to LPS is marked with *. Within each genotype, 
significant differences in the response to LPS (as compared to saline) are marked as #P<0.05 or ###P<0.001. Number of animals 
in the corresponding groups are indicated in the figure. From Pakai et al. [66]. 
 
4.2. The role of TRPV1 channels in thermoregulation under physiological 
conditions and in systemic inflammation 
4.2.1. Significance of TRPV1 channels in Tb regulation and thermoeffector activities 
In order to determine the role of TRPV1 channel in thermoregulation we studied 
circadian fluctuations in deep Tb and thermoeffector activities of a large number of Trpv1+/+ 
and Trpv1-/- mice in our telemetry and respirometry experimental setups [65]. In both setups the 
light-phase mean deep Tb of Trpv1-/- mice was slightly, but significantly (P<0.05) lower than 
that of the controls. During the dark (active) phase, however, the intergenotype Tb difference 
was attenuated in the respirometry setup and completely disappeared in the telemetry setup (Fig 
5). As the result of such biphasic dynamics, the daily mean Tb of Trpv1-/- mice was either similar 
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to or slightly lower than that of the controls in both setups. We conclude, that these alterations 
are phase specific and somewhat depend on the experimental setup. 
 
Figure 5. During the inactive (light) phase, Trpv1-/- mice have a lower deep Tb than their genetically unaltered counterparts 
in the telemetry (A), and respirometry (B) setups. Number of animals in the corresponding groups are indicated in the figure. 
From Garami et al. [65]. 
 
Next, we studied two autonomic effectors under basal conditions, namely 
thermogenesis (measured as VO2) and tail skin vasomotor tone (measured as Tsk). It has been 
revealed, that Trpv1-/- mice maintained a lower metabolic rate and showed a more pronounced 
cutaneous vasoconstriction than their Trpv1+/+counterparts, regardless of the phase (Fig. 6). The 
daily means for VO2 and Tsk for the KO versus control mice were 18.9±1.0 versus 26.3±1.3 
ml/kg/min (p˂0.0001) and 35.0±0.2 versus 35.7±0.2°C (p˂0.05), respectively.  
In summary, Trpv1-/- mice have a thermoregulatory phenotype that shows a specific 
thermoeffector pattern: these mice are are hypometabolic, and vasoconstricted while maintain 
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lower Tb as compared to control mice, therefore this animal model is suitable to investigate the 
role of TRPV1 in systemic inflammation. 
 
 
Figure 6. Compared to genetically unaltered controls, Trpv1-/- mice regulate Tb by using a different thermoeffector pattern. In 
the respirometry setup, they are hypometabolic (have a lower VO2) and vasoconstricted (have a lower tail Tsk). Number of 
animals in the corresponding groups are indicated in the figure. From Garami et al. [65]. 
 
4.2.2. The role of TRPV1 channels in aseptic or microbial sepsis 
In the laboratory, systemic administration of LPS in rodents is often used to induce SIRS 
aseptically, while polymicrobial sepsis is often studied in mice and rats subjected to CLP 
procedure. To discover the role of TRPV1 channel in systemic inflammation, we investigated 
the effect of LPS and CLP in mice either present or missing the channel [68]. 
Young adult mice responded to LPS (40 mg/kg, i.p.) with a marked, rapidly progressing 
SIRS (Fig. 7A). Pretreatment with AMG517 (210 μg/kg, s.c.), a potent and selective TRPV1 
antagonist, profoundly decreased the survival rate at multiple time points (e.g., from 50% to 
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5% at 26 h, P<0.001) and also shortened the mean time to death (from 26±2 to 19±1 h, P=0.003). 
All LPS-treated mice within the present study developed profound hypothermia (decrease from 
~36°C to ~33°C at 10 h). Similar to our previous studies [73, 74] in this study AMG517 caused 
a short-lasting increase in Tb compared with the vehicle (P<0.01, Fig. 7B), thus confirming an 
effective systemic blockade of TRPV1 channels. Overall, the results of our experiment show 
that pharmacological blockade of TRPV1 increases mortality of young mice in LPS-induced 
SIRS. 
 
 
Figure 7. Systemic pretreatment with AMG517 (210 μg/kg, s.c.) decreases survival of young mice in LPS-induced SIRS (A). 
Confirming an effective blockade of TRPV1 channels, the AMG517 pretreatment increases deep Tb in young mice (B). From 
Wanner et al. [68]. 
 
The outcome of LPS-induced SIRS in older mice was more severe than in young mice. 
Pretreatment of aged mice with AMG517 increased the survival rate, delayed the mean time to 
death and decreased the risk of mortality, which effects are directly the opposite of those 
observed in the young mice (figure not shown).  
Then, we tested whether genetic deletion of TRPV1 would have the same effects on 
SIRS in middle-aged mice as a pharmacological blockade. Experiments were conducted in 43-
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44-week-old Trpv1-/- mice of both sexes and in their age- and sex-matched Trpv1+/+ controls. 
LPS caused death in all wild-type control mice but only in 80% of Trpv1-/- mice. Survival rate 
of Trpv1-/- mice was 2-3 times higher at certain time points than of Trpv1-/- mice. Genetic 
deletion of TRPV1 channels decreased the risk of mortality and tended to delay death. 
Importantly, Trpv1-/- mice exhibited a 70% suppression of the TNF-α response at 12 h post-
LPS (figure not shown). 
After these results, we investigated whether the attenuation of aseptic SIRS observed in 
older Trpv1-/- mice would result in attenuation of the body’s defense against CLP-induced 
polymicrobial infection. We observed that CLP sepsis caused substantial mortality in aged mice 
of both genotypes (Fig. 8A), however, Trpv1-/- mice died significantly faster than their Trpv1+/+ 
controls. The mean time to death in Trpv1-/- mice was 20±2 h, compared to 52±11 h in Trpv1+/+ 
mice (P<0.01), and the survival rate in Trpv1+/+ mice was 3.9 times higher than in Trpv1-/- mice 
(86% vs. 22%, P<0.001). The delayed recovery of deep Tb after the CLP procedure also 
confirms the higher severity of sepsis in Trpv1-/- mice (P<0.001, Fig. 4B). 
 
 
Figure 8. Compared with their age-matched wild-type littermates, middle-aged Trpv1-/- mice have a shorter survival time (A) 
and a slower Tb recovery (B) during CLP-induced sepsis. From Wanner et al. [68]. 
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4.3 Characterization of the thermoregulatory effects of PACAP 
4.3.1. Aspects of the thermoregulatory response to central and systemic PACAP38 
administration in rats 
To identify the thermoregulatory effect of PACAP38 in details, we infused 10 or 100 
μg/kg of the peptide (or saline) into the lateral cerebral ventricle of rats and recorded their Tc, 
Tsk, and VO2 in our respirometry setup [64]. Both of the applied doses of PACAP38 caused a 
marked rise in the Tc starting already at 10 min after the injection (P<0.001 for both; Fig. 9). 
The magnitude of the PACAP38-induced hyperthermia was dose-dependent with a maximal Tc 
change of 2.0±0.3°C and 1.4±0.3°C at the dose of 100 and 10 μg/kg, respectively (P<0.001 for 
both). Significant difference (P<0.001) could be statistically confirmed also between the effects 
of the 10 vs. 100 μg/kg dose of PACAP38 on Tc. 
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The increased Tb response to central administration of PACAP38 is in harmony with 
earlier reports in rats [57, 58, 75, 76]. In the case of the higher dose, the development of the 
hyperthermia was accompanied by significant tail skin vasoconstriction [as indicated by a 
decreased heat loss index (HLI); P<0.05]. It is a novel finding to report cutaneous vasomotor 
responses to i.c.v. PACAP38 in conscious rats. The presence of the vasomotor response 
indicates that the thermoregulatory (constrictor) effect of PACAP38 on the cutaneous vascular 
tone is different from its direct (dilator) effect on skin vessels, which was shown earlier in small 
rodents [77, 78]. The initial drop of HLI lasted for ~40 min, and then, it was followed by a 
marked elevation of HLI due to tail skin vasodilation, which remained significantly (P<0.05) 
higher than the HLI of saline-treated rats until the end of the experiment. Similarly to the Tc 
response, the VO2 of the rats increased already at 10 min after administration the peptide i.c.v. 
as compared to control animals in a dose-dependent manner. It reached a maximal rise of 21±6 
and 14±6 ml/kg/min at 100 and 10 μg/kg, respectively (P<0.001 for both). This finding is in 
harmony with previous studies, in which PACAP38 increased the metabolic rate [57, 79, 80]. 
In addition, our results demonstrate that simultaneous immediate activation of both autonomic 
cold-defense thermoeffectors [cutaneous vasoconstriction and brown adipose tissue (BAT) 
thermogenesis] contribute to the development of hyperthermia in response to PACAP38.  
To consider the possibility of a peripheral site of action for PACAP38 in a comparative 
experiment, we looked into whether the higher dose of PACAP38 (100 μg/kg) that caused 
pronounced hyperthermia when injected centrally has a similar effect on deep Tb in the case of 
a systemic administration. When PACAP38 at 100 μg/kg was infused i.v., it caused a slight, 
but significant (P<0.05) rise of Tc. Both the maximum Tc elevation and the duration of the 
hyperthermic effect to systemic PACAP38 infusion were substantially less than what i.c.v. 
administration of the same dose evoked (P<0.05). Similarly to what we observed after i.c.v. 
drug delivery, after i.v. administration the hyperthermia also developed due to decreased heat 
loss and increased VO2, but all parameters changed to a much lesser extent compared to i.c.v. 
injection (figure not shown). Our results certainly show that the site of action for the 
thermoregulatory response to PACAP38 is situated within the CNS. 
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4.3.2. Characteristics of the thermoregulatory response in the absence of PACAP 
After characterization of the thermoregulatory response to exogenous PACAP38 
administration, we studied how deep Tb is affected by the absence of PACAP [64]. 
For that, we analyzed the circadian changes of Tab and locomotor activity in freely 
moving Pacap-/- and Pacap+/+ mice (Fig. 10A). Mice of both genotypes had lower Tab and 
activity levels during the inactive (light) phase compared to the active (dark) phase, however 
Pacap-/- mice were more active than their wild-type littermates during both phases of the day 
(P<0.001). During most of the light phase, the increased locomotor activity resulted in a slightly 
higher Tab in the KO mice compared to controls (P<0.05); but in the night, there was no 
significant difference in Tab between the groups. It can be hypothesized that the different light-
dark influence of locomotor activity on deep Tb can originate from the circadian changes of 
cutaneous vasodilation, thus heat loss mechanisms [81]. 
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Figure 10. Circadian changes of Tab and locomotor activity in freely moving Pacap-/- and Pacap+/+ mice. These experiments 
were performed in the telemetry setup at a Ta of 27°C (A). Basal Tc and VO2 of loosely restrained Pacap-/- and Pacap+/+ mice. 
Recordings of Tc and VO2 were performed in the respirometry setup at a Ta of 31°C (B). From Banki et al. [64]. 
 
Then, we measured the basal (resting) Tc and VO2 in loosely restrained Pacap-/- and 
Pacap+/+ mice in our respirometry setup (Fig. 10B). We recorded the basal thermoregulatory 
parameters for 60 min starting from 11 a.m. because this time period corresponded to the biggest 
difference in deep Tb between freely moving Pacap-/- and Pacap+/+ mice (Fig. 10A). As shown 
in Figure 10B, the basal VO2 appeared to be significantly lower in Pacap-/- mice as compared 
to controls throughout the experiment (P<0.001). In correlation with their hypometabolism, Tc 
of the Pacap-/- mice was also slightly lower than that of controls (P<0.01). 
Finally, to determine which neurons are responsible for maintaining the reduced resting 
metabolic rate in Pacap-/- mice, we measured expression of the inducible transcription factor c-
Fos, a marker of neuronal activation [82], in the MnPO and MPO (Fig. 11A). It is well known 
from previous studies, that neurons in these brain areas are involved in the regulation of 
thermogenesis [47, 83]. In the MnPO, we have not found statistical difference in the number of 
c-Fos-positive cells between genotypes; however, c-Fos expression was nearly three times 
higher (p<0.05) in the MPO of the Pacap-/- mice as compared to controls (Fig. 11B).  
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It has been revealed that gamma-aminobutyric acid (GABA)ergic neurons in the MPO 
tonically suppress BAT thermogenesis [84] and are believed as the first effector neurons of the 
thermoregulatory loops controlling autonomic thermoeffectors [47]. Therefore, our findings in 
Pacap-/- mice suggest that the absence of PACAP results in an increased activation of the 
inhibitory MPO neurons leading to more pronounced suppression of thermogenesis. 
 
Figure 11. The expression of c-Fos positive cells in the MnPO and MPO of Pacap-/- and Pacap+/+ mice (A). Quantitative 
analyses of c-Fos immunoreactive cells in the MnPO and MPO (B). From Banki et al. [64]. 
 
4.4. The role of the NK1 receptor in systemic inflammatory processes 
4.4.1. Characteristics of the thermoregulatory response of Tacr1+/+ and Tacr1-/- mice 
to LPS 
Neurokinin signaling is thought to be involved in various inflammatory processes. To 
identify how the NK1 receptor contributes to the febrile response, we first determined the 
thermoregulatory phenotype of mice with the gene encoding the NK1 receptor either present 
(Tacr1+/+) or absent (Tacr1-/-) [67]. The basal deep Tb of the mice was identical regardless of 
either gender or genotype in the thermocouple setup throughout the recordings. To evaluate 
whether Tacr1-/- mice are able to appropriately activate warmth- and cold-defense mechanisms, 
we studied the thermoregulatory response of these mice to ambient heating and cooling, 
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respectively. It could be concluded, that the extent and dynamics of Tb or Tsk response did not 
differ between the two groups, hence, the thermoregulatory response of Tacr1-/- mice to heat or 
cold exposure is unaltered compared to controls (figure not shown). 
In our thermophysiological experiments, when treated with LPS (120 μg/kg, i.p.), the 
mice of both genotypes developed fever as compared to saline-treated groups (Fig. 12A, B).  
 
 
Figure 12. Thermoeffector and Tc responses of Tacr1+/+ and Tacr1-/- mice to LPS (A) or saline (B) administered i.p. These 
experiments were performed in the respirometry setup at an Ta of 31°C. Number of animals in the corresponding groups are 
indicated in the figure. *P<0.05, intergenotype difference in the response to LPS. #P<0.05, LPS vs. saline difference within the 
same genotype. From Pakai et al. [67]. 
 
LPS-treated Tacr1+/+ mice responded with a typical fever response: their deep Tb started 
to increase at 20 min, reached plateau (~38.5°C) between 40 and 100 min, then it gradually 
decreased, but remained elevated compared to saline treatment throughout the experiment 
(P<0.05 at 30-360 min). In Tacr1-/- mice, the LPS-induced fever response was less pronounced, 
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reaching the level of significance at 40-140 min compared to controls (P<0.05; Fig. 12A). The 
LPS-induced increase in deep Tb was generated by an elevation of VO2, changing with parallel 
dynamics as Tb in both genotypes (Fig. 12A, B). After LPS injection, the VO2 was significantly 
higher compared to saline treatment at 40-350 min in Tacr1+/+ mice (P<0.05) and at 40-110 min 
in Tacr1-/- mice (P<0.05). Since the experiments were performed at the lower end of the 
thermoneutral zone (TNZ), the mice showed cutaneous vasoconstriction (as indicated by their 
low tail Tsk), thus no further decrease in tail Tsk was observed. 
Importantly, in Tacr1-/- mice the LPS-induced elevation of the Tb and VO2 were 
markedly suppressed compared to their Tacr1+/+ littermates starting from 40 min post-LPS 
infusion until the end of the experiment; both parameters were significantly attenuated at 40-
120 min (P<0.05 for intergenotype difference). Our results demonstrate that LPS-induced fever 
is attenuated in Tacr1-/- mice already in the early stage. 
 
4.4.2. LPS-induced changes in serum cytokines levels and COX-2 expression in 
Tacr1+/+ and Tacr1-/- mice 
Next, we wanted to know the suppression of which part of the “pyrogenic cytokine-
COX-2-PGE2” axis is responsible for attenuating the fever response in the absence of Tacr1 
gene [67]. 
In response to PGE2 administered i.c.v., in the mice of both genotypes a marked 
elevation in deep Tb and VO2 rapidly developed, but there was no attenuation in either the Tb 
or VO2 rise in the Tacr1-/- mice compared to their Tacr1+/+ littermates (figure not shown). The 
lack of attenuation in the PGE2-induced thermoregulatory response of the Tacr1-/- mice suggests 
that their reduced fever response to LPS is due to suppression of an earlier phase in the 
febrigenic molecular pathway. 
One of the early steps in LPS-induced fever signaling is the activation of immune cells, 
which causes augmented production of inflammatory cytokines, including TNF-α and IL-6. 
Thus, in our next experiments we measured serum concentrations of these cytokines in the 
Tacr1+/+ and Tacr1-/- mice to determine whether the LPS-induced cytokine production is 
suppressed in the absence of the NK1 receptor. The administration of LPS resulted in a massive 
rise of TNF-α (P<0.001 vs. saline for both genotypes) and IL-6 (P<0.01 for Tacr1+/+ mice and 
36 
 
P<0.001 for Tacr1-/- mice) (figure not shown). We did not find any significant intergenotype 
difference in the TNF-α and IL-6 levels. These data indicate that impaired pyrogenic cytokine 
production does not contribute to the attenuated fever response of Tacr1-/- mice to LPS. 
We moved downstream in the fever signaling pathway and compared the LPS-induced 
expression of COX-2 between Tacr1+/+ and Tacr1-/- mice. At the mRNA level, COX-2 
expression is upregulated in rats already in the early phase of the febrile response (~30–40 min 
after LPS infusion) both in peripheral organs (lungs and liver) and to a lesser extent in the brain 
[85]. As our present study revealed that the fever response of Tacr1-/- mice was attenuated 
already in the early phase post-LPS infusion, we collected lung, liver, and brain samples at ~40 
min time point and studied the COX-2 mRNA expression in these tissues. The administration 
of LPS caused transcriptional upregulation of COX-2 mRNA in the lungs (Fig. 13A), in the 
liver (Fig. 13B), and in the brain (Fig. 13C) of both genotypes (P<0.001 vs. saline for all three 
tissues) without any significant intergenotype difference. The magnitude of the LPS-induced 
increase in the level of COX-2 expression was diverse in the three organs studied: ~5-fold in 
the lungs, 17-20-fold in the liver, and 2-fold in the brain. These results are well in accordance 
with earlier findings on the dynamics of LPS-induced COX-2 mRNA expression, but cannot 
explain the attenuation of the febrile response in the Tacr1-/- mice. 
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Figure 13. Relative COX-2 gene expression in the lungs (A), liver (B), and in the brain (C) of Tacr1+/+ and Tacr1-/- mice after 
infusion of LPS or saline. Tissue samples were collected at 40 min postinfusion. Number of animals in the corresponding 
groups are indicated in the figure. Significant differences in the response to LPS compared to saline are marked as ###P<0.001. 
From Pakai et al. [67]. 
 
Besides the LPS-induced amplified expression of COX-2 mRNA, the expression of the 
COX-2 protein was also described to increase in the periphery (but not in the brain) already in 
the early phase of the febrile response [86]. Therefore, we also analyzed the COX-2 protein 
expression between LPS-treated Tacr1+/+ and Tacr1-/- mice (Fig. 14).  
In Tacr1+/+ mice, the administration of LPS resulted in a marked increase in COX-2 
protein expression in the lungs (P<0.01 vs. saline) (Fig. 14A) and in the liver (P<0.05) (Fig. 
14B), but not in the brain (P=0.264) (Fig. 14C). In LPS-treated Tacr1-/- mice, the COX-2 protein 
expression did not change significantly in either the lungs or the liver compared to saline 
treatment. In LPS-treated mice, the COX-2 protein expression was attenuated in the lungs of 
Tacr1-/- mice compared with their controls presenting the gene (P<0.01), while in the liver only 
a tendency could be seen for reduced COX-2 expression in Tacr1-/- mice (P=0.101). These 
findings indicate that the absence of the NK1 receptor interferes with the increase of COX-2 
expression at the protein level. 
0,0
0,7
1,4
2,1
C
Re
lat
ive
 CO
X-2
 ge
ne
 ex
pre
ssi
on
 in
 th
e b
rai
n
(8) (8) (9) (9)
saline i.p. LPS  120 μg/kg i.p.
# # # # # #
38 
 
 
 
Figure 14. Relative COX-2 protein expression in the lungs (A), liver (B), and in the brain (C) of the Tacr1+/+ and Tacr1-/- mice 
after infusion of LPS or saline. Tissue samples were collected at 40 min postinfusion. Number of animals in the corresponding 
groups are indicated in the figure. **P<0.01, intergenotype difference in the response to LPS; #P<0.05 or ##P<0.01, LPS vs. 
saline difference within the same genotype. From Pakai et al. [67]. 
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5. Discussion 
 
We identified novel mechanisms which contribute to the mediation of systemic 
inflammatory processes. In particular, we showed that 1) hyperbilirubinemia exaggerates the 
hypothermic response to bacterial endotoxin; 2) genetic ablation of the TRPV1 channel results 
in minor changes of thermoregulatory phenotype of mice as they use different pattern of 
thermoeffectors to regulate Tb; 3) in systemic inflammation, TRPV1 has an anti-inflammatory 
role in the young, which is reversed to pro-inflammatory in older age; 4) the thermoregulatory 
effects of PACAP38 make the peptide a potential contributor to the febrile response in systemic 
inflammation; and 5) SP signaling modulates LPS fever through peripheral COX-2 protein 
expression. 
The first novel and unexpected finding was that hyperbilirubinemia in Gunn rats was 
associated with an exaggerated hypothermic response to high dose of LPS (Fig. 2C) [66]. This 
exaggeration is unlikely to be due to an attenuation of the ROS-mediated inflammatory 
signaling by bilirubin. Indeed, attenuating inflammatory signaling should decrease the 
hypothermic response. Furthermore, while bilirubin, a potent ROS scavenger, has been shown 
repeatedly to attenuate inflammatory signaling [87-89] we did not find any literature data 
suggesting that it may amplify inflammatory signaling. An alternative, more reasonable 
mechanism of the exaggeration of LPS hypothermia might be an action of bilirubin on 
thermoeffectors. Based on literature findings, Gunn rats respond to administration of exogenous 
bilirubin (that further intensifies their hyperbilirubinemia) with a pronounced (∼3°C) drop in 
Tb [90]. This drop is likely to reflect decreased thermogenesis, because bilirubin has been 
demonstrated to depress mitochondrial respiration in liver, heart, and brain tissues in vitro [91-
93]. In addition, although BAT, which is the main source of nonshivering, temperature-driven 
thermogenesis in rodents [94] has not been studied, bilirubin is likely to have the same effect 
in brown fat as in all other tissues studied. A profound decrease in the threshold Tb for activation 
of thermogenesis is the principle autonomic thermoeffector mechanism of LPS-induced 
hypothermia [95]. Although skin vasodilation is not the main mechanism of LPS-induced 
hypothermia [95], increased skin vasodilation in J/J rats could have contributed to their 
enhanced hypothermic response to LPS as well. Hyperbilirubinemia has been shown to 
attenuate the pressor effects of angiotensin II in Gunn rats [96] and to lower angiotensin II-
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dependent hypertension in mice [97, 98] the latter effect being attributed to the blockade of 
superoxide production and possibly to enhanced vasorelaxation [97]. In a study conducted in 
humans [99] hyperbilirubinemia exaggerated endothelium-dependent vasodilation of the 
brachial artery, which supplies subcutaneous and cutaneous tissues of the arm. 
The same action on thermoeffectors could be responsible for the attenuation of the late 
fever response to the high dose of LPS in J/J rats, which was also observed in our study (Fig. 
2C) [66]. Since the thermoregulatory response to the high dose is a combination of early 
hypothermia and late fever, in our case the exaggeration of the hypothermic response may be 
difficult to distinguish from an independent attenuation of the fever response. Interestingly, the 
fever response to the low dose of LPS was not affected by hyperbilirubinemia in Gunn rats (Fig. 
2B), which was another novel observation. It suggests that ROS signaling is not involved in the 
febrile response, at least not to weak stimuli. 
Compared to J/+ rats, J/J rats responded to the high dose of LPS with a blunted surge in 
GGT (Fig. 4C) [66]. The LPS-induced surges in ALT and AST tended to be reduced, but the 
magnitude of the reduction did not reach the level of statistical significance (Fig. 4A, B). The 
revealed high sensitivity of GGT to hyperbilirubinemia was expected. Indeed, GGT is also a 
marker of oxidative stress, [100] and the blood concentration of this enzyme is inversely related 
to the blood antioxidant activity [101, 102]. The observed effect of hyperbilirubinemia on the 
LPS-induced GGT response and the tendencies revealed (with regard to ALT and AST 
responses) agree with the previously reported protective action of bilirubin in endotoxin shock 
[103] and other pathological conditions [104, 105]. 
As discussed in Pakai et al. [66], the cytoprotective action of bilirubin is likely to be due 
to the suppression of oxidative stress, either directly (by scavenging ROS) or indirectly (by 
inhibiting the expression of free radical-generating enzymes, such as NO synthase and 
nicotinamide adenine dinucleotide phosphate oxidase) [103]. By either mechanism, bilirubin 
potently suppresses the accumulation of lipophilic ROS in cell membranes [42, 43] and the 
decreased accumulation of ROS prevents cell apoptosis and tissue injury associated with 
oxidative stress [105]. Yet another mechanism of tissue protection by bilirubin in LPS-induced 
systemic inflammation could be the exaggeration of hypothermia. Hypothermia is an adaptive, 
active thermoregulatory response to high doses of LPS and other strong inflammatory stimuli 
[17]. It involves cold-seeking behavior [95, 106, 107] and is thought to be aimed at decreasing 
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the metabolic requirements of tissues [16, 17]. In previous studies [108, 109], when rats were 
either allowed to select their preferred low Ta or maintained at a lower Ta chosen by the 
investigators during endotoxin shock or Escherichia coli infection, their survival rates 
increased. At least in some cases, the increased survival was coupled with a suppressed surge 
in ALT [108]. 
While markers of hepatocyte damage were affected by hyperbilirubinemia, markers of 
renal dysfunction were not (Fig. 3), thus suggesting the lack of tissue protection in the kidneys. 
The observed tissue specificity for the protective action of bilirubin may relate to the fact that 
the liver is the principal site for bilirubin metabolism. Due to this, bilirubin concentration in 
hepatocytes should be higher than anywhere else in the body, including renal epitheliocytes. 
Although bilirubin conjugation is defective in J/J rats [110], and these animals excrete only 
traces of bilirubin in the bile [111], they still have more than a 2-fold-higher concentration of 
bilirubin in the liver than in the kidneys [112]. 
After we showed that bilirubin, a potent ROS scavenger, can influence the systemic 
inflammation response, we studied receptorial mechanisms, which can be also important in 
addition to ROS. Since the TRPV1 channel and the nerve endings expressing the channel (i.e., 
capsaicin-sensitive sensory fibers) also play a role in inflammatory processes, also including 
systemic, next we focused our attention on the role of the TRPV1 channel and on mediators 
released from TRPV1-expressing neurons in thermoregulation (see Fig. 1). The second novel 
finding was that the main thermoregulatory abnormality of Trpv1-/- mice appears to be not an 
altered level of Tb, but a different pattern of thermoeffectors used to regulate Tb under various 
thermal, housing, and restraint conditions [65]. Trpv1 KO mice were consistently 
hypometabolic (had a lower VO2) (Fig. 6) and preferred a lower Ta than controls. These 
thermoeffector changes tend to decrease Tb. At the same time, the KO mice expressed two 
thermoeffector activities aimed at increasing Tb. First, they had more pronounced tail skin 
vasoconstriction (Fig. 6) and, in agreement with this, had a higher TNZ. Second, they expressed 
strong hyperkinesis with the average locomotion velocity during the second half of the inactive 
phase exceeding that of wild-type mice during the active phase. As we discussed in details 
elsewhere [65], the increased spontaneous locomotion was unlikely to be due to changes in 
anxiety or exploratory behavior, because the mice were extensively adapted to experimental 
conditions and observed over long periods of time. Autonomic thermoregulatory responses of 
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Trpv1-/- mice showed no attenuation in our study and in studies by others [113-115], while 
Trpv1-/- mice preferred a lower Ta and were hyperactive as compared to the controls. Similar to 
how humans prefer to exercise in a cooler environment, experimental rodents select a lower Ta 
when their activity is higher. A similar adjustment accompanies the exploratory behavior of rats 
in a thermogradient apparatus when the animals are not adapted to the apparatus [107]. Having 
excluded profound deficiencies in the two major autonomic effectors directly and knowing that 
a decrease in the thermopreferendum often occurs secondarily to an increase in locomotor 
activity, we hypothesized that the increased locomotion may be one of the “primary” symptoms 
of the Trpv1-/- phenotype [65]. 
After clarifying the role of the TRPV1 channel in the thermoregulation system of mice, 
we looked at the function of the channel in systemic inflammation. We showed that 
pharmacological blockade of TRPV1 channels increased LPS-induced mortality in the young 
(Fig. 7A) [68], and discussed that similar observations have been made in adolescent (6-8 wk) 
mice and in rats treated with capsazepine [49, 116]. However, capsazepine is not a highly 
selective TRPV1 antagonist and has a low potency of blocking the proton mode of TRPV1 
activation in the rat and mouse [47]. In fact, a non-TRPV1-mediated effect of capsazepine on 
the outcome of systemic inflammation has been proposed recently [49]. Our results also agreed 
with the exaggerated symptoms of LPS-induced shock found in young mature (13-20 wk) 
Trpv1-/- mice [48]. The effect of AMG517 on LPS-induced systemic inflammation in aged mice 
was the opposite to that found in young mice, the effect on Tb was qualitatively the same. It is 
possible that the role of TRPV1 in different functions changes with age in a different way. In 
the regulation of locomotor activity [65, 117] and inflammation [68], the role of TRPV1 
reverses with age. In the modulation of Tb [118], it does not. In the regulation of body mass, 
TRPV1 channels are either uninvolved [65] or counteract obesity [114] in the young but 
promote obesity in the aged [65, 117]. 
As reviewed by others [49, 119] many treatments affect mortality in LPS-induced 
aseptic inflammation and CLP-induced sepsis in opposite ways, confirming that the systemic 
inflammatory response per se can be harmful to the host, even though it is crucial for defending 
the host against infection [35, 36]. For example, mice with a dysfunctional toll-like receptor 4 
are resistant to LPS but are highly susceptible to Gram-negative bacterial infection [120-122]. 
This susceptibility to infection can be reserved by pretreating the toll-like receptor 4-deficient 
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mice with TNF and interleukin-1α [121]. In contrast to aseptic SIRS, polymicrobial sepsis 
(induced by CLP) caused accelerated mortality in aged Trpv1-/- mice as compared with wild-
type littermates. The recovery of Trpv1-/- mice from hypothermia associated with the CLP 
procedure was delayed [68]. Overall, prior literature data obtained in young rodents 
(adolescents to mature adults) and the experiment with AMG517 in young adult mice show that 
the effects of TRPV1 blockade on both LPS-induced SIRS and antibiotic-treated sepsis vary 
from none to strong exaggeration of severity and mortality [48, 49, 116], whereas the effect of 
TRPV1 blockade on mortality in untreated sepsis is the opposite: attenuation [123]. 
Mechanisms of the age-associated reversal of the anti-inflammatory role of TRPV1 are 
unknown. Our TNF-α data suggest that the reversal occurs at initial stages of the pathogenesis 
of SIRS, at or upstream of TNF-α production [68]. The TNF-α response to LPS has been shown 
to be under suppressive control of TRPV1 channels on sensory nerves [124]. Loss of TRPV1-
mediated suppression of TNF-α production in aged animals may reflect reduced translation of 
the TRPV1 protein and its reduced transport to the periphery [125], possibly due to age-
associated decline in neurotrophic support to ganglionic neurons [126]. Changes in TNF-α 
production may be central to aging-related changes in the pathobiology of sepsis: elderly 
patients respond to infection, including septic shock, with higher TNF-α [127, 128], and 
inflammatory cytokine production in intensive-care-unit patients with sepsis is affected by 
TNF-α-related genetic polymorphisms [129].  
Since the activation of TRPV1 channels on neural endings (i.e., on capsaicin-sensitive 
afferent nerve fibers) results in the release of different inflammatory substances, also including 
SP and PACAP38, in the remaining of the present work, we also wanted to study the 
thermoregulatory effects of these substances. Our findings on the thermoregulatory response to 
PACAP clearly demonstrate that central, rather than peripheral mechanisms are involved in the 
hyperthermia-inducing effect of PACAP38 [64]. Although PACAP38-induced hyperthermia 
has been studied earlier in small rodents, based on data available from those experiments, no 
firm conclusion could be drawn about the site of the thermoregulatory action of PACAP38. To 
fill this gap, we compared the effects of central and systemic administration, and showed that 
the same or even a tenfold lower dose of PACAP38 evokes stronger hyperthermia, when given 
i.c.v. than when delivered i.v. This result unequivocally supports the central mediation 
hypothesis. The slight increase of Tc in response to peripherally infused PACAP38 could be 
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attributed to its penetration of the blood-brain barrier [130, 131]. To our knowledge, ours was 
the first report [64], in which the central and peripheral thermoregulatory responses to 
PACAP38 were compared under identical experimental conditions. 
We also studied the characteristics of the thermoregulatory response to PACAP38 and 
found that the hyperthermia started to develop promptly: already 10 min after drug 
administration, we could detect the activation of thermoeffectors and a slight increase of Tc 
(Fig. 9). This was a novel finding of the study as in all of the earlier studies investigating the 
thermal effect of PACAP38, Tb was recorded hourly and the substance was administered in a 
stressful manner, thus the developing stress-induced hyperthermia, which was also present in 
the vehicle-treated animals masked the early phase of the response. We found that PACAP38 
administration resulted in the simultaneous activation of non-shivering thermogenesis and 
cutaneous vasoconstriction (Fig. 9), which are the two principal autonomic cold-defense 
thermoeffectors [132]. The initial skin vasoconstriction seems to contradict the reported 
vasodilatory effect of PACAP38 [77, 78], but this contradiction can be resolved by considering 
that in the current study PACAP38 was delivered into the lateral ventricle of the brain, from 
where it can broadly access the POA, where neurons of the thermoeffector pathway for tail skin 
vasomotor tone are situated [83, 133]. Therefore, it is plausible that PACAP38 acted on central 
thermoregulatory elements resulting in skin vasoconstriction, but when the peptide spread to 
more distant (non-thermoregulatory) areas, it caused vasodilatory effect, which was also 
observed in our study ~40 min after PACAP38 injection (Fig. 9) [64]. 
As an alternative approach to study the role of PACAP in thermoregulation, we 
investigated deep Tb and locomotor activity of Pacap-/- mice and found that these mice were 
hyperactive throughout the day and hyperthermic during the light phase as compared to controls 
(Fig. 10A). The hyperactivity of Pacap-/- mice was also observed in an earlier study [134], 
although another group reported no alteration in the locomotor activity of the Pacap-/- mice 
compared to controls [135]. It was a novel finding in our experiments [64], that the increased 
activity of the Pacap-/- mice resulted in elevated Tb during the light phase of the day, in which 
phase locomotor activity correlates strongly with Tb [81, 136]. In contrast to our findings, in 
the study by Hashimoto et al. [137] Pacap-/- mice had lower Tb during the night than controls, 
but those experiments were conducted at a Ta of 23°C, which could be presumably below the 
TNZ of mice. Locomotor activity is widely viewed as a thermoregulatory effector in mice [65, 
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138, 139]. Our findings suggest that freely moving Pacap-/- mice utilize locomotor activity as 
a thermoeffector to maintain an elevated Tb during the light phase and normal Tb during the 
night phase of the day.  
We then asked whether the basal daytime Tb of loosely restrained Pacap-/- mice (i.e., 
those that can not use locomotion as a thermoeffector) also differs from their wild-type 
littermates. In contrast to our results in freely moving animals, when restrained, Pacap-/- mice 
were hypometabolic and had lower Tb than controls (Fig 10B) [64]. The decreased metabolic 
rate and Tb in the absence of PACAP is in harmony with our results demonstrating the 
hypermetabolic and hyperthermic effect of PACAP38 injection in rats. When we measured the 
expression of c-Fos positive cells in the POA of the mice, we found that the number of c-Fos 
positive cells in the MPO was markedly higher in Pacap-/- mice than in controls, suggesting 
that the absence of PACAP results in an increased activation of MPO neurons. Since 
GABAergic neurons in the MPO tonically suppress thermogenesis [84], we proposed that in 
Pacap-/- mice inhibitory MPO neurons are more activated and this results in an enhanced 
suppression of thermogenesis [64]. This hypothesis is also in harmony with an action of 
PACAP38 injection on GABAergic MnPO neurons, because activation of these neurons results 
in an increased suppression of the inhibitory MPO neurons, which leads to elevated metabolic 
rate and hyperthermia. Although alternate explanations are also plausible, it can be assumed 
that the absence of PACAP38 results in a lower resting metabolic rate (and Tb) and as a 
compensatory mechanism for the hypometabolism, Pacap-/- mice become hyperkinetic to 
maintain normal (or even higher) Tb. Interestingly, a similarly altered thermoeffector pattern 
(hypometabolism and hyperkinesis) was observed with the abovementioned mice lacking the 
TRPV1 channel (see above). The similar thermoregulatory consequences of the absence of 
PACAP and TRPV1 can be explained with the alteration of the same neural pathways as 
PACAP38 is released from activated capsaicin-sensitive (i.e., TRPV1-expressing) neural 
afferents into the systemic circulation [51]. 
Last, we also studied the role of SP signaling in thermoregulation [67]. We showed that 
the absence of the NK1 receptor results in the attenuation of LPS-induced fever for the first 
time by using Tacr1-/- mice (Fig. 12A, B). Our experimental model allowed us to detect the 
suppression of the febrile response already in the early phase of fever (starting from ~40 min 
post-LPS infusion), which was also a novel finding. When we looked at the molecular 
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mechanism, we did not find a difference in the PGE2-induced febrile response between Tacr1+/+ 
and Tacr1-/- mice. The LPS-induced serum cytokine production and COX-2 mRNA expression 
in the lungs, liver, and brain of the mice were also statistically indistinguishable between the 
genotypes. In contrast with mRNA, when we measured COX-2 expression at the protein level, 
we found that the LPS-induced surge was significantly attenuated in the lungs and tended to be 
suppressed in the liver of Tacr1-/- mice as compared with their Tacr1+/+ littermates. 
As discussed in details in Pakai et al. [67], the involvement of SP signaling and the NK1 
receptor in experimental fever was reported in earlier studies [59-62, 140]. Antagonists of SP 
reduced the febrile response to LPS in rats and guinea pigs from the beginning of the response, 
which was detectable 45-90 min after LPS infusion [59, 60]. However, when the authors looked 
at the mechanisms connecting the NK1 receptor with the fever signaling pathway, they focused 
on the later phases of fever (i.e., 2 h or more post-LPS infusion), presumably, because the early 
phase was absent in their experiments due to stress-hyperthermia as a consequence of stressful 
(needle-pinch) drug injection [62]. We conducted the experiments under such conditions 
(extensive habituation, moderate LPS dose, non-stressful substance administration, and near 
neutral ambient temperature) that allowed us to study LPS-induced fever from 40 to 360 min 
postinfusion in mice, thus we could detect the attenuation of the response already at 40 min in 
the absence of Tacr1 gene. 
The later phases of fever are mediated mostly by increased PGE2 production in the brain, 
and it is well established that brain-derived PGE2 is an important mediator for the maintenance 
of LPS-induced fever [141-144]. However, the early phase of fever is triggered from peripheral 
organs such as the lungs and the liver [85, 86]. Therefore, our results suggest that the genetic 
blockade of the NK1 receptor interferes with fever signaling at a peripheral site of action in the 
early phase of LPS-induced fever. We further supported the peripheral action site of NK1 
receptor in fever by showing that the Tacr1-/- mice were equally able to increase their 
thermogenesis and deep Tb in response to i.c.v. administration of PGE2, then we focused on 
exploring which step of fever signaling is altered in the Tacr1-/- mice [67]. In the periphery, SP 
signaling has been shown to play a role in the induction of pyrogenic cytokine production by 
macrophages [145] and in pulmonary macrophage activation [146]. In acute lung injury after 
burns, SP was found to upregulate COX-2 activity [147]. The expression of the NK1 receptor 
by macrophages is well documented [148-153], but it was also found in various other immune 
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cells [154]. We did not find difference in the serum levels of inflammatory cytokines (TNF-α 
and IL-6) between the LPS-treated Tacr1+/+ and Tacr1−/− mice, which indicates that the 
activation of macrophages and their cytokine production is not impaired in the absence of the 
NK1 receptor. We did not measure the levels of the third major pro-inflammatory cytokine, IL-
1β, because it has been shown that it exerts its pyrogenic actions independently from the NK1 
receptor [62]. LPS can also modulate COX-2 transcriptionally and posttranscriptionally in 
macrophages independently from inflammatory cytokines [155]. When we determined the 
COX-2 mRNA expression, we found that at this early time point (~40 min) it was greatly 
amplified in the lungs and liver, and to lesser extent in the brain of the mice [67], which results 
are in harmony with the previous findings [85]. The lack of difference between the genotypes 
indicates that transcriptional upregulation of COX-2 is not influenced by the NK1 receptor. The 
correlation of mRNA and protein levels in biological samples is often poor [156], moreover, 
the expression of COX-2 is regulated not only at the level of transcription but also at the levels 
of post-transcription and translation [155, 157, 158]. Therefore, we also determined the 
expression of the COX-2 protein in the lungs, liver, and brain of the mice [67]. In accordance 
with previous reports showing augmented expression of the COX-2 protein in the periphery 
[86], we also detected LPS-induced amplification of the COX-2 protein expression in the lungs 
and liver of Tacr1+/+ mice as compared with saline treatment, whereas we did not find 
significant increase in their brain. Importantly, however, the LPS-induced amplification of the 
expression of the COX-2 protein was attenuated in the lungs and tended to be suppressed in the 
liver of Tacr1-/- mice as compared with their Tacr1+/+ littermates. In accordance with the 
different COX-2 protein expression between the genotypes, the administration of LPS caused 
a significant surge of PGE2 concentration in the lungs of Tacr1+/+ mice, which was absent in 
the Tacr1-/- mice. The sensitive site where PGEs produce fever is located within the region of 
the brain that includes the organum vasculosum laminae terminalis and the surrounding POA 
of the hypothalamus [159]. Peripherally borne PGE2 can broadly penetrate in the perivascular 
space in the periventricular organs (such as the organum vasculosum laminae terminalis) and 
activate neurons or non-neural cells, thus trigger the febrile response [160]. It has to be noted 
that fever signaling was not examined at later time points in the current experiments due to the 
study design, and therefore it cannot be excluded that COX-2 expression and PGE2 production 
in the brain are also affected by the blockade of the NK1 receptor, especially during the 
maintenance phase of fever. In sum, our results demonstrated that at the onset of the fever 
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response the NK1 receptor contributes to the augmentation of COX-2 protein expression in 
peripheral organs, for further discussion, see Pakai et al. [67]. The exact mechanism, how SP 
signaling interacts with COX-2 expression remains to be elucidated in future studies.  
Taken together, these findings can help the better understanding of the 
pathophysiological mechanisms involved in inflammatory processes and, as a perspective, can 
serve as the bases of new prognostic and therapeutical approaches in patients with systemic 
inflammation, including sepsis. We explored ligand, receptor, and neurotransmitter 
mechanisms which play a part in the processes of systemic inflammation. By further extending 
the plethora of inflammatory mediators, these results can advance our knowledge about the 
pathophysiology of systemic inflammation, and, from a translational research point of view, 
they can open new ways for the development of diagnostic and prognostic tools as well as for 
prevention and perhaps for drug development. 
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6. Summary and conclusions 
 
1) We showed that hyperbilirubinemia in J/J Gunn rats was associated with a marked 
exaggeration of the early hypothermic response to the high dose of LPS, supposedly 
through a direct inhibition of nonshivering thermogenesis by bilirubin and possibly 
also through a direct vasodilatatory action of bilirubin in the skin. This novel, 
hypothermia-exaggerating effect might be responsible, at least in part, for the 
observed tendency of J/J rats to respond to the high dose of LPS with attenuated 
hepatic damage. Hyperbilirubinemia in Gunn rats was also associated with a deep 
attenuation of the late febrile response to the high dose of LPS, but did not attenuate 
the fever response to the low dose. The attenuation of the fever response to high 
dose of LPS could be due to either direct actions of bilirubin on thermoeffectors 
(inhibition of nonshivering thermogenesis and induction of skin vasodilation) or the 
ROS-scavenging action of bilirubin attenuating pyrogenic signaling. However, the 
experiments with the low dose strongly suggest that ROS signaling is not involved 
in the fever response to low doses of LPS [66]. 
2) We described that Trpv1 KO mice possess a distinct thermoregulatory phenotype, 
which includes hypometabolism, enhanced skin vasoconstriction, preference for a 
lower Ta, and an increased locomotor activity [65]. 
3) We showed that the anti-inflammatory role firmly established for TRPV1 channels 
in young rodents [48, 49, 116] is reversed with aging [68]. Whereas pharmacological 
or genetic TRPV1 antagonism decreases the survival rate in aseptic SIRS and in 
antibiotic-treated sepsis in the young, both types of TRPV1 antagonism have the 
opposite effect on aseptic SIRS in middle-aged mice. The age-dependent reversal of 
the anti-inflammatory role of TRPV1 to proinflammatory is likely due, at least in 
part, to a reversal of the suppressive control of TRPV1 on TNF-α production. These 
pathobiological changes are highly important, as evident from the decreased ability 
of aged Trpv1-/- mice to resist polymicrobial sepsis. These findings may influence 
the development of TRPV1 antagonists, widely viewed as new-generation 
painkillers [47, 73, 161-163]. If what we found for murine models applies to human 
sepsis, anti-TRPV1 therapy may suppress the systemic inflammatory response in 
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the previously uninfected (untreated with antibiotics) elderly and, hence, decrease 
their resistance to bacterial infection and sepsis. This potential side effect is 
especially serious, because recognition of infection is often complicated in older 
patients by a variety of factors, including the absence of fever, which often delays 
treatment [164, 165]. 
4) We showed that PACAP38 causes hyperthermia by acting on targets within the 
CNS. The PACAP38-induced hyperthermia is brought about through the 
simultaneous activation of both autonomic cold-defense effectors: elevation of non-
shivering thermogenesis and cutaneous vasoconstriction. We hypothesize that 
GABAergic neurons within the MnPO are involved in mediation of 
thermoregulatory response to PACAP38. The absence of PACAP results in 
hyperkinesis and daytime hyperthermia in freely-moving Pacap-/- mice through 
mechanisms which need to be clarified, but an involvement of TRPV1 and altered 
central biochemical processes can be suspected. The increased locomotor activity is 
presumably a compensatory mechanism for the hypometabolism and hypothermia, 
which is present under resting conditions in the absence of PACAP [64]. 
5) We showed that the NK1 receptor contributes to the early phase of LPS-induced 
fever by enhancing COX-2 protein expression in the periphery. These findings about 
the role of the NK1 receptor in LPS-induced fever further advance our 
understanding about the interactions between SP signaling and the “cytokine-COX-
2-PGE2” axis in experimental fever [67]. As a perspective, these results can help to 
identify NK1 receptor as a drug target, as recently proposed against the novel 
coronavirus (COVID-19) [166].  
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Neurokinin (NK) signaling is involved in various inflammatory processes. A common manifes-
tation of systemic inflammation is fever, which is usually induced in animal models with the 
administration of bacterial lipopolysaccharide (LPS). A role for the NK1 receptor was shown 
in LPS-induced fever, but the underlying mechanisms of how the NK1 receptor contributes 
to febrile response, especially in the early phase, have remained unknown. We administered 
LPS (120 µg/kg, intraperitoneally) to mice with the Tacr1 gene, i.e., the gene encoding the 
NK1 receptor, either present (Tacr1+/+) or absent (Tacr1−/−) and measured their thermoreg-
ulatory responses, serum cytokine levels, tissue cyclooxygenase-2 (COX-2) expression, 
and prostaglandin (PG) E2 concentration. We found that the LPS-induced febrile response 
was attenuated in Tacr1−/− compared to their Tacr1+/+ littermates starting from 40  min 
postinfusion. The febrigenic effect of intracerebroventricularly administered PGE2 was not 
suppressed in the Tacr1−/− mice. Serum concentration of pyrogenic cytokines did not differ 
between Tacr1−/− and Tacr1+/+ at 40 min post-LPS infusion. Administration of LPS resulted in 
amplification of COX-2 mRNA expression in the lungs, liver, and brain of the mice, which was 
statistically indistinguishable between the genotypes. In contrast, the LPS-induced augmen-
tation of COX-2 protein expression was attenuated in the lungs and tended to be suppressed 
in the liver of Tacr1−/− mice compared with Tacr1+/+ mice. The Tacr1+/+ mice responded to 
LPS with a significant surge of PGE  production in the lungs, whereas Tacr1−/−2  mice did not. 
In conclusion, the NK1 receptor is necessary for normal fever genesis. Our results suggest 
that the NK1 receptor contributes to the early phase of LPS-induced fever by enhancing 
COX-2 protein expression in the periphery. These findings advance the understanding of the 
crosstalk between NK signaling and the “cytokine-COX-2-prostaglandin E2” axis in systemic 
inflammation, thereby open up the possibilities for new therapeutic approaches.
Keywords: fever, thermoregulation, systemic inflammation, endotoxin, cyclooxygenase, autonomic thermoeffectors, 
substance P, Tacr1
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inTrODUcTiOn
The neurokinin-1 (NK1) receptor, formerly also known as 
substance P (SP) receptor, plays an important role in mediation 
of local and systemic inflammatory processes (1). As part of sys-
temic inflammation the most often developing thermoregulatory 
response is fever, which is commonly induced in experimental 
animals by the administration of bacterial lipopolysaccharide 
(LPS). In the development of the febrile response to LPS several 
molecular mechanisms have been already identified (2, 3). In 
brief, LPS triggers the activation of peripheral macrophages, 
which then produce inflammatory cytokines such as interleukin 
(IL)-1β, IL-6, and tumor necrosis factor (TNF)-α and induce the 
activation of the arachidonic acid cascade. Arachidonic acid is 
produced from membrane phospholipids by the action of phos-
pholipases A2 [PLA2; reviewed in Ref. (4)] and via alternative 
pathways, such as monoacylglycerol lipase-dependent hydrolysis 
(5). In the next step of febrigenesis, the cyclooxygenase-2 (COX-
2) enzyme is of crucial importance as it has been shown that selec-
tive blockade of COX-2 completely abolishes the fever response 
(6, 7). Among the end products of the cascade, prostaglandin 
(PG) E2 is synthesized by terminal PGE synthases, which can be 
microsomal and cytosolic (8). PGE2 is a key mediator, since it is 
produced in the periphery already in the early stage of fever (9) 
and because its binding to EP3 receptors in the hypothalamus 
triggers the activation of thermogenesis and cutaneous vaso-
constriction, thereby resulting in fever (10, 11). In addition to 
the aforementioned mechanisms, various further substances 
have been identified as mediators of fever, which also include SP 
signaling (3, 12).
Indicating the role of SP in fever, when the effects of SP were 
antagonized with peptide SP analogs, the fever response to LPS was 
blocked in guinea pigs (13) and in rats (14). Similar attenuation of 
the LPS-induced fever was observed in rats after administration 
of the NK1 receptor antagonists CP-96,345 (15) and SR140333B 
(16). These studies strongly support that SP signaling contributes 
to the development of LPS-induced fever, but it has remained 
largely unknown which mediators of the febrile process are influ-
enced by SP or its receptors. In all of these studies, the authors 
used antagonists, which can be problematic because of their short 
half-lives, poor brain penetration, and off-target effects (17). In 
an earlier study, SP inhibited pancreatic bicarbonate secretion 
via NK2 and NK3 receptors (18), suggesting that the effects of 
SP or its peptide analog antagonists are not solely mediated by 
NK1 receptors. In the case of the non-peptide antagonists, it was 
shown that at higher doses CP-96,345 and SR140333B also block 
L-type calcium channels (19, 20). Alternative approaches, such as 
the use of knockout mice, can help to complement the findings 
with antagonists about the contribution of the NK1 receptor to 
fever. In addition to complementing the earlier findings with 
antagonists, by using knockout mice our main goal was to better 
clarify which step(s) of the classical molecular mechanisms of 
fever are influenced by the NK1 receptor.
In the present work, we studied how genetic ablation of the 
NK1 receptor influences the LPS-induced fever response in 
mice. In thermophysiological experiments, we recorded changes 
in deep body temperature (Tb) and in the activity of autonomic 
thermoeffectors in response to LPS and PGE2. To identify the 
involved molecular mechanisms, we measured serum cytokine 
levels, as well as tissue COX-2 mRNA and protein expression, and 
PGE2 concentration in the same animal model.
MaTerials anD MeThODs
animals
The experiments were performed in 174 adult mice of both 
sexes. To minimize the possibility that gender of the mice has 
an influence on our results, male and female mice were approxi-
mately equally distributed in age-matched experimental groups. 
Of the mice, 86 had the Tacr1 gene, i.e., the gene encoding the 
NK1 receptor, homozygously present (Tacr1+/+), while 88 absent 
(Tacr1−/−) due to a targeted disruption (21). The Tacr1−/− mice 
were generated at the University of Liverpool as described in 
detail elsewhere (21). The original breeding pairs of the Tacr1−/− 
mice were donated to the University of Pecs by Dr. John Quinn 
(University of Liverpool). Their breeding and backcrossing on a 
C57BL/6 background (for at least 10 generations) were reported 
in our recent study (22). The mice were housed in standard plastic 
cages kept in a room with an ambient temperature maintained 
at 25–27°C and with a humidity of 30–40%. The room was on 
a 12 h light–dark cycle (lights on at 5:00 a.m.). Standard rodent 
chow and tap water were available ad libitum. At the time of the 
experiments, the Tacr1+/+ and Tacr1−/− mice weighed 21 ± 2 and 
19 ± 2 g, respectively.
The mice were extensively handled and then habituated to 
staying inside wire-mesh cylindrical confiners. The cylindrical 
confiner prevented the animal from turning around, but allowed 
for some back-and-forth movements; it was used in the thermo-
couple and respirometry setups (see Experimental Setups).
All procedures were conducted under protocols approved by 
Institutional Animal Use and Care Committee of the University 
of Pecs and were in accordance with the directives of the National 
Ethical Council for Animal Research and those of the European 
Communities Council (86/609/EEC).
surgeries
Mice were anesthetized with the intraperitoneal (i.p.) admin-
istration of a ketamine–xylazine cocktail (81.7 and 9.3 mg/kg, 
respectively) and received antibiotic protection intramuscularly 
(gentamycin, 6  mg/kg). During surgery, a mouse was heated 
with a temperature-controlled heating pad (model TMP-5a; 
Supertech Instruments UK Ltd., London, UK) placed under a 
surgery board. For pain management, ketoprofen (5 mg/kg) was 
administered subcutaneously at the end of surgery and on the 
next day. The experiments were performed 4–7 days after the 
surgery.
Abbreviations: COX, cyclooxygenase; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; GM-CSF, granulocyte-macrophage colony-stimulating factor; 
i.c.v., intracerebroventricular(ly); i.p., intraperitoneal(ly); IL, interleukin; LPS, 
lipopolysaccharide; NK, neurokinin; PG, prostaglandin; PKC, protein kinase C; 
PLA2, phospholipase A2 (e.g., cytosolic, cPLA2); SP, substance P; Tb, body tempera-
ture; Tsk, skin temperature; PE, polyethylene; TNF, tumor necrosis factor; VO2, rate 
of oxygen consumption.
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For i.p. catheter implantation, a small midline incision was made 
on the abdominal wall, and then a polyethylene (PE)-50 catheter 
filled with pyrogen-free saline was inserted into the peritoneal 
cavity. The internal end of the catheter was fixed to the left side of 
the abdominal wall with a suture; the free end of the catheter was 
tunneled under the skin to the nape where it was exteriorized and 
heat-sealed. The surgical wound was sutured in layers. The catheter 
was flushed with 0.1 ml of saline on the day after the surgery and 
every other day thereafter. No sign of discomfort or inflammation 
was associated with this procedure in the present study and in our 
other studies in mice (23, 24) and in rats (24, 25).
For intracerebroventricular (i.c.v.) cannula implantation, each 
mouse was fixed to a stereotaxic apparatus similarly as in our 
earlier study (26). The scalp was incised over the sagittal suture; 
the periosteum was excised; the skull was cleaned and dried; two 
supporting microscrews were driven into the skull; and a small 
hole was drilled in the skull 0.5 mm posterior from bregma and 
1.0 mm lateral from midline. A 22-G steel guide cannula (Plastics 
One, Roanoke, VA, USA) was attached to a plastic tube fitted 
into a stereotaxic manipulator (Narishige Scientific Instruments 
Laboratory, Tokyo, Japan), which was used to insert the cannula 
into the brain through the bone hole. The tip of the cannula was 
placed within the right lateral ventricle (2.0 mm from dura). The 
cannula was secured to the supporting microscrews with dental 
cement and released from the manipulator. The guide cannula 
was closed by a dummy cannula.
experimental setups
The thermophysiological experiments were performed in the 
thermocouple or in the respirometry setup.
In the thermocouple setup, the mouse was placed in a cylin-
drical confiner and equipped with copper-constantan thermo-
couples (Omega Engineering, Stamford, CT, USA) to measure 
colonic temperature (a form of deep Tb) and tail skin temperature 
(Tsk). The colonic thermocouple was inserted 3 cm deep beyond 
the anal sphincter and was fixed to the base of the tail with a 
loop of adhesive tape. The skin thermocouple was positioned on 
the lateral surface of tail at the border between the proximal and 
middle third of the tail and secured in place with tape. The ther-
mocouples were plugged into a data logger device (Cole-Palmer, 
Vernon Hills, IL, USA) connected to a computer. Mice in their 
confiners were then placed into a temperature-controlled incuba-
tor (model MIDI F230S; PL Maschine Ltd., Tarnok, Hungary) 
set to an ambient temperature of 31°C, which is at the lower end 
of the thermoneutral zone for mice in this setup. When present, 
the i.p. catheter was connected to a PE-50 extension filled with 
the drug of interest. When the mouse had an i.c.v. cannula, a 
needle injector was fitted into the guide cannula and connected 
to a PE-50 extension. The extension was passed through a port 
of the chamber and connected to a syringe. In a separate set of 
experiments, the mice were exposed to heat or cold by applying 
similar protocols as in our earlier studies (26, 27). The mice in 
their confiners were placed into a biochemistry incubator (model 
BJPX-Newark; Biobase, Jinan, China) initially set to an ambient 
temperature of 33°C, which was then either raised to 39°C or 
decreased to 15°C over ~30 min and maintained at 39 or 15°C to 
expose the mice to heat or cold, respectively.
A mouse designated for an experiment in the respirometry 
setup was equipped with thermocouples and placed in a con-
finer as in experiments in the thermocouple setup. Then, the 
mouse in its confiner was transferred to a Plexiglas chamber 
of the four-chamber open-circuit calorimeter integrated system 
(Oxymax Equal Flow, Columbus Instruments), as in our earlier 
studies (25, 27). The chamber was sealed, submerged into a 
temperature-controlled (31°C) water bath, and continuously 
ventilated with room air (200 ml/min). The fractional concen-
tration of oxygen was measured in the air entering and exiting 
the chamber, and the rate of oxygen consumption (VO2) was 
calculated according to the manufacturer’s instructions using 
the Oxymax Windows software (version 3.1). The extension of 
the i.p. catheter or the i.c.v. needle injector was passed through 
a port of the chamber and connected to a syringe, which was 
placed in a syringe pump (model 975; Harvard Apparatus Inc., 
Holliston, MA, USA).
substance administration
Lipopolysaccharide from Escherichia coli 0111:B4 was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). A stock suspension 
of LPS (5  mg/ml) in pyrogen-free saline was stored at −20°C. 
On the day of the experiment, the stock was diluted to a final 
concentration of 36 µg/ml. The diluted LPS suspension or saline 
was infused (26 µl/min for 4 min) through the extension of the i.p. 
catheter to deliver LPS at a final dose of 120 µg/kg. Deep Tb, tail 
Tsk, and VO2 were monitored for 6 h after the injection.
Substance P and PGE2 were purchased from Tocris Bioscience 
(Bristol, UK). Aliquots of ethanolic stock solutions of SP and 
PGE2 (10 and 12.5  mg/ml, respectively) were stored at −80°C. 
On the day of the experiment, the stock solutions were diluted 
with ethanol and saline to give working solutions of SP and PGE2 
(1,000 and 33 µg/ml, respectively) in 10% ethanol. By infusing 
these solutions into the lateral ventricle (1 µl/min for 3 min), a 
total dose of either 100 µg/kg SP or 3.3 µg/kg PGE2 was delivered 
i.c.v. Control mice were infused with the vehicle (10% ethanol in 
saline). For the infusion, the dummy injector was removed from 
the preimplanted guide cannula and replaced with a 28-G injector 
needle (Plastics One) connected to a 10-µl Hamilton syringe by a 
PE-50 extension. The injector needle protruded 1.0 mm beyond 
the tip of the guide cannula.
Administration of the substances was carried out between 
10:30 a.m. and 12:00 p.m. in the experiments.
Molecular Biology
Tissue Harvesting
Each mouse was implanted with an i.p. catheter and extensively 
adapted to the experimental setup. On the day of experiment, 
each mouse was placed in a confiner and transferred to an 
incubator chamber, which was set to an ambient temperature 
of 31°C. The i.p. catheter was connected to a PE-50 extension 
filled with LPS or saline. The extension was passed through a port 
of the chamber and connected to a syringe, which was placed 
in a syringe pump (Harvard Apparatus Inc.). Mice were left to 
acclimate for ~2 h and then infused with LPS or saline as in the 
thermophysiological experiments. Forty minutes after infusion, 
the mice were anesthetized with ketamine–xylazine cocktail, 
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which was injected through the extension of the i.p. catheter. 
Blood samples were collected from the left ventricle. Each sample 
was transferred to an ice-cold Eppendorf tube containing EDTA 
(40 µl) and trasylol (20 µl). The collected blood was immediately 
centrifuged at 1,000 rpm for 5 min, then at 4,000 rpm for 10 min, 
and the resulting plasma was stored at −80°C. For collection of 
lung, liver, and brain tissue samples for RT-qPCR, Western blot, 
and immunoassay protocols, each mouse was perfused through 
the left ventricle with 0.1 M phosphate-buffered saline. Samples of 
the liver and the right lung were collected rapidly and snap frozen 
in liquid nitrogen. The anesthetized mouse was decapitated, its 
entire brain was removed and frozen. All tissue samples were 
stored at −80°C.
Immunoassays
The serum level of TNF-α was determined with enzyme-linked 
immunosorbent assay (ELISA) by using a commercially avail-
able mouse TNF ELISA kit (BD OptEIA catalog nr: 560478; BD 
Biosciences, San Jose, CA, USA), which had a detection limit of 
31 pg/ml for TNF-α. PGE2 concentrations in the lungs, liver, and 
brain were measured by ELISA using a commercially available kit 
(catalog nr: 514010; Cayman Chemical, Ann Arbor, MI, USA); 
the samples were prepared according to the manufacturer’s 
instructions. The assay had a sensitivity of 15  pg/ml for PGE2. 
Detections were performed by using the Labsystem Multiskan 
RC plate reader (Thermo Scientific, Waltham, MA, USA), as in 
our earlier study (22).
Serum concentrations of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-6 were determined by 
Luminex’s xMAP® Technology using a multiplex bead immuno-
assay kit (catalog nr: LMC0003; Invitrogen, Carlsbad, CA, USA). 
After thawing, serum samples were centrifuged (1,000  g for 
10 min) to prevent clogging of the filter plate. The measurement 
was performed according to the manufacturer’s instructions. 
Following previous optimizations, all samples were tested undi-
luted in a blind fashion. Luminex 100 (Luminex Corporation, 
Austin, TX, USA) was used for the immunoassay and Luminex 
100 IS software to analyze the bead median fluorescence intensity, 
as in our recent study (28). All the tests were run in duplicate. 
50 µl of each sample or standard solution was added to a 96-well 
filter plate (provided with the kit) containing 25 µl of antibody-
coated fluorescent beads. Biotinylated secondary antibodies and 
streptavidin-PE were added to the samples with alternate incuba-
tion and washing steps. After the last washing, 100 µl of working 
wash solution was added to the wells. The plate was read on the 
Luminex 100 array reader. The detection limits for IL-6 and 
GM-CSF with this method were 29 and 18 pg/ml, respectively. 
Data were analyzed with the MasterPlex 2.0 software, using a 
five-PL regression curve to plot the standard curve.
RNA Isolation, RT-qPCR
As in previous studies by our group (28, 29), total RNA was 
prepared using the TRI Reagent (Molecular Research Center, 
Inc., Cincinnati, OH, USA) and Direct-Zol™ RNA isolation 
kit (Zymo Research, Irvine, CA, USA) following the manufac-
turer’s instructions. Then, the samples were treated with DNase 
I (Zymo Research, Irvine, CA, USA) to remove contaminating 
genomic DNA and quantified with a NanoDrop ND-2000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). One microgram of total RNA was reverse transcribed 
with a Maxima™ First Strand cDNA Synthesis Kit for RT-qPCR 
(Thermo Scientific). Reactions were performed on Stratagene 
Mx3000P QPCR System (Agilent Technologies, Santa Clara, 
CA, USA), using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the reference gene. GAPDH was chosen because of 
its stable expression and because it was successfully used in earlier 
studies to measure relative COX-2 mRNA expression in LPS-
induced fever (30–32). Each reaction contained 2  µl of cDNA, 
10  µl Luminaris Color HiGreen Low ROX qPCR Master Mix 
(Thermo Scientific), 0.3 µM of each primer (10 µM), and 6.8 µl 
of water. The following primer pairs were used to amplify the 
target loci: GAPDH sense: 5'-TTCACCACCATGGAGAAG-3' 
and antisense: 5'-GGCATGGACTGTGGTCATGA-3'. COX-2 
sense: 5'-GGGTTGCTGGGGGAAGAAA-3' and antisense: 5'- 
CTCTGCTCTGGTCAATGGAGG-3'. Amplification was carried 
out under the following conditions: 95°C for 10 min, followed by 
40 cycles of 95°C for 30 s, 60°C for 45 s, and 72°C for 45 s. All 
RT-PCR reactions were carried out in triplicate and included a 
melt curve analysis to ensure specificity of signal. Relative expres-
sion ratios were calculated using MxPro QPCR Software (Agilent 
Technologies) with the ΔΔCt method, using samples of untreated 
animals, as a control. Primer efficiencies were taken into account 
when calculating gene expression ratios (33).
Western Blot
Western blot procedures were carried out according to the 
protocols used in our recent study (34). Lung, liver, and brain 
tissue samples (~50 mg) were homogenized in ice-cold Tris buffer 
(50 mM, pH 8.0), containing protease inhibitor cocktail (1:100) 
and 50 mM of sodium vanadate (Sigma-Aldrich).
Brain samples required additional preparation procedures. To 
each brain sample, 625 µl of a methanol:chloroform (2:1) mixture 
was added, and the samples were incubated for 10 min at room 
temperature with slight agitation. Then, without inhibitors an 
equal volume (208 µl) of chloroform and Tris buffer (50 mM) was 
added to each brain sample, and the samples were centrifuged 
for 10  min (13,000  rpm, room temperature). The supernatants 
were removed from the protein disks into a new Eppendorf tube, 
and the bottom layer (containing chloroform) was discarded. 
Then, the supernatants and protein disks were sonicated on ice 
twice for 3  s. Trichloroacetic acid was added to the samples at 
a final concentration of 5% followed by incubation on ice for 
10  min. The precipitates were pelleted by centrifugation for 
10 min (13,000 rpm, room temperature). The supernatants were 
discarded, and the pellets were redissolved in Tris buffer (70 mM, 
pH 8.0). The sonication was repeated as described earlier.
Then, the lung, liver, and prepared brain samples were processed 
similarly. To each sample, 2× concentrated sodium dodecyl sul-
fate (SDS)-polyacrylamide gel electrophoresis sample buffer was 
added. Proteins were separated on 10% SDS-polyacrylamide gel 
and transferred to nitrocellulose membranes. After blocking (1 h 
with 2% non-fat milk in Tris-buffered saline), membranes were 
probed overnight at 4°C with primary antibodies (1:1,000) bind-
ing to the 75-kDa COX-2 protein (catalog nr: ab15191; Abcam 
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Plc., Cambridge, UK). Based on the previous studies measuring 
LPS-induced COX-2 protein expression with Western blot (30, 
35, 36), we used GAPDH as the loading reference. Membranes 
were washed six times for 5 min in Tris-buffered saline, contain-
ing 0.1% Tween before addition of goat anti-rabbit horseradish 
peroxidase-conjugated secondary antibody (1:3,000 dilution; 
Bio-Rad, Budapest, Hungary). Membranes were washed again as 
before, and the antibody–antigen complexes were visualized by 
enhanced chemiluminescence. After scanning, the results were 
quantified by using ImageJ software (NIH, Bethesda, MD, USA).
Data Processing and analysis
Data on deep Tb, tail Tsk, and VO2 were compared by three-way 
ANOVA, while for comparison of serum cytokine levels, COX-2 
expression, and PGE2 concentrations two-way ANOVA was used. 
As in our previous studies (25, 26), ANOVA was followed by the 
Fisher least significant difference post  hoc test. For statistical 
analysis, Sigmaplot 11.0 (Systat Software, San Jose, CA, USA) 
software was used. The effects were considered significant when 
P < 0.05. All data are reported as mean ± SE.
resUlTs
Thermoregulatory Phenotype of Tacr1+/+ 
and Tacr1−/− Mice
The basal deep Tb of the mice was nearly identical regardless of 
either gender or genotype in the thermocouple setup throughout 
the time period when substance administrations were performed 
in the fever experiments (Figure S1 in Supplementary Material).
To evaluate whether Tacr1−/− mice can appropriately activate 
warmth- and cold-defense mechanisms, we studied the ther-
moregulatory response of these mice to ambient heating and 
cooling, respectively. To reveal even a small deficiency in heat 
defenses, we used a severe heat exposure model that results in 
~6°C rise in deep Tb. When exposed to heat, the mice of both 
genotypes (Tacr1+/+ and Tacr1−/−) responded with rapid, near-
maximal tail skin vasodilation with Tsk approaching 41°C (Figure 
S2A in Supplementary Material). Neither the Tsk response nor the 
Tb response differed between the genotypes. Hence, Tacr1−/− mice 
are fully capable of increasing heat loss through their tails and 
defending their deep Tb against heat.
To reveal even a small deficiency in cold defenses, we used a 
severe cold exposure model that results in a pronounced drop in 
deep Tb. When exposed to cold in this model, the mice of both 
genotypes responded with tail skin vasoconstriction (a decrease 
in Tsk), but even so their Tb decreased by ~6°C (Figure S2B in 
Supplementary Material). The response dynamics did not dif-
fer between the two genotypes. Hence, the thermoregulatory 
response of Tacr1−/− mice to cooling is unaltered.
characteristics of the Thermoregulatory 
response of Tacr1+/+ and Tacr1−/− Mice to 
lPs
In thermophysiological experiments, we compared the fever 
response between Tacr1+/+ and Tacr1−/− mice. When treated with 
LPS (120 µg/kg, i.p.), the mice of both genotypes developed fever 
as compared to saline-treated mice (Figures  1A,B). However, 
the effects of both the treatment ×  time interaction [ANOVA, 
F(42,1376) = 2.114, P < 0.001] and treatment ×  genotype interac-
tion [F(1,1376)  =  40.908, P  <  0.001] were significant on their 
Tb response. LPS-treated Tacr1+/+ mice responded with a 
typical fever response: their deep Tb started to increase at 
20  min, plateaued (~38.5°C) between 40 and 100  min, then it 
gradually decreased, but remained elevated compared to saline 
treatment throughout the experiment (Fisher LSD test, P < 0.05 
at 30–360 min). These findings are in line with those reported 
previously (37). In Tacr1−/− mice, the LPS-induced fever response 
was less pronounced than in Tacr1+/+ mice, reaching the level of 
significance at 40–110 min compared to saline treatment (Fisher 
LSD test, P <  0.05) (Figure  1A). The LPS-induced increase in 
deep Tb was brought about by an elevation of VO2, changing 
with parallel dynamics as Tb in both genotypes (Figures 1A,B). 
Similar to Tb, the effects of both the treatment × time interaction 
[ANOVA, F(42,1161) = 1.618, P < 0.01] and treatment × genotype 
interaction [F(1,1161) = 15.802, P < 0.001] were significant on the 
VO2 of the mice. After LPS treatment, the VO2 was significantly 
higher compared to saline at 40–350 min in Tacr1+/+ mice (Fisher 
LSD test, P < 0.05) and at 40–140 min in Tacr1−/− mice (Fisher 
LSD test, P < 0.05). Since the experiments were carried out at the 
lower end of the thermoneutral zone, the mice exhibited cutane-
ous vasoconstriction (as indicated by their low tail Tsk), thus no 
further decrease in tail Tsk was observed. Importantly, the Tb of 
the LPS-treated Tacr1−/− mice was markedly (0.5–0.7°C) lower 
than that of Tacr1+/+ mice starting from 40 min post-LPS infusion 
until the end of the experiment. Parallel with Tb, the LPS-induced 
elevation of VO2 was also suppressed in Tacr1−/− mice compared 
to their Tacr1+/+ littermates (Figure  1A). The LPS-induced 
elevation of both parameters was significantly attenuated in 
Tacr1−/− mice compared to Tacr1+/+ mice at 40–120 min (Fisher 
LSD test, P < 0.05 for intergenotype difference) (Figure 1A). The 
infusion of saline did not cause any effect on deep Tb, tail Tsk, 
and VO2 in the mice of either genotype (Figure 1B). Our results 
demonstrate that LPS-induced fever is attenuated in Tacr1−/− mice 
already in the early stage (i.e., starting from ~40 min). Next, we 
wanted to know the suppression of which part of the “pyrogenic 
cytokine-COX-2-PGE2 axis” is responsible for attenuating the 
fever response in the absence of Tacr1.
The Thermoregulatory effects of Pge2 and 
sP in Tacr1+/+ and Tacr1−/− Mice
First, we studied whether the effect of PGE2, i.e., the key mediator 
of fever (2), is also reduced in the Tacr1−/− mice. As the main site of 
the febrigenic action of PGE2 is situated in the preoptic area of 
the hypothalamus (10), we compared the thermoregulatory 
effects of i.c.v. injected PGE2 between Tacr1+/+ and Tacr1−/− 
mice. In response to PGE2 the mice of both genotypes rapidly 
developed a marked elevation in deep Tb and VO2 (Figure 2A), 
while administration of the vehicle did not cause any effects in 
either genotype (Figure 2B). The effect of the treatment × time 
interaction was significant with regard to both Tb and VO2 
[ANOVA, F(18,380)  =  29.406, P  <  0.001 and F(18,380)  =  11.922, 
P < 0.001, respectively], whereas the effects of the genotype or the 
FigUre 1 | Thermoeffector and colonic temperature responses of Tacr1+/+ and Tacr1−/− mice to lipopolysaccharide (LPS) (a) or saline (B) administered 
intraperitoneally (i.p.). The changes in colonic temperature [a form of deep body temperature (Tb)] are shown in the upper panel; alterations in the activity of the two 
main autonomic thermoeffectors, skin temperature (Tsk) and rate of oxygen consumption (VO2) are depicted in the middle and lower panels, respectively. These 
experiments were performed in the respirometry setup at an ambient temperature of 31°C. Number of animals in the corresponding groups are indicated in the figure. 
*P < 0.05, intergenotype difference in the response to LPS. #P < 0.05, LPS vs. saline difference within the same genotype as determined by the Fisher LSD test.
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treatment × genotype interaction were not significant on either 
deep Tb or VO2. Of note, there was no attenuation in either the 
Tb or VO2 rise in the Tacr1−/− mice compared to their Tacr1+/+ 
littermates. These experiments were conducted under identical 
conditions as those with LPS, including the ambient temperature 
(31°C) near the lower end of the thermoneutral zone, which can 
explain why we did not observe any change in the tail Tsk in the 
mice of either genotype. Our results with PGE2 rule out the possi-
bility that Tacr1−/− mice are unable to activate their thermogenesis 
and increase their Tb to stimuli other than LPS. More importantly, 
the lack of attenuation in the PGE2-induced thermoregulatory 
response of the Tacr1−/− mice suggests that their reduced fever 
response to LPS is due to a more upstream suppression in the 
febrigenic molecular pathway.
In a separate set of experiments, we confirmed the absence 
or presence of functional NK1 receptors in the Tacr1−/− and 
Tacr1+/+ mice, respectively. It has been repeatedly shown that 
SP evokes an increase in deep Tb by acting on the NK1 receptor 
(15, 16), therefore, we injected SP (100 µg/kg, i.c.v.) or its vehicle 
to Tacr1+/+ and Tacr1−/− mice and compared their Tb responses 
(Figures  2C,D). We found that the SP-induced increase in 
deep Tb was practically absent in Tacr1−/− mice, whereas it was 
significant in Tacr1+/+ mice at 20–60 min compared to vehicle 
treatment (Fisher LSD test, P  <  0.05) (Figures  2C,D). The 
effects of both the genotype [ANOVA, F(1,260) = 10.538, P < 0.01] 
and the treatment  ×  genotype interaction [F(1,260)  =  13.233, 
P < 0.001] were significant. In the SP-treated mice, there was 
a significant difference between the Tb of Tacr1+/+ and Tacr1−/− 
mice at 10–40 min (Fisher LSD test, P < 0.05), which confirms 
the validity of this animal model.
lPs-induced changes in serum cytokine 
levels of Tacr1+/+ and Tacr1−/− Mice
One of the early steps in LPS-induced fever signaling is the activa-
tion of innate immune cells, including macrophages, leukocytes, 
and dendritic cells, which, in turn leads to augmented production 
of inflammatory cytokines, including TNF-α and IL-6 (3). Thus, 
in our next experiments we measured serum concentrations 
of TNF-α and IL-6 in the Tacr1+/+ and Tacr1−/− mice to assess 
FigUre 2 | The thermoregulatory response of Tacr1+/+ and Tacr1−/− mice to prostaglandin (PG) E2 and substance P (SP) administered intracerebroventricularly 
(i.c.v.). Changes in colonic temperature (upper panel), skin temperature (Tsk) (middle panel), and rate of oxygen consumption (VO2) (bottom panel) in response to 
PGE2 (dose indicated) (a) and its vehicle (B) in Tacr1+/+ and Tacr1−/− mice. The experimental conditions were identical to those described in Figure 1 (respirometry 
setup, ambient temperature of 31°C). At the time of the injection, the values of colonic temperature of the Tacr1+/+ and Tacr1−/− mice were, respectively, 37.0 ± 0.2 
and 37.1 ± 0.1°C for PGE2-treated mice and 36.8 ± 0.3 and 36.9 ± 0.2°C for vehicle-treated mice. These values did not differ statistically from each other. Changes 
in colonic temperature and Tsk in response to SP (dose indicated) (c) and its vehicle (D) in Tacr1+/+ and Tacr1−/− mice. These experiments were performed in the 
thermocouple setup at an ambient temperature of 33°C. At the time of the injection, the values of colonic temperature of the Tacr1+/+ and Tacr1−/− mice were, 
respectively, 37.2 ± 0.2 and 37.1 ± 0.2°C for SP-treated mice and 37.3 ± 0.3 and 37.3 ± 0.1°C for vehicle-treated mice. These values did not differ statistically from 
each other. Number of animals in the corresponding groups are indicated in the figure. *P < 0.05, intergenotype difference in the response to SP. #P < 0.05, 
treatment (PGE2 or SP) vs. vehicle difference within the same genotype as determined by the Fisher LSD test.
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whether the LPS-induced cytokine production is suppressed in the 
absence of the NK1 receptor. The serum concentrations of TNF-α 
and IL-6 did not differ between the genotypes after the infusion 
of saline (Figures 3A,B). The administration of LPS resulted in 
a substantial upsurge of TNF-α (Fisher LSD test, P < 0.001 vs. 
saline for both genotypes) (Figure  3A) and IL-6 (P <  0.01 for 
Tacr1+/+ mice and P <  0.001 for Tacr1−/− mice) (Figure  3B). 
Importantly, we did not detect any significant difference in the 
FigUre 3 | Serum cytokine concentrations in Tacr1+/+ and Tacr1−/− mice.  
(a) Serum tumor necrosis factor (TNF)-α concentrations in Tacr1+/+ and 
Tacr1−/− mice in response to lipopolysaccharide (LPS) (dose indicated) or 
saline. (B) Serum IL-6 concentrations in Tacr1+/+ and Tacr1−/− mice in 
response to LPS (dose indicated) or saline. (c) Serum granulocyte-
macrophage colony-stimulating factor (GM-CSF) concentrations in Tacr1+/+ 
and Tacr1−/− mice in response to LPS (dose indicated) or saline. Blood 
samples were collected at 40 min postinfusion. Number of animals in the 
corresponding groups are indicated in the figure. Within each genotype, 
significant differences in the response to LPS (as compared to saline) are 
marked as ##P < 0.01 or ###P < 0.001 as determined by the Fisher LSD test.
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FigUre 3 | Continued
TNF-α and IL-6 concentrations between Tacr1+/+ and Tacr1−/− 
mice (Figures 3A,B).
It was shown that LPS can induce the secretion of GM-CSF 
in mice, which, in turn, can stimulate the production of inflam-
matory cytokines, such as TNF-α (38). We wanted to know 
whether changes in serum GM-CSF concentration can play a 
role in the attenuated fever response of the Tacr1−/− mice to LPS. 
In our experimental model, we did not find any difference in 
the serum concentrations of GM-CSF between LPS-treated and 
saline-treated mice of either genotype (Figure 3C). The absence 
of a surge in GM-CSF concentration in response to LPS could be 
due to the early time point (40 min post-LPS infusion) chosen for 
blood collection in our experiments.
These data indicate that impaired pyrogenic cytokine pro-
duction does not contribute to the attenuated fever response of 
Tacr1−/− mice to LPS.
lPs-induced changes in cOX-2 
expression in Tacr1+/+ and Tacr1−/− Mice
Changes in COX-2 mRNA Expression in the Lungs, 
Liver, and Brain of Tacr1+/+ and Tacr1−/− Mice
We moved downstream in the fever signaling pathway and 
compared the LPS-induced expression of COX-2 between 
Tacr1+/+ and Tacr1−/− mice. At the mRNA level, COX-2 expres-
sion is upregulated in rats already in the early phase of the febrile 
response (~30–40  min after LPS infusion) both in peripheral 
organs (lungs and liver) and to a lesser extent in the brain (31). 
In the present study, our experiments with LPS revealed that the 
fever response of Tacr1−/− mice was attenuated already at ~40 min 
post-LPS infusion (Figure 1A), and therefore, we collected lung, 
liver, and brain samples at this time point and studied the COX-2 
mRNA expression in these tissues. As compared with the values 
of expression in saline-treated mice, the administration of LPS 
caused transcriptional upregulation of COX-2 mRNA in the lungs 
(Figure 4A), in the liver (Figure 4B), and in the brain (Figure 4C) 
of Tacr1+/+ and Tacr1−/− mice (Fisher LSD test, P < 0.001 vs. saline 
for all three tissues). There was no significant difference between 
the genotypes in any of the three tissue samples. The magnitude 
of the LPS-induced increase in the level of COX-2 expression was 
not the same in the three organs studied: ~5-fold in the lungs, 
17–20-fold in the liver, and 2-fold in the brain (Figures 4A–C). 
These results are well in accordance with earlier findings on the 
dynamics of LPS-induced COX-2 mRNA expression (31), but 
cannot explain the attenuation of the febrile response in the 
Tacr1−/− mice.
FigUre 4 | Relative cyclooxygenase-2 (COX-2) gene expression in the 
lungs (a), liver (B), and in the brain (c) of Tacr1+/+ and Tacr1−/− mice 
after infusion of lipopolysaccharide (LPS) (dose indicated) or saline. 
Tissue samples were collected at 40 min postinfusion. Number of 
animals in the corresponding groups are indicated in the figure. Within 
each genotype, significant differences in the response to LPS (as 
compared to saline) are marked as ###P < 0.001 as determined by the 
Fisher LSD test.
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FigUre 4 | Continued
Changes in COX-2 Protein Expression in the Lungs, 
Liver, and Brain of Tacr1+/+ and Tacr1−/− Mice
Besides the LPS-induced amplified expression of COX-2 
mRNA, the expression of the COX-2 protein was also found 
to increase in the periphery (but not in the brain) already in 
the early phase of the febrile response (9). Therefore, we also 
compared the COX-2 protein expression between LPS-treated 
Tacr1+/+ and Tacr1−/− mice (Figure 5). In the lungs, the effects 
of both the treatment [ANOVA, F(1,26) = 6.165, P < 0.05] and 
genotype [F(1,26) = 8.532, P < 0.01] were significant (Figure 5A). 
In the liver, the effect of treatment was also significant [ANOVA, 
F(1,28) =  6.555, P <  0.05] (Figure  5B), whereas no significant 
change was found in the brain (Figure 5C). In Tacr1+/+ mice, the 
administration of LPS resulted in a marked increase in COX-2 
protein expression in the lungs (Fisher LSD test, P < 0.01 vs. 
saline) and in the liver (Fisher LSD test, P < 0.05), but not in the 
brain (Fisher LSD test, P = 0.264). In contrast with the Tacr1+/+ 
mice, the COX-2 protein expression did not change significantly 
in either the lungs or the liver of LPS-treated Tacr1−/− mice as 
compared to saline treatment. In LPS-treated mice, the COX-2 
protein expression was attenuated in the lungs of Tacr1−/− mice 
compared with their Tacr1+/+ littermates (Fisher LSD test, 
P < 0.01), while in the liver there was a tendency for reduced 
COX-2 expression in the LPS-treated Tacr1−/− mice (Fisher 
LSD test, P = 0.101). These findings indicate that the absence of 
the NK1 receptor interferes with the augmentation of COX-2 
expression at the protein level.
changes in Pge2 concentration in the 
lungs, liver, and Brain of Tacr1+/+ and 
Tacr1−/− Mice
To assess whether the attenuated expression of COX-2 protein 
results in reduced production of PGE2 in the LPS-treated Tacr1−/− 
mice, we measured PGE2 concentrations in the lungs, liver, and 
brain of the mice. We found that the LPS treatment resulted in 
the biggest (~80%) increase in PGE2 concentration in the lungs 
(Figure 6A), followed by the liver (~40%) (Figure 6B), and then 
by the brain (~10%) (Figure  6C). The effect of treatment was 
significant in the lungs [ANOVA, F(1,15) = 7.065, P < 0.05], but 
not in the other two organs. Post hoc analysis revealed that the 
LPS-induced increase in PGE2 concentration was significant in 
the lungs of Tacr1+/+ mice compared with saline (Fisher LSD test, 
P < 0.05), whereas in the lungs of Tacr1−/− mice the PGE2 level 
did not increase significantly in response to LPS (Fisher LSD test, 
P = 0.275 vs. saline). These results suggest that in the lungs of 
Tacr1−/− mice the LPS-induced surge in PGE2 concentration is 
reduced.
FigUre 5 | Relative cyclooxygenase-2 (COX-2) protein expression in the 
lungs (a), liver (B), and in the brain (c) of Tacr1+/+ and Tacr1−/− mice after 
infusion of lipopolysaccharide (LPS) (dose indicated) or saline. Tissue 
samples were collected at 40 min postinfusion. Number of animals in the 
corresponding groups are indicated in the figure. **P < 0.01, intergenotype 
difference in the response to LPS; #P < 0.05 or ##P < 0.01, LPS vs. saline 
difference within the same genotype as determined by the Fisher LSD test.
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DiscUssiOn
In our study, we showed that the absence of the NK1 receptor 
results in the attenuation of LPS-induced fever for the first time by 
using Tacr1−/− mice. Our experimental model allowed us to detect 
the suppression of the febrile response already in the early phase 
of fever (starting from ~40 min post-LPS infusion), which is also 
a novel finding. When we looked at the molecular mechanism, 
we did not find a difference in the PGE2-induced febrile response 
between Tacr1+/+ and Tacr1−/− mice. The LPS-induced serum 
cytokine production and COX-2 mRNA expression in the lungs, 
liver, and brain of the mice were also statistically indistinguish-
able between the genotypes. In contrast with mRNA, when we 
measured COX-2 expression at the protein level, we found that 
the LPS-induced surge was significantly attenuated in the lungs 
and tended to be suppressed in the liver of Tacr1−/− mice as com-
pared with their Tacr1+/+ littermates.
The involvement of SP signaling and the NK1 receptor in 
experimental fever was reported in earlier studies (13–16, 39). 
Antagonists of SP reduced the febrile response to LPS in rats 
and guinea pigs from the beginning of the response, which was 
detectable 45–90 min after LPS infusion (13, 14). However, when 
the authors looked at the mechanisms connecting the NK1 recep-
tor with the fever signaling pathway, they focused on the later 
phases of fever (i.e., 2 h or more post-LPS infusion), presumably, 
because the early phase was absent in their experiments due 
to stress–hyperthermia as a consequence of stressful (needle-
pinch) drug injection (16). In the present study, we conducted 
the experiments under such conditions (extensive habituation, 
moderate LPS dose, non-stressful substance administration, and 
near neutral ambient temperature) that allowed us to study LPS-
induced fever from 40 to 360 min postinfusion in mice, thus we 
could detect the attenuation of the response already at 40 min in 
the absence of Tacr1 gene. A caveat in knockout mouse models 
is that compensatory mechanisms may develop. With regard to 
alteration of other NK receptors in mice genetically lacking the 
NK1 receptor, it was shown with RT-PCR and immunostain-
ing that the expression of NK3 receptors was unchanged in the 
retina of Tacr1−/− mice as compared with Tacr1+/+ mice (40). 
However, in a mouse model of meningoencephalitis, the effects 
of combined treatment with NK2 and NK3 receptor antagonists 
were reduced on the neuroinflammatory scores in Tacr1−/− mice 
compared with similarly treated Tacr1+/+ mice (41). It was con-
cluded that in the genetic absence of NK1 receptors, tachykinins 
may utilize NK2 and NK3 receptors (41), although expression of 
the NK receptors was not measured. Taken together, in Tacr1−/− 
mice the expression of other NK receptors is presumably 
unchanged, but there might be an alteration in the utilization of 
NK2 and NK3 receptor-mediated mechanisms, which warrants 
FigUre 5 | Continued
FigUre 6 | Prostaglandin (PG) E2 concentration in the lungs (a), liver  
(B), and in the brain (c) of Tacr1+/+ and Tacr1−/− mice after infusion of 
lipopolysaccharide (LPS) (dose indicated) or saline. Tissue samples were 
collected at 40 min postinfusion. Number of animals in the corresponding 
groups are indicated in the figure. #P < 0.05, LPS vs. saline difference within 
the same genotype as determined by the Fisher LSD test.
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for further characterization of the tachykinin pathways in this 
mouse model.
The later phases of fever are mediated mostly by increased 
PGE2 production in the brain, and it is well established that brain-
derived PGE2 is an important mediator for the maintenance of 
LPS-induced fever (32, 42–44). However, the early phase of fever 
is triggered from peripheral organs such as the lungs and the liver 
(9, 31). Therefore, our results suggest that the genetic blockade of 
the NK1 receptor interferes with fever signaling at a peripheral 
site of action in the early phase of LPS-induced fever. We further 
supported the peripheral action site of NK1 receptor in fever by 
showing that the Tacr1−/− mice were equally able to increase their 
thermogenesis and deep Tb in response to i.c.v. administration 
of PGE2. We focused the second part of our study on exploring 
which step of fever signaling is altered in the Tacr1−/− mice. In 
the periphery, SP signaling has been shown to play a role in the 
induction of pyrogenic cytokine production by macrophages 
(45) and in pulmonary macrophage activation (46). In acute lung 
injury after burns, SP was found to upregulate COX-2 activity 
(47). The expression of the NK1 receptor by macrophages is 
well documented (48–53), but it was also found in various 
other immune cells (1). With regard to leukocytes, neutrophil 
accumulation was significantly inhibited in Tacr1−/− mice in lung 
injury induced by immune complexes (54) or acute pancreatitis 
(55). Attenuated leukocyte recruitment and lung injury were 
also observed with the NK1 receptor antagonist SR140333 in a 
murine model of polymicrobial sepsis induced by cecal ligation 
and puncture (56). In the same model, the authors later showed 
that the SP-induced pro-inflammatory response was mediated 
mainly by protein kinase C (PKC)-α (57). Whether the NK1 
receptor-mediated leukocyte recruitment occurs via a direct 
action on granulocytes or indirectly through other cell types 
(e.g., endothelial cells and bronchial epithelial cells) remains a 
question of debate [for a review, see Ref. (58)]. On the one hand, 
the expression of functional NK1 receptors was demonstrated on 
granulocytes in mice (59) and humans (60). In the latter study, 
it was also shown that the SP-induced COX-2 expression was 
mediated by NK1 receptors (60). On the other hand, different 
authors failed to detect the presence of NK1 receptors in human 
granulocytes (52, 61), which indicates that the NK1 receptor-
mediated granulocyte migration develops via a primary effect 
of SP on other cell types. In line with such scenario, expression 
of the NK1 receptor was shown in several types of stromal cells 
in the lung, including bronchial glands, bronchial vessels, and 
bronchial smooth muscle (62), as well as airway epithelial cells 
(63, 64) and postcapillary venular endothelial cells (65). With the 
help of nested PCR, the expression of the NK1 receptor was dem-
onstrated also in the liver, predominantly in non-parenchymal 
cells, most likely macrophages, lymphocytes, and granulocytes, 
but also in hepatocytes (53), which contradicted earlier studies 
FigUre 6 | Continued
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reporting no detectable expression of the NK1 receptor in the 
liver by using classical techniques (66–68). In lung epithelial cell 
cultures, SP via NK1 receptors stimulated neutrophil adherence 
(69) and pro-inflammatory cytokine production (70). Moreover, 
LPS enhanced the SP-induced neutrophil adherence and associ-
ated cytokine release via an involvement of NK1 receptors (71). 
Taken together, it is possible that LPS-induced leukocyte traf-
ficking is reduced in Tacr1−/− mice, which may be caused either 
by a direct effect of the NK1 receptor’s absence on leukocytes or 
indirectly through other cell types such as lung epithelial cells. 
The reduced trafficking and therefore a reduced cellular infiltrate 
within the lung and the liver might contribute to reduced expres-
sion of COX-2.
As discussed earlier, many peripheral events of the fever 
response can be influenced by SP signaling. In the present study, 
we did not find difference in the serum levels of inflammatory 
cytokines (TNF-α and IL-6) between the LPS-treated Tacr1+/+ and 
Tacr1−/− mice, which indicates that the activation of macrophages 
and their cytokine production is not impaired in the absence of 
the NK1 receptor. We did not measure the levels of the third 
major pro-inflammatory cytokine, IL-1β, because it has been 
shown that it exerts its pyrogenic actions independently from the 
NK1 receptor (16). LPS can also modulate COX-2 transcription-
ally and posttranscriptionally in macrophages independently 
from inflammatory cytokines (72). When we determined the 
COX-2 mRNA expression, we found that at this early time point 
(~40 min) it was greatly amplified in the lungs and liver, and to 
lesser extent in the brain of the mice, which results are in harmony 
with the previous findings (31). The lack of difference between 
the genotypes indicates that transcriptional upregulation of 
COX-2 is not influenced by the NK1 receptor. The correlation of 
mRNA and protein levels in biological samples is often poor (73), 
moreover, the expression of COX-2 is regulated not only at the 
level of transcription but also at the levels of post-transcription 
and translation (72, 74, 75). Therefore, we also determined the 
expression of the COX-2 protein in the lungs, liver, and brain 
of the mice. In accordance with previous reports showing aug-
mented expression of the COX-2 protein in the periphery (9), we 
also detected LPS-induced amplification of the COX-2 protein 
expression in the lungs and liver of Tacr1+/+ mice as compared 
with saline treatment, whereas we did not find significant increase 
in their brain. Importantly, however, the LPS-induced amplifica-
tion of the expression of the COX-2 protein was attenuated in the 
lungs and tended to be suppressed in the liver of Tacr1−/− mice 
as compared with their Tacr1+/+ littermates. In accordance with 
the different COX-2 protein expression between the genotypes, 
the administration of LPS caused a significant surge of PGE2 
concentration in the lungs of Tacr1+/+ mice, which was absent in 
the Tacr1−/− mice. It can be expected that the observed difference 
in pulmonary PGE2 synthesis also results in different plasma 
concentrations of PGE2 between the genotypes. The sensitive site 
where PGEs produce fever is located within the region of the brain 
that includes the organum vasculosum laminae terminalis and the 
surrounding preoptic area of the hypothalamus (76). Peripherally 
borne PGE2 can broadly penetrate in the perivascular space in the 
periventricular organs (such as the organum vasculosum laminae 
terminalis) and activate neurons or non-neural cells, thus trigger 
the febrile response (77). It has to be noted that fever signaling 
was not examined at later time points in the current experiments 
due to the study design, and therefore it cannot be excluded that 
COX-2 expression and PGE2 production in the brain are also 
affected by the blockade of the NK1 receptor, especially during 
the maintenance phase of fever. The experimental confirmation 
of the LPS-induced temporospatial distribution of PGE2 in the 
plasma, cerebrospinal fluid, and specific brain regions in the 
absence of the NK1 receptor remains subjects for future studies.
Our results demonstrate for the first time that at the onset 
of the fever response the NK1 receptor contributes to the aug-
mentation of COX-2 protein expression in peripheral organs. In 
accordance with our findings, the modulation of COX-2 protein 
expression by SP signaling has been shown in several human 
cell lines, including polymorphonuclear leukocytes (60), colonic 
epithelial cells (78), and endothelial cells (79). Furthermore, an 
autocrine circuitry between SP and PGE2 production was recently 
suggested in the fever response to endogenous pyrogens (39). 
The exact mechanism, how SP signaling interacts with COX-2 
expression remains to be elucidated in future studies. It is possible 
that the absence of the NK1 receptor leads to alterations in the 
expression of enzymes upstream (e.g., PLA2) or downstream of 
COX-2 (e.g., PGE synthases). An alteration in the phosphoryla-
tion (i.e., activation) of the cytosolic (c) form of PLA2 could be of 
particular interest, as in the fundamental study by Steiner et al. (9) 
LPS increased the contents of phosphorylated cPLA2 and COX-2 
in the lung, but did not alter the protein level of constitutively 
expressed microsomal PGE2 synthase-1. In Chinese hamster 
ovary cells stably expressing NK1 receptors, SP induced the 
release of arachidonic acid, presumably by the activation of cPLA2, 
which was blocked by an antagonist of the NK1 receptor (80). 
Furthermore, in a mouse model of nerve injury, the enhanced 
activation of cPLA2 was abolished by NK1 receptor antagonist in 
neurons and possibly microglia in the spinal cord (81). These data 
indicate a link between activation of cPLA2 and NK1 receptor-
mediated SP signaling at least in some cell types. Further studies 
are needed to assess whether the LPS-induced phosphorylation 
of cPLA2 is altered in the lungs of Tacr1−/− mice in addition to 
the decreased COX-2 protein expression as shown in this study. 
A potential link in signal transduction between SP and COX-2 
may coexist through PKC, as it was shown earlier that inhibitory 
effects of SP are mediated, at least in part by PKC isoenzymes 
(82), which play a key role in the biosynthesis of PGE2, likely by 
regulating the induction of COX-2 (83).
The findings of the present study further advance our 
understanding about the interactions between SP signaling and 
the “cytokine-COX-2-PGE2” axis in experimental fever. As a 
perspective, our results can help to identify NK1 receptor as a 
drug target to suppress peripheral COX-2 activity.
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Hyperbilirubinemia exaggerates
endotoxin-induced hypothermia
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Systemic inflammation is accompanied by an increased production of reactive oxygen species (ROS) and by either
fever or hypothermia (or both). To study aseptic systemic inflammation, it is often induced in rats by the intravenous
administration of bacterial lipopolysaccharide (LPS). Knowing that bilirubin is a potent ROS scavenger, we compared
responses to LPS between normobilirubinemic Gunn rats (heterozygous, asymptomatic; J/C) and hyperbilirubinemic
Gunn rats (homozygous, jaundiced; J/J) to establish whether ROS mediate fever and hypothermia in aseptic systemic
inflammation. These two genotypes correspond to undisturbed versus drastically suppressed (by bilirubin) tissue
accumulation of ROS, respectively. A low dose of LPS (10 mg/kg) caused a typical triphasic fever in both genotypes,
without any intergenotype differences. A high dose of LPS (1,000 mg/kg) caused a complex response consisting of early
hypothermia followed by late fever. The hypothermic response was markedly exaggerated, whereas the subsequent
fever response was strongly attenuated in J/J rats, as compared to J/C rats. J/J rats also tended to respond to 1,000 mg/
kg with blunted surges in plasma levels of all hepatic enzymes studied (alanine aminotransferase, aspartate
aminotransferase, gamma-glutamyl transferase), thus suggesting an attenuation of hepatic damage. We propose that
the reported exaggeration of LPS-induced hypothermia in J/J rats occurs via direct inhibition of nonshivering
thermogenesis by bilirubin and possibly via a direct vasodilatatory action of bilirubin in the skin. This hypothermia-
exaggerating effect might be responsible, at least in part, for the observed tendency of J/J rats to be protected from
LPS-induced hepatic damage. The attenuation of the fever response to 1,000 mg/kg could be due to either direct
actions of bilirubin on thermoeffectors or the ROS-scavenging action of bilirubin. However, the experiments with
10 mg/kg strongly suggest that ROS signaling is not involved in the fever response to low doses of LPS.
Introduction
Fever and hypothermia are symptoms of infection and inflam-
mation. They are triggered via the production and release of
endogenous proinflammatory mediators, including prostaglandin
(PG) E2, by pathogen-sensing immune cells in peripheral tissues
and in the brain.1-5 Intracellular signaling cascades activated by
these endogenous mediators are complex and involve lipid, pep-
tide, gaseous, and other messengers (for review, see reference 6).
They also include the reactive oxygen species (ROS), such as
hydrogen peroxide, superoxide anion, and nitric oxide (NO).7,8
ROS are unstable, short-lived molecules that are thought to have
2 major functions. First, they are downstream molecular effectors
of immune cell activation and, as such, are directly involved in
killing and clearing microbial pathogens.9 Second, they are mes-
sengers within several intracellular signaling pathways and, in this
role, affect multiple cell functions.10 Signaling properties of ROS are
based on their ability to interact with many intracellular proteins,
including redox-sensitive transcriptional factors and ion channels, as
well as metal-containing enzymes responsible for production of
proinflammatorymediators (for review, see reference 11).
While production of ROS by different cells and tissues in
response to bacterial lipopolysaccharide (LPS; often referred to as
endotoxin) is well documented (for review, see reference 8), it is
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not clear whether ROS play roles in fever and hypothermia, the 2
thermoregulatory responses to LPS. Riedel et al.12,13 has proposed
that oxidative stress is a crucial component in the pathogenesis of
LPS fever, but the data used to substantiate their proposal are diffi-
cult to interpret. Riedel et al.12,13 observed an attenuation of LPS
fever by high doses of dithiotreitol, methylene blue, aspirin, or
a-lipolic acid and attributed fever-attenuating effects of these com-
pounds to their free radical-scavenging action. However, all these
compounds are nonselective radical scavengers; they also inhibit
cyclooxygenase (COX),14 guanylyl cyclase,15 and secretory phos-
pholipase A2
16 —important enzymes participating in the inflam-
matory response to LPS. Hence, the observed attenuation of LPS
fever might have been due to inhibition of COX and other
enzymes and not due to free radical scavenging.
Further complicating the issue, most exogenous ROS scav-
engers are water soluble and, therefore, can neutralize efficiently
only substances dissolved in water (but not in lipids), whereas a
large pool of free radicals accumulates in cellular membranes as
lipoperoxides.17 These lipoperoxides are important mediators of
oxidative stress, but they cannot be inactivated by conventional
administration of water-soluble ROS scavengers. To dissect the
roles of membrane ROS requires using lipophilic antioxidants.
Bilirubin is the end product of heme catabolism in mammals.
This lipophilic molecule is generally considered a toxic waste that
needs to be excreted.18,19However, many studies have shown that
bilirubin is a powerful antioxidant and efficient scavenger of lipo-
peroxide radicals in membranes.20,21Hence, bilirubin can be used
as a tool to inactivate water-insoluble, lipid-associated ROS. An
established animal model to study the antioxidant activity of bili-
rubin in vivo is the Gunn rat model,22-24 named after C. H.
Gunn, who characterized an autosomal recessive deficiency in uri-
dine diphosphate glucuronyltransferase activity.25 This deficiency
prevents the conjugation of bilirubin, which explains hyperbiliru-
binemia and neonatal jaundice in Gunn rats with the homozygous
mutation (J/J), while heterozygous (J/C) rats are nonjaundiced. In
J/J rats, the increased antioxidant activity due to hyperbilirubine-
mia has been proposed to contribute to the protection against the
harmful effects of hyperoxia22 and of angiotensin II.23
Continuing our studies of the thermoregulatory responses to
LPS in mutant rats (Zucker,26,27 Otsuka Long-Evans Tokushima
fatty,26,28 Koletsky,29 and Nagase analbuminemic30), the present
work was focused on LPS-induced fever and hypothermia in J/J
and J/C Gunn rats. We also measured blood levels of biochemi-
cal markers of renal disfunction and hepatocyte damage in these
rats following LPS administration.
Results
LPS-induced fever and hypothermia in Gunn rats
All experiments were conducted at an ambient temperature
(Ta) of 30
C, which is within the thermoneutral zone for rats in
our experimental setup.31 Two intravenous doses of LPS were
used: the low (10 mg/kg) and the high (1,000 mg/kg). At 30C,
rats respond to the low dose of LPS with a polyphasic fever, and
to the high dose with hypothermia followed by fever.3 In the
Figure 1. Deep (colonic) Tb responses of J/J and J/C rats to the low
(10 mg/kg, iv) and high (1,000 mg/kg, iv) doses of LPS. (A) Administration
of the vehicle (saline) does not affect Tb in rats. (B) The low dose of LPS
causes polyphasic fevers in J/J and J/C rats, without any significant dif-
ferences between the genotypes. (C) In J/C rats, the high dose of LPS
induces early hypothermia followed by late fever. In J/J rats, the hypo-
thermic response is exaggerated, and the subsequent febrile response is
attenuated, as compared to the J/C controls. Time periods correspond-
ing to significant intergenotype differences in the response to LPS are
marked as * (P < 0.05) or ** (P < 0.01).
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present study, the intravenous injection of saline did not affect
the colonic temperature (an index of deep body temperature, Tb)
in either J/J or J/C Gunn rats (Fig. 1A). To the low dose of LPS,
both J/J and J/C rats responded with a triphasic fever, with peaks
at »50, 130, and 280 min post-injection (Fig. 1B). There were
no significant differences in the Tb dynamics between the geno-
types. To the high dose of LPS, J/C rats responded with early
hypothermia (nadir of –0.5C at »90 min; P D 0.034 vs. saline)
followed by fever (peak of 0.9C at »360 min; P < 0.001 vs.
saline) (Fig. 1C). The Tb response of J/J rats to the high dose of
LPS was different from that of J/C rats: the early hypothermic
response (nadir of –1.2C at »90 min, P < 0.001 vs. saline) was
markedly exaggerated (P  0.004 for 40–180 min vs. J/C rats),
whereas the subsequent fever response (peak of 0.3C, P D
0.039 vs. saline) was significantly attenuated (P < 0.05 for 240–
420 min vs. J/C rats).
Plasma bilirubin in Gunn rats
Since LPS administration could induce liver failure, thereby
causing (or exaggerating) hyperbilirubinemia, we examined
blood bilirubin levels in J/J and J/C rats under basal conditions
and in LPS-induced systemic inflammation. As expected, the
total plasma bilirubin level in saline-treated J/J rats was higher
(by 2 orders of magnitude) than that in J/C rats (P < 0.001,
Fig. 2). The low dose of LPS did not affect the total bilirubin
level in either genotype. However, in response to the injection of
the high dose of LPS, the total bilirubin level surged in both J/C
and J/J rats (P < 0.001 vs. saline, for both genotypes). In J/J rats
treated with the high dose of LPS, the total plasma bilirubin level
remained higher than in J/C controls (P < 0.001).
Renal disfunction and hepatic damage in Gunn rats after
LPS administration
Plasma blood urea nitrogen (BUN) and creatinine levels were
measured as markers of renal function.32 Neither of these
markers differed significantly between saline-treated J/J and J/C
rats (Fig. 3). While administration of the low dose of LPS did
not raise the renal disfunction markers, the high dose increased
both BUN (Fig. 3A) and creatinine (Fig. 3B) in J/J (P  0.001
for both BUN and creatinine) and J/C rats (P D 0.010 for BUN;
P < 0.001 for creatinine) without any significant differences
between the genotypes.
Plasma alanine aminotransferase (ALT), aspartate amino-
transferase (AST), and gamma-glutamyl transferase (GGT)
Figure 2. Blood bilirubin levels in J/J and J/C rats. The total bilirubin level
in blood plasma is dramatically higher in saline-treated J/J rats than in
saline-treated J/C controls. The low dose of LPS (10 mg/kg, iv) does not
change the bilirubin level in either genotype. In response to the high
dose of LPS (1,000 mg/kg, iv), the total bilirubin level increases in both
genotypes, but remains substantially higher in J/J rats than in J/C con-
trols. ***, P < 0.001, intergenotype difference in the response to LPS.
###, P < 0.001, LPS vs. saline difference within the same genotype.
Figure 3. Biochemical markers of renal disfunction in J/J and J/C rats. (A)
Plasma BUN levels do not differ between saline-treated J/J and J/C rats
and remain unchanged after administration of the low dose of LPS
(10 mg/kg, iv). The high dose of LPS (1,000 mg/kg, iv) raises BUN in both
genotypes, without any intergenotype difference. (B) Plasma creatinine lev-
els do not differ between saline-treated J/J and J/C rats and remain
unchanged after administration of the low dose of LPS. The high dose of
LPS raises plasma creatinine in both genotypes, without any intergenotype
difference. Within each genotype, significant differences in the response to
LPS (as compared to saline) are marked as ## (P < 0.01) or ### (P < 0.001).
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were used to assess hepatocyte damage.33 Activities of all 3
enzymes were within the normal range in J/J and J/C rats
after the injection of saline or the low dose of LPS (Fig. 4).
When LPS was administered at the high dose, rats exhibited
marked surges in ALT (P D 0.019 for J/C; P D 0.015 for
J/J; Fig. 4A), AST (P D 0.021 for J/C; P D 0.041 for J/J;
Fig. 4B), and GGT (P < 0.001 for both genotypes;
Fig. 4C). In J/J rats, the surge was blunted for GGT (P D
0.042) and tended to be reduced for ALT (P D 0.208) and
AST (P D 0.179), as compared to J/C rats.
Discussion
LPS hypothermia is exaggerated in hyperbilirubinemic
Gunn rats
The novel—and unexpected—finding of the present study
is that hyperbilirubinemia in Gunn rats was associated with
an exaggerated hypothermic response to LPS (Fig. 1C). This
exaggeration is unlikely to be due to an attenuation of the
ROS-mediated inflammatory signaling by bilirubin. Indeed,
attenuating inflammatory signaling should decrease (not
increase) the hypothermic response. Furthermore, while bili-
rubin, a potent ROS scavenger, has been shown repeatedly to
attenuate inflammatory signaling,34-36 we did not find any lit-
erature data suggesting that it can amplify inflammatory sig-
naling. An alternative, more plausible, mechanism of the
exaggeration of LPS hypothermia might be an action of bili-
rubin on thermoeffectors. Gunn rats respond to administra-
tion of exogenous bilirubin (that further increases their
hyperbilirubinemia) with a pronounced (»3C) drop in Tb.
37
This drop is likely to reflect decreased thermogenesis, because
bilirubin has been demonstrated to depress mitochondrial res-
piration in liver, heart, and brain tissues in vitro.38-40 And
although brown adipose tissue (the main source of nonshiver-
ing, temperature-driven thermogenesis in rodents41) has not
been studied, bilirubin is likely to have the same effect in
brown fat as in all other tissues studied. A profound decrease
in the threshold Tb for activation of thermogenesis is the
principle autonomic thermoeffector mechanism of LPS-
induced hypothermia.42 Although skin vasodilation is not the
main mechanism of LPS-induced hypothermia,42 increased
skin vasodilation in J/J rats could have contributed to their
enhanced hypothermic response to LPS as well. Hyperbiliru-
binemia has been shown to attenuate the pressor effects of
angiotensin II in Gunn rats23 and to lower angiotension II-
dependent hypertension in mice,43,44 the latter effect being
attributed to the blockade of superoxide production and pos-
sibly to enhanced vasorelaxation.43 In a study conducted in
humans,45 hyperbilirubinemia exaggerated endothelium-
dependent vasodilation of the brachial artery, which supplies
subcutaneous and cutaneous tissues of the arm.
Figure 4. Biochemical markers of hepatocyte damage in J/J and J/C rats.
(A) Plasma ALT levels do not differ between saline-treated J/J and J/C
rats and remain unchanged after the administration of the low dose of
LPS (10 mg/kg, iv). In response to the high dose of LPS (1,000 mg/kg, iv),
plasma ALT surges in both genotypes, but this surge tends to be blunted
in J/J rats (as compared to the J/C controls). (B) Plasma AST levels do not
differ between J/J and J/C rats after administration of saline or LPS at
the low dose. In response to the high dose of LPS, AST surges in both
genotypes, but the surge tends to be blunted in J/J rats). (C) Plasma GGT
levels are near the detection threshold in J/J and J/C rats after adminis-
tration of saline or the low dose of LPS. Plasma GGT rises in both geno-
types in response to the high dose of LPS, but the rise is significantly
reduced in J/J rats. A significant (P < 0.05) intergenotype difference in
the response to LPS is marked with *. Within each genotype, significant
differences in the response to LPS (as compared to saline) are marked as
# (P < 0.05) or ### (P< 0.001).
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Hyperbilirubinemia differently affects fevers caused by low
vs. high doses of LPS
The same action (or actions) on thermoeffectors could be
responsible for the attenuation of the late fever response to the
high dose of LPS in J/J rats, which was also observed in the pres-
ent study (Fig. 1C). Since the thermoregulatory response to the
high dose is a combination of early hypothermia and late fever,
the exaggeration of the hypothermic response (and the resultant
prolongation of this response) may be difficult to distinguish
from an independent attenuation of the fever response.
Interestingly, the fever response to the low dose of LPS
was not affected by hyperbilirubinemia in Gunn rats in our
study (Fig. 1B), which is another novel observation. It sug-
gests that ROS signaling is not involved in the febrile
response, at least not to weak stimuli. It also extends our ear-
lier conclusion that NO, a known ROS, is not involved in
the pyrogenic signaling of LPS.46 However, it cannot be
ruled out that hyperbilirubinemia blocks pro-pyretic ROS-
mediated signaling triggered by high doses of LPS, i.e., doses
that cause a prominent ROS response. For example, high
doses of LPS (those that lead to shock and hypothermia)
induce overexpression of the inducible NO synthase iso-
form,47,48 thus leading to the massive production of NO in
rats.48,49 In contrast, lower (pyrogenic) doses of LPS suppress
NO synthesis, possibly by inhibiting constitutive NO syn-
thase isoforms.50,51
This proposed antipyretic, ROS-mediated action of biliru-
bin upon fevers caused by high doses of LPS would agree with
several studies.12,13,52,53 In these studies, the febrile response to
LPS was attenuated by antioxidants, whether water-soluble
(such as methylene blue, dithiothreitol, aspirin, lipoic acid, nat-
ural antioxidants purified from spinach, or apocynin)12,13,52 or
lipid-soluble (such as resveratrol and lipoic acid).12,53 Of those
4 studies, one53 involved administering an extremely high dose
of LPS (4 mg/kg) to rats, whereas 3 other studies12,13,52 used
1–100 mg/kg doses in rabbits, the species that is »100 times
more sensitive to LPS than rats. Interestingly, the high sensitiv-
ity of rabbits to LPS has been explained by the agile production
of ROS in this species without a concomitant increase in the
protective antioxidative enzymes.54 On the other hand, the rela-
tive resistance of rats to LPS has been ascribed to an increased
activity of the endogenous antioxidant systems.54,55 It should
also be noted that several ROS scavengers used in the studies
discussed above12,13,52,53 inhibit the synthesis of PGE2, the
principle mediator of fever,56,57 by acting on COX14,58-60 and
secretory phospholipase A2.
16 However, it is unlikely that all
the reports of the fever-attenuating effects of ROS scavengers
reflect an action on PG synthesis, because the antipyretic effect
has been reported for multiple, structurally unrelated com-
pounds. Furthermore, bilirubin (the focus of the present study)
and several other ROS scavengers have not been shown to
inhibit PGE2 synthesis, definitely not by an action independent
from ROS neutralization. There are several studies showing
that antioxidants (e.g., bilirubin, methylene blue, and apocy-
nin) did not affect PGE2 synthesis or COX-2 expression in vari-
ous models.61-64
Hyperbilirubinemia attenuates LPS-induced hepatic damage
in Gunn rats
Compared to J/C rats, J/J rats responded to the high dose of
LPS with a blunted surge in GGT (Fig. 4C). The LPS-induced
surges in 2 other transferases studied (ALT and AST) tended to
be reduced, but the magnitude of the reduction did not reach the
level of statistical significance (Fig. 4A, B). The revealed high sen-
sitivity of GGT to hyperbilirubinemia was expected. Indeed,
GGT is also a marker of oxidative stress,65 and the blood concen-
tration of this enzyme is inversely related to the blood antioxidant
activity.66,67 The observed effect of hyperbilirubinemia on the
LPS-induced GGT response and the tendencies revealed (with
regard to ALT and AST responses) agree with the previously
reported protective action of bilirubin in endotoxin shock68 and
other pathological conditions.69,70
The cytoprotective action of bilirubin is likely to be due to the
suppression of oxidative stress, either directly (by scavenging
ROS) or indirectly (by inhibiting the expression of free radical-
generating enzymes, such as NO synthase and nicotinamide ade-
nine dinucleotide phosphate oxidase).68 By either mechanism,
bilirubin potently suppresses the accumulation of lipophilic ROS
in cell membranes,20,21 and the decreased accumulation of ROS
prevents cell apoptosis and tissue injury associated with oxidative
stress.70 Yet another mechanism of tissue protection by bilirubin
in LPS-induced systemic inflammation could be the exaggeration
of hypothermia. Hypothermia is an adaptive, active thermoregu-
latory response to high doses of LPS and other strong inflamma-
tory stimuli.71 It involves cold-seeking behavior42,72,73 and is
thought to be aimed at decreasing the metabolic requirements of
tissues.3,71 In our studies,74,75 when rats were either allowed to
select their preferred low Ta or maintained at a lower Ta chosen
by the investigators during endotoxin shock or Escherichia coli
infection, their survival rates increased. At least in some cases, the
increased survival was coupled with a suppressed surge in ALT.75
Whereas markers of hepatocyte damage were affected by
hyperbilirubinemia in the present study, markers of renal dis-
function (BUN and creatinine) were not (Fig. 3), thus suggesting
the lack of tissue protection in the kidneys. This is despite the
fact that bilirubin has been shown to play a protective role in
the kidneys, e.g., in diabetic nephropathy.76 The observed in the
present study tissue specificity for the protective action of biliru-
bin may relate to the fact that the liver is the principal site for bil-
irubin metabolism. Due to this, bilirubin concentration in
hepatocytes should be higher than anywhere else in the body,
including renal epitheliocytes. Although bilirubin conjugation is
defective in J/J rats,25 and these animals excrete only traces of bil-
irubin in the bile,77 they still have more than a 2-fold-higher con-
centration of bilirubin in the liver than in the kidneys.78
Summary and conclusions
We showed that hyperbilirubinemia in J/J Gunn rats was asso-
ciated with a marked exaggeration of the early hypothermic
response to the high dose of LPS (1,000 mg/kg), presumably
through a direct inhibition of nonshivering thermogenesis by bil-
irubin and possibly also through a direct vasodilatatory action of
bilirubin in the skin. This novel, hypothermia-exaggerating effect
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might be responsible, at least in part, for the observed tendency
of J/J rats to respond to the high dose of LPS with attenuated
hepatic damage.
Hyperbilirubinemia in Gunn rats was also associated with
a deep attenuation of the late febrile response to the high
(1,000 mg/kg) dose of LPS, but did not attenuate the fever
response to the low (10 mg/kg) dose. The attenuation of the
fever response to 1,000 mg/kg could be due to either direct
actions of bilirubin on thermoeffectors (inhibition of non-
shivering thermogenesis and induction of skin vasodilation)
or the ROS-scavenging action of bilirubin attenuating pyro-
genic signaling. However, the experiments with 10 mg/kg
strongly suggest that ROS signaling is not involved in the
fever response to low doses of LPS.
Materials and Methods
Animals
Adult male J/J and J/C Gunn rats were obtained from Harlan.
They were housed in cages kept in a rack equipped with a Smart
Bio-Pack ventilation system and Thermo-Pak temperature con-
trol system (Allentown Caging Equipment); the temperature of
incoming air was maintained at 28C. Standard rodent chow
and tap water were available ad libitum. The room was on a 12 h
light/dark cycle (lights on at 7:00 A.M.). The rats were housed in
groups until they were subjected to surgery, after which they
were caged singly. Animals were extensively handled and habitu-
ated to staying in wire-mesh conical confiners, which were later
used in the experiments. At the time of the experiments the rats
weighed 200–245 g, there was no significant difference between
the body mass of rats of different genotypes. All procedures were
conducted under protocols approved by the Legacy Health Sys-
tem and St. Joseph’s Hospital and Medical Center Animal Care
and Use Committees.
Intravenous catheterization
Four days before an experiment, each rat was implanted with a
jugular catheter. The procedure was performed under ketamine-
xylazine-acepromazine (55.6, 5.5, and 1.1 mg/kg ip, respectively)
anesthesia and antibiotic (enrofloxacin, 1.1 mg/kg sc) protection.
During the surgery, a rat was heated with a Deltaphase isother-
mal pad (Braintree Scientific). A small longitudinal incision was
made on the ventral surface of the neck, left to the trachea. The
left jugular vein was exposed, freed from its surrounding connec-
tive tissue, and ligated. A silicone catheter (ID 0.5 mm, OD
0.9 mm) filled with heparinized saline (50 U/ml) was passed
into the superior vena cava through the jugular vein and secured
in place with ligatures. The free end of the catheter was knotted,
tunneled under the skin to the nape, and exteriorized. The
wound on the ventral surface of the neck was sutured. To prevent
postsurgical hypothermia, the animals were allowed to recover
from anesthesia in an environmental chamber (model 3940;
Forma Scientific) set to 28C. The intravenous catheters were
flushed with heparinized saline every other day.
Experimental setup
On the day of the experiment, each rat was placed in a
confiner and equipped with a copper-constantan thermocou-
ple (Omega Engineering) to measure colonic temperature (a
measure of deep Tb). The thermocouple was inserted in the
colon 10 cm deep beyond the anal sphincter and fixed to the
tail with a loop of adhesive tape. To record Tb data, the ther-
mocouple was plugged into a data logger (Cole-Parmer) con-
nected to a computer. The rat in its confiner was then placed
in an environmental chamber (Forma Scientific) set to a Ta
of 30C, which is a neutral Ta for rats in this setup.
31 The
implanted venous catheter was extended with a length of PE-
50 tubing filled with saline. The extension was passed
through a wall port and connected to a syringe filled with
LPS or saline.
LPS administration
LPS from E. coli 0111:B4 was purchased from Sigma-Aldrich.
A stock suspension of LPS (5 mg/ml) in pyrogen-free saline was
stored at –20C. On the day of the experiment, the stock was
diluted to a final concentration of either 10 or 1,000 mg/ml. The
diluted LPS suspension or saline was injected in a bolus (1 ml/
kg) through the extension of the venous catheter. Deep Tb was
monitored for 7 h after the injection.
Biochemical assays
To determine blood levels of total bilirubin and markers of
renal disfunction and hepatocyte damage, rats were anesthetized
with ketamine-xylazine-acepromazine (5.6, 0.6, and 0.1 mg/kg
ip, respectively) 24 h after LPS injection, and their arterial blood
(5 ml) was collected by cardiac (left ventricle) puncture. The
blood was immediately transferred to EDTA-containing Vacu-
tainer tubes (Beckton Dickinson). The plasma was separated by
centrifugation, aliquoted, and stored at –80C until biological
assays were performed. All samples were sent to the Legacy Cen-
tral Laboratory, Portland, OR. ALT and AST activities in serum
were determined according to the method of Reitman and
Frankel,79 whereas GGT levels were assessed by the Szasz
method.80 Total plasma bilirubin level, BUN, and creatinine
concentration was determined according to the method described
by Jendrassik et al.,81 Patton and Crouch,82 and Van Pilsum,83
respectively.
Statistical analysis
The Tb responses were compared by 2-way ANOVA followed
by the Fisher least significant difference test by using Sigmaplot
11.0 (Systat Software). Blood levels of bilirubin and biochemical
markers of renal and hepatic disfunction were compared with
Student’s t test. The effects were considered significant when P <
0.05. The data are reported as means § SE.
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Abstract Administration of the long form (38 amino acids)
of pituitary adenylate cyclase-activating polypeptide
(PACAP38) into the central nervous system causes hyperther-
mia, suggesting that PACAP38 plays a role in the regulation of
deep body temperature (Tb). In this study, we investigated the
thermoregulatory role of PACAP38 in details. First, we in-
fused PACAP38 intracerebroventricularly to rats and mea-
sured their Tb and autonomic thermoeffector responses. We
found that central PACAP38 infusion caused dose-dependent
hyperthermia, which was brought about by increased thermo-
genesis and tail skin vasoconstriction. Compared to intra-
cerebroventricular administration, systemic (intravenous) in-
fusion of the same dose of PACAP38 caused significantly
smaller hyperthermia, indicating a central site of action. We
then investigated the thermoregulatory phenotype of mice
lacking the Pacap gene (Pacap−/−). Freely moving Pacap−/−
mice had higher locomotor activity throughout the day and
elevated deep Tb during the light phase. When the Pacap
−/−
mice were loosely restrained, their metabolic rate and Tb were
lower compared to their wild-type littermates. We conclude
that PACAP38 causes hyperthermia via activation of the au-
tonomic cold-defense thermoeffectors through central targets.
Pacap−/− mice express hyperkinesis, which is presumably a
compensatory mechanism, because under restrained condi-
tions, these mice are hypometabolic and hypothermic com-
pared to controls.
Keywords PACAP . Hyperthermia . Thermoregulation .
Locomotor activity . Autonomic thermoeffectors
Introduction
The long form of the pituitary adenylate cyclase-activating
polypeptide (PACAP) consists of 38 amino acids (PACAP38),
and together with its receptors (PAC1 and VPAC1/2 recep-
tors), it is widely expressed both in peripheral organs and in
the central nervous system (CNS), explaining its diverse bio-
logical functions (for review, see Vaudry et al. 2009). A
shorter form of the peptide (PACAP27) has also been identi-
fied (Miyata et al. 1990), but since in most tissues PACAP38
is the predominant form with a concentration ratio of
PACAP27:PACAP38 to <1:9 (Vaudry et al. 2000, 2009) and
because the effects of the PACAP27 and PACAP38 on cAMP
formation (Nowak and Kuba 2002), vascular responses (Lenti
et al. 2007), and on body temperature (Seeliger et al. 2010) are
similar, the current study focused on the effects of PACAP38.
In the CNS, PACAP exerts neurotrophic effects (Vaudry et al.
1999; Njaine et al. 2014) as well as neuroprotective actions in
experimental models of ischemia (Reglodi et al. 2000;
Danyadi et al. 2014), Parkinson’s disease (Brown et al.
2013, 2014) and viral neurotoxicity (Rozzi et al. 2014). The
peptide is known to regulate pituitary hormone secretion
(Koves et al. 2014) and improve barrier properties of the
endothelial cells in the brain (Wilhelm et al. 2014). On the
periphery, PACAP has been shown to have an anti-
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inflammatory role in diabetic kidney damage (Banki et al.
2013, 2014), neurogenic inflammation (Helyes et al. 2007),
and contact dermatitis (Kemeny et al. 2010). PACAP has been
reported to play an important role in the regulation of numer-
ous homeostatic processes by influencing circadian rhythm
(Nagy and Csernus 2007; Racz et al. 2008) and food intake
(Hawke et al. 2009; Resch et al. 2011). Since the isolation of
PACAP38 by Miyata et al. (1989), a large number of studies
have been conducted to identify the role of the peptide in
various homeostatic functions, including the regulation of
deep body temperature (Tb).
Supporting the role of PACAP38 in thermoregulation, the
peptide and its receptors are broadly expressed in main ther-
moregulatory areas of the brain, including the lateral
parabrachial area, the preoptic area of the hypothalamus
(POA), the dorsomedial nucleus of the hypothalamus, the
periaqueductal gray matter, and the nucleus raphe pallidus
(Palkovits et al. 1995; Joo et al. 2004; Das et al. 2007). In
physiological studies, the injection of PACAP38 into the
lateral cerebral ventricle (Pataki et al. 2000, 2003; Hawke
et al. 2009), the intrathecal space (Inglott et al. 2011), or into
the ventromedial hypothalamic nucleus (Resch et al. 2011,
2013) caused an increase of Tb in rats and mice. Although
elevation of non-shivering thermogenesis (Hawke et al. 2009;
Inglott et al. 2011; Resch et al. 2011) and increase of locomo-
tor activity (Resch et al. 2011, 2013) have been shown to
contribute to the PACAP38-induced hyperthermia, no study
has yet been conducted to investigate simultaneous activation
of autonomic thermoeffectors.
The thermoregulatory system operates as a federation of
independent thermoeffector loops, in which each loop consists
of a sensor, an afferent, and an efferent branch (Romanovsky
2007a). For example, environmental cold activates cutaneous
cold receptors and signals from the skin are conveyed to
thermoregulatory centers in the brain from where autonomic
(thermogenesis, cutaneous vasonconstriction) and behavioral
(warmth seeking) cold-defense effectors are driven
(Romanovsky 2014). These defense mechanisms can be mod-
ulated from peripheral (Almeida et al. 2012) as well as from
central sites (Nakamura and Morrison 2008b). A substance
such as PACAP38 can act at any element of a thermoeffector
loop and cause the same effect: hyperthermia. Since the ther-
moregulatory response to PACAP38 has not been compared
between systemic (outside the blood–brain barrier) and central
(into CNS) substance delivery, it cannot be firmly stated
whether the primary site of action of PACAP38 is on periph-
eral afferents, in the brain as proposed by Resch et al. (2011,
2013), in the spinal cord as suggested by Inglott et al. (2011),
or on the efferent neural pathway of a thermoeffector (e.g.,
that of the brown adipose tissue).
In addition to exogenous PACAP38 administration, geneti-
cally modified mice lacking the Pacap gene have also been
utilized to investigate how the absence of PACAP affects deep
Tb. These studies obtained contradictory results showing that
the absence of PACAP in mice lead to increased (Hashimoto
et al. 2001) versus unchanged locomotor activity (Adams et al.
2008), as well as to lower (Hashimoto et al. 2009) versus
unchanged Tb as compared to controls (Cummings et al. 2008).
In the present study, we characterized the dose-dependency
of and the autonomic thermoeffector pattern involved in the
response to PACAP38. Then, in a comparative experiment,
we addressed the question whether exogenous PACAP38
administration acts primarily through peripheral or central
targets in rats. Lastly, as an additional approach to identify
the role of PACAP in thermoregulation, we used mice lacking
the Pacap gene and studied how the absence of PACAP
affects circadian changes of their deep Tb and locomotor
activity as well as their basal Tb and metabolic rate.
Materials and Methods
Animals
The physiological experiments were performed in 40 adult
male Wistar rats and 42 adult mice of both sexes. The mice
had the Pacap gene homozygously either present (Pacap+/+) or
absent (Pacap−/−) due to a targeted disruption (Hashimoto et al.
2001). Generation by a gene-targeting technique, maintenance,
and backcrossing of Pacap−/− mice on a CD1 background has
been reported previously (Hashimoto et al. 2001, 2009). Ani-
mals were housed in temperature-controlled rooms on a 12 h
light–dark cycle. Standard rodent chow and tap water were
available ad libitum. At the time of the experiments, the rats
weighed 331±33 g and the mice weighed 24±2 g.
Rats and mice were extensively handled and then habitu-
ated to staying inside wire-mesh cylindrical confiners. The
cylindrical confiner prevented the animal from turning
around, but allowed for some back-and-forth movements; it
was used in the respirometry setup (see the “Experimental
Setups” section below).
All procedures were conducted under protocols approved
by Institutional Animal Use and Care Committee of the Uni-
versity of Pecs and were in accordance with the directives of
the National Ethical Council for Animal Research and those of
the European Communities Council (86/609/EEC).
Surgeries
Mice
Mice were anesthetized with a ketamine–xylazine cocktail
(81.7 and 9.3 mg/kg, respectively, i.p.) and received antibiotic
protection (gentamycin, 6 mg/kg, i.m.). During surgery, a
mouse was heated with a temperature-controlled heating pad
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(model TMP-5a; Supertech Instruments UK Ltd., London,
UK) placed under a surgery board.
A mouse designated for an experiment in the telemetry
setup was implanted with a miniature telemetry transmitter
(G2 E-Mitter series; Mini Mitter, Bend, OR, USA) to record
abdominal temperature (Tab, a measure of deep Tb) and loco-
motor activity. The device was inserted into the peritoneal
cavity via midline laparotomy and fixed to the lateral abdom-
inal wall (right side) with a suture. The surgical wound was
sutured in layers. After the surgery, mice were allowed to fully
recover for 10 days before data collection started.
Rats
Surgeries were performed under ketamine–xylazine (55.6 and
5.5 mg/kg, respectively, i.p.) anesthesia and antibiotic protec-
tion (gentamycin, 6 mg/kg, i.m.). Experiments were per-
formed 2 to 4 days after surgery. Each rat was implanted with
either an intravenous (i.v.) catheter or an intracerebroventric-
ular (i.c.v.) cannula as described below.
For i.v. catheter implantation, a small longitudinal incision
was made on the ventral surface of the neck, left of the trachea.
The left jugular vein was exposed, freed from its surrounding
connective tissue, and ligated. A silicone catheter (ID 0.5 mm,
OD 0.9 mm) filled with heparinized (10 U/ml) saline was
passed into the superior vena cava through the jugular vein
and secured in place with ligatures. The free end of the
catheter was knotted, tunneled under the skin to the nape,
and exteriorized. The wound was sutured. The catheter was
flushed with heparinized saline (10 U/ml) on the day
after the surgery and every other day. This technique
was repeatedly used in our earlier studies (Petervari
et al. 2005; Garami et al. 2010).
For i.c.v. cannulation, each rat was fixed to a stereotaxic
apparatus as carried out in our earlier studies (Petervari et al.
2009, 2010). The scalp was incised over the sagittal suture; the
periosteum was excised; the skull was cleaned and dried; two
supportingmicroscrewswere driven into the skull; and a small
hole was drilled in the skull 1.0 mm antero-posterior from
bregma and 1.5 mm lateral from midline. A 22-G steel guide
cannula was attached to a plastic tube fitted into a stereotaxic
manipulator (Narishige Scientific Instruments Laboratory, To-
kyo, Japan), which was used to insert the cannula into the
brain through the bone hole. The tip of the cannula was placed
within the right lateral ventricle (3.8 mm from dura). The
cannula was secured to the supporting microscrews with
dental cement and released from the manipulator. The guide
cannula was closed by a dummy cannula.
Experimental Setups
Physiological experiments in unanesthetized animals were
conducted in either the respirometry setup or the telemetry
setup. The respirometry setup was used (a) to measure the
thermoregulatory responses of rats to non-stressful adminis-
tration of PACAP38 and (b) to assess the basal thermoregula-
tory parameters of untreated, loosely restrained Pacap−/− and
Pacap+/+ mice. The telemetry setup was used only in untreat-
ed, freely-moving Pacap−/− and Pacap+/+mice to record their
Tab and locomotor activity over a longer period (24 h) of time.
In the respirometry setup, a rat or mouse equipped with
copper–constantan thermocouples (Omega Engineering,
Stamford, CT, USA) to measure colonic (Tc), and tail skin
temperature (Tsk) was placed in a confiner. The colonic ther-
mocouple was inserted 10 or 3 cm beyond the anal sphincter
in rats and mice, respectively, and fixed to the base of the tail
with a loop of adhesive tape. The skin thermocouple was
positioned on the lateral surface of the tail (at the boundary
of the proximal and middle thirds) and insulated from the
environment with tape. The thermocouples were plugged into
a data logger (Cole-Parmer, Vernon Hills, IL, USA). Then,
each animal in its confiner was transferred to a Plexiglas
chamber of the four-chamber open-circuit calorimeter inte-
grated system (Oxymax Equal Flow, Columbus Instruments,
Columbus, OH, USA). The chamber was sealed, submerged
into a temperature-controlled water bath, and continuously
ventilated with room air (1,000 and 200 ml/min for rats and
mice, respectively). The fractional concentration of oxygen
was measured in the air entering and exiting the chamber, and
the rate of oxygen consumption (VO2) was calculated accord-
ing to the manufacturer’s instructions using the OxymaxWin-
dows software (v3.1). When present, the venous catheter was
connected to a polyethylene-50 extension filled with the drug
of interest. When the animal had an i.c.v. cannula, a needle
injector was fitted into the guide cannula and connected to a
polyethylene extension (ID 0.28 mm, OD 0.61 mm). The
extension was passed through a port of the chamber and
connected to a syringe. All experiments were conducted at
an ambient temperature (Ta) of 28.0 °C or 31.0 °C, which is
thermoneutral for rats and mice, respectively, in this setup
(Balasko et al. 2010; de Oliveira et al. 2014).
In the telemetry setup, mice were studied inside their home
cages. Telemetry receivers (model ER-4000; Mini Mitter)
were positioned in a temperature-controlled room, and the
home cages of mice were placed on top of the receivers. In
this setup, a Ta of 27.0 °C was used, which is near the lower
end of the thermoneutral zone for mice (Kanizsai et al. 2009).
The mouse was preimplanted with a telemetry transmitter to
measure Tab and locomotor activity. The latter has been shown
to play an important thermoregulatory role in small rodents
such as rats and mice (Mount andWillmott 1967; Brown et al.
1991; Weinert and Waterhouse 1998). A similar method was
also used to detect small differences in the thermoregulatory
phenotype between transient receptor potential vanilloid-1
(TRPV1) channel knockout and control mice (Kanizsai et al.
2009; Garami et al. 2011).
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Substance Administration
PACAP38 was synthesized at the University of Szeged as
described in details elsewhere (Gasz et al. 2006). Lyophilized
aliquots of PACAP38 were stored at 4 °C. On the day of the
experiment, an aliquot was dissolved in saline to give a
working solution of PACAP38 at 0.3, 0.6, or 6 mg/ml. For
the i.v. drug administration, the 0.3 mg/ml working solution
was infused to rats at a rate of 87 μl/min/kg (~29 μl/min/rat)
for 4 min to deliver a final dose of PACAP38 at 100 μg/kg
(~33 μg/rat). For i.c.v. drug administration, 5 μl of the 0.6 or
6 mg/ml working solutions were infused over a 3-min time
period to deliver PACAP38 at doses of 10 and 100 μg/kg
(~3.3 and 33 μg/rat), respectively. Control animals were in-
fused with saline.
Immunocytochemistry for c-Fos
The labeling was performed as published earlier
(Gaszner et al. 2012). Briefly, Pacap−/− and Pacap+/+
mice were injected within a time period of 2 min with
i.p. administered Nembutal (sodium-pentobarbital;
100 mg/kg body weight; Sanofi, Budapest, Hungary).
All mice became unconscious within 2 min. Then, they
were transcardially perfused with 25 ml of 0.1 M sodi-
um phosphate-buffered saline (PBS; pH 7.4) for 2 min,
followed by perfusion with 150 ml of ice-cold 4 %
paraformaldehyde in 0.2 M Millonig sodium phosphate
buffer (pH 7.4), for 20 min. Brains were removed and
post-fixed for 24 h. Coronal sections (30 μm) were
prepared on vibratome (Lancer, Ted Pella Inc., Redding,
CA, USA) and stored in anti-freeze solution at−20 °C.
For free-floating diaminobenzidine (DAB; Sigma Chem-
ical, Zwijndrecht, The Netherlands) immunocytochemis-
try, sections were washed 6×10 min in 0.1 M PBS.
Consecutively, sections were incubated in 0.5 % Triton
X-100 (Sigma Chemical), then in a blocking buffer of
2 % normal goat serum (NGS, Jackson Immunoresearch
Europe Ltd., Suffolk, UK) in PBS for 30 min. Sections
were transferred into an antiserum solution (1:500)
raised against c-Fos (Santa Cruz Biotechnology Inc.,
sc-52, Santa Cruz, CA, USA). After 3×10 min washes,
sections were treated with biotinylated goat anti-rabbit
IgG, (1:200) containing 2 % NGS, for 2 h at 20 °C.
After a rinse in cold PBS, sections were placed into
avidin–biotin-complex solution (Vectastain Elite ABC
Kit, Vector Laboratories, Burlingame, CA, USA), for
1 h at 20 °C, followed by PBS for 3×10 min washes.
The immunoreaction was visualized using 0.02 % DAB
in Tris buffer with 0.003 % H2O2, for 10 min. The
reaction was observed under microscope and stopped
with PBS. After washes, sections were mounted on
gelatin-coated slides, dried, cleared by 2×10 min xylene
treatment, coverslipped with DePex (Fluka, Heidelberg,
Germany), and studied with a Nikon Microphot FXA
microscope and Spot RT color digital camera (Nikon,
Tokyo, Japan).
The polyclonal c-Fos antiserum (Santa Cruz Biotechnolo-
gy Inc., sc-52, Santa Cruz, CA, USA) had been generated
against the 3–16 amino acid c-Fos peptide fragment of
human origin. Preadsorption with 0.1, 1, and 10 μg
synthetic c-Fos blocking peptide (Santa Cruz Biotech-
nology Inc., sc-52 P, Santa Cruz, CA, USA); moreover,
omission or replacement of the c-Fos serum by nonim-
mune rabbit serum effectively prevented the staining.
The cross reactivity of this antiserum with other Fos-
related proteins was excluded earlier by Ryabinin et al.
(1999). Western blot analysis support the specificity of
the antibody used (for details see supplier’s web site:
http://datasheets.scbt.com/sc-52.pdf).
Microscopy, Digital Imaging, and Morphometry
Per animal, the cell counts positive for c-Fos were
determined in five serial sections, each interspaced by
60 μm in the median preoptic nucleus (MnPO) and
medial preoptic area (MPO) according to Paxinos and
Franklin (2004) atlas. Cell counting was carried out on
non-edited digital images using ImageJ software (ver-
sion 1.37, NIH, Bethesda, MD, USA). Quantitation was
performed in a double-blind setup by a colleague who
is an expert in the rodent neuroanatomy, but was
blinded to the identity of preparations. Two representa-
tive digital images were grayscaled and contrasted using
Photoshop software (Adobe, San Jose, CA, USA) for
publication purposes.
Data Processing and Analysis
Data on Tc, Tab, heat loss index (HLI), and VO2 were
compared by two-way ANOVA followed by Fisher’s
LSD post hoc tests, as appropriate. The HLI was calcu-
lated as:
HLI ¼
Tsk − Ta
T c−Ta
:
The HLI changes between 0 (maximum heat conservation
due to skin vasoconstriction) and 1 (theoretical maximum heat
loss due to skin vasodilation; Romanovsky et al. 2002). Num-
bers of the c-Fos-positive cells were compared by Student’s
two sample t test (alpha = 5 %). For statistical analysis,
Sigmaplot 11.0 (Systat Software, San Jose, CA, USA) soft-
ware was used. All data are reported as mean±SE.
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Results
Characteristics of the Thermoregulatory Response to Central
(i.c.v.) PACAP38 Administration
To characterize the thermoregulatory effect of PACAP38 in
details, we infused 10 or 100 μg/kg of the peptide (or saline)
into the lateral cerebral ventricle of rats and recorded their Tc,
Tsk, and VO2 in the respirometry setup. In all rats studied,
infusion of saline did not have any influence on Tc, HLI, and
VO2 (Fig. 1). On the contrary, both of the applied doses of
PACAP38 caused a marked rise in the Tc starting already at
10 min after the injection (p<0.001 for both; Fig. 1). The
magnitude of the PACAP38-induced hyperthermia was dose-
dependent with a maximal Tc change of 2.0±0.3 °C and 1.4±
0.3 °C at the dose of 100 and 10 μg/kg, respectively (p<0.001
for both). Statistical analysis also revealed significant
difference (p<0.001) between the effects of the 10 vs.
100 μg/kg dose of PACAP38 on Tc. The hyperthermic re-
sponse to intrabrain administration of PACAP38 is in harmo-
ny with earlier reports on the effect of PACAP38 injection on
Tb in rats (Pataki et al. 2000, 2003; Resch et al. 2011, 2013).
In the case of the 100 μg/kg dose, the development of the
hyperthermia was preceded by significant tail skin vasocon-
striction (as indicated by a decreased HLI; p<0.05). This is a
novel finding of our study, and to our knowledge, the first to
report cutaneous vasomotor responses to i.c.v. PACAP38 in
conscious rats. It indicates that the thermoregulatory
(constrictor) effect of PACAP38 on the cutaneous vascular
tone is different from its direct (dilator) effect on skin vessels,
which was shown earlier in small rodents (Absood et al. 1992;
Tsueshita et al. 2002). The initial drop of HLI lasted for
~40 min, and then, it was followed by a pronounced elevation
of HLI due to tail skin vasodilation, which remained signifi-
cantly (p<0.05) higher than theHLI of saline-treated rats until
the end of the experiment in accordance with the vasodilatory
effect of PACAP38 reported earlier (Absood et al. 1992;
Tsueshita et al. 2002). Rats treated with 10 μg/kg PACAP38
i.c.v. had low HLI already before substance administration;
thus, the initial drop of HLI in this group could not be ob-
served, however, ~50 min after drug infusion HLI increased
above baseline levels and became higher than that of controls
(p<0.05), although the magnitude and the duration of HLI
elevation were smaller than those observed at 100 μg/kg.
Similarly to Tc, the VO2 of the rats increased already at
10 min after i.c.v. PACAP38 administration as compared to
saline-treated animals in a dose-dependent manner. It reached
a maximal rise of 21±6 and 14±6 ml/kg/min at 100 and
10 μg/kg, respectively (p<0.001 for both). This finding is in
harmony with previous studies, in which PACAP38 elevated
the metabolic rate (Hawke et al. 2009; Inglott et al. 2011;
Resch et al. 2011). In addition, our results demonstrate that
simultaneous immediate activation of both autonomic cold-
defense thermoeffectors (cutaneous vasoconstriction and
brown adipose tissue thermogenesis) contribute to the devel-
opment of hyperthermia in response to PACAP38.
Investigation of the Thermoregulatory Response to Systemic
(i.v.) PACAP38 Administration
The dose-dependent hyperthermia in response to PACAP38
injection either into the lateral ventricle (current study; Pataki
et al. 2000, 2003) or into the hypothalamus (Resch et al. 2011,
2013) suggests that the site of action for PACAP38 is located
in the CNS, but one can not rule out the possibility that
intrabrain PACAP38 administration acts on central elements
of a thermoregulatory loop, which receives its afferentation
from the periphery and through central neural structures in-
nervates the corresponding thermoeffector. Such scenario is
plausible based on the modern concept of thermoregulation,
Fig. 1 Thermoeffector and Tc responses of rats to different doses (10 and
100μg/kg) of PACAP38 or saline administered i.c.v. The changes of Tc (a
measure of deep Tb) are shown in the upper panel; alterations in the
activity of the two main autonomic thermoeffectors, HLI and VO2, are
depicted in the middle and lower panel, respectively. These experiments
were performed in the respirometry setup at a Ta of 28 °C. Numbers of
animals in the corresponding groups are indicated in the figure
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according to which deep Tb is controlled by a federation of
independent loops of thermoeffectors (for review, see
Romanovsky 2007b). In such a loop, activation of the afferent
pathway upstream from the central nuclei can evoke equal effects
as its activation at any, for example central, part of the loop.
To study the possibility of a peripheral site of action for
PACAP38 in a comparative experiment, we investigated
whether the same (100 μg/kg) dose of PACAP38 that caused
pronounced hyperthermia when injected i.c.v. has a similar
effect on deep Tb in the case of a systemic (i.v.) administration.
Infusion of saline did not have thermoregulatory effects in the
rats studied (Fig. 2). When PACAP38 at 100 μg/kg was
infused i.v., it caused a slight, but significant (p<0.05) rise
of Tc. Both the maximum Tc elevation (~0.3 °C) and the
duration (60 min) of the hyperthermic response to systemic
PACAP38 infusion were markedly less than what i.c.v. ad-
ministration of the same dose evoked (p<0.05). One can argue
that neurons in the CNS were exposed to higher local concen-
trations of PACAP38 than neurons on the periphery after
infusion of the same dose into the two compartments, but
the differences in local concentrations are unlikely to account
for the substantial differences observed in the Tc response.
Importantly, the response to PACAP38 at 100 μg/kg i.v. was
substantially smaller both in magnitude (~5-fold lesser) and in
duration (~2 times shorter) than the effect of a tenfold smaller
dose (10 μg/kg) delivered i.c.v. (Fig. 1). Similarly to what we
observed after i.c.v. drug delivery, in the case of the i.v.
infusion of PACAP38, the hyperthermia was also brought
about by a decreased heat loss and an increased VO2, although
activity of both thermoeffectors changed to a much lesser
extent than after i.c.v. delivery (Fig. 2). The result that even
a tenfold lower dose of PACAP38 caused much stronger
hyperthermia after i.c.v. administration compared to i.v.
delivery, unequivocally shows that the site of action for
the thermoregulatory response to PACAP38 is situated
within the CNS.
Thermoregulatory Characteristics of Pacap−/− Mice
After we characterized the thermoregulatory response to ex-
ogenous PACAP38 administration, we wanted to know how
the absence of PACAP affects deep Tb.
First, we studied the circadian changes of Tab and locomo-
tor activity in freely moving Pacap−/− and Pacap+/+ mice
(Fig. 3a). Representing the characteristic circadian rhythm of
rodents, mice of both genotypes had lower Tab and activity
levels during the light (inactive) phase than during the dark
(active) phase. In accordance with the study by Hashimoto
et al. (2001), we found that Pacap−/− mice were more active
than their wild-type littermates during both the light and the
dark phase of the day (p<0.001). During most of the light
phase (between 5 a.m. and 3 p.m.), the increased locomotor
activity resulted in a moderately higher Tab in the Pacap
−/−
mice compared to controls (p<0.05); but in the night, there
was no significant difference in Tab between the genotypes
(Fig. 3a). Similar results on the effect of hyperactivity on deep
Tbwere also demonstrated in chicken (Aschoff and von Saint-
Paul 1973) and inmice (Weinert andWaterhouse 1998, 1999),
showing that elevated locomotor activity resulted in higher Tb
during the inactive phase, but not during the active phase. It
can be assumed that the different light–dark influence of
locomotor activity on deep Tb can originate from the circadian
changes of cutaneous vasodilation, thus heat loss mechanisms
(Weinert and Waterhouse 1998).
Next, we measured the basal Tc and VO2 in loosely re-
strained Pacap−/− and Pacap+/+ mice (Fig. 3b). These exper-
iments were performed in the respirometry setup (see the
“Materials and Methods” section), so we could minimize the
influence of locomotor activity on Tc and VO2. We recorded
the basal thermoregulatory parameters for 60 min starting
from 11 a.m. because this time period corresponded to the
biggest difference in deep Tb between freely moving Pacap
−/−
and Pacap+/+ mice (Fig. 3a). As shown in Fig. 3b, the basal
VO2 was significantly lower in Pacap
−/− mice as compared to
Fig. 2 The thermoregulatory response of rats to PACAP38 (100 μg/kg)
or saline administered i.v. Changes of Tc (upper panel), HLI (middle
panel), and VO2 (bottom panel) are shown with the same scale intervals
as in Fig. 1. The experimental conditions were also identical to those
described in Fig. 1 (respirometry setup, Ta of 28 °C). Numbers of animals
in the corresponding groups are indicated in the figure
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controls throughout the experiment (p<0.001). As a conse-
quence of their hypometabolism, Tc of the Pacap
−/−mice was
also slightly lower than that of controls (p<0.01).
To assess which neurons are responsible for maintaining
the reduced resting metabolic rate in Pacap−/− mice, we
measured expression of the inducible transcription factor c-
Fos, a marker of neuronal activation (Sagar et al. 1988), in the
MnPO and MPO (Fig. 4a). It is well established that neurons
in these brain areas are involved in the regulation of thermo-
genesis (Nakamura and Morrison 2008b; Romanovsky et al.
2009). In the MnPO, we found no statistical difference in the
number of c-Fos-positive cells between Pacap−/− and
Pacap+/+ mice; however, c-Fos expression was nearly three
times higher (p<0.05) in the MPO of the Pacap−/− mice as
compared to their wild-type littermates (Fig. 4b). It has been
shown that GABAergic neurons in the MPO tonically sup-
press BAT thermogenesis (Osaka 2004) and can be regarded
as the first effector neurons of the thermoregulatory loops
controlling autonomic thermoeffectors (Romanovsky et al.
2009), therefore, our current findings in Pacap−/− mice sug-
gest that the absence of PACAP results in an increased acti-
vation of the inhibitory MPO neurons leading to more pro-
nounced suppression of thermogenesis.
Discussion
Our findings clearly demonstrate that central, rather than
peripheral mechanisms are involved in the hyperthermia-
Fig. 3 The thermoregulatory phenotype of Pacap−/− and Pacap+/+mice.
a Circadian changes of Tab and locomotor activity in freely moving
Pacap−/− and Pacap+/+ mice. These experiments were performed in the
telemetry setup at a Ta of 27 °C. b Basal Tc and VO2 of loosely restrained
Pacap−/− and Pacap+/+ mice. Recordings of Tc and VO2 were performed
between 11 a.m. and 12 p.m. in the respirometry setup at a Ta of 31 °C.
Numbers of animals in the corresponding groups are indicated in the
figure
Fig. 4 The expression of c-Fos positive cells in the MnPO and MPO of
Pacap−/− and Pacap+/+ mice. a Schematic drawing from Paxinos and
Franklin (2004) atlas and representative photomicrographs of coronal
sections from the MnPO and MPO at the anterior–posterior coordinate
of 0.14 mm from Bregma. The anterior commissure (ac) and the third
ventricle (3V) are shown as landmarks. b Quantitative analyses of c-Fos
immunoreactive cells in the MnPO and MPO. Numbers of animals in the
corresponding groups are indicated in the figure
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inducing effect of PACAP38. Although PACAP38-induced
hyperthermia has been studied earlier in small rodents, based
on data currently available from those experiments, no firm
conclusion could be drawn about the site of the thermoregu-
latory action of PACAP38. In previous studies, PACAP38was
administered only into the CNS (Pataki et al. 2000, 2003;
Hawke et al. 2009; Inglott et al. 2011; Resch et al. 2011,
2013) and evoked prominent thermoregulatory responses,
suggesting a central mediation of the effect. However, taken
into account the organization of the thermoregulatory system,
which consists of independently operating thermoeffector
loops (Romanovsky 2007a, b), the interpretation of the results
obtained with one single injection of a substance into the CNS
can be misleading, because it can not be excluded that activa-
tion of an upstream or downstream peripheral structure of the
same thermoregulatory pathway could cause the same or
similar effect. For example, Inglott et al. (2011) found that
i n t r a t h e c a l l y a dm i n i s t e r e d PACAP38 e x e r t s
sympathoexcitation even after spinal transection and the
authors concluded that the effect is, therefore, evoked from
the spinal cord itself. Based on the functional architecture of
the thermoregulatory system, however, the results by Inglott
et al. (2011) can also be explained by a direct effect of
PACAP38 on efferent spinal structures (most likely the
intermediolateral column) of the same thermoregulatory loop,
which can be also activated upstream in the brain by i.c.v.
(current s tudy; Pataki et al . 2000, 2003) or by
intrahypothalamic infusions (Resch et al. 2011, 2013) and
the activation of which leads to equivalent effects regardless
of the order of the neuron being activated in the loop.
Supporting a peripheral site of action, PACAP38 and its
receptor have been shown to be widely expressed on sensory
neurons in the periphery (for review, see Mulder et al. 1999;
Vaudry et al. 2000) and in the enteric nervous system
(Miampamba et al. 2002). In the present study, we compared
the effects of central and systemic administration, and showed
that the same or even a tenfold lower dose of PACAP38
evokes stronger hyperthermia, when given i.c.v. than when
delivered i.v. This result unequivocally supports the central
mediation hypothesis. The slight increase of Tc in response to
peripherally infused PACAP38 could be attributed to its pen-
etration of the blood–brain barrier (Banks et al. 1993; Nonaka
et al. 2002). To our knowledge, this is the first report in
which the central and peripheral thermoregulatory re-
sponses to PACAP38 were compared under identical
experimental conditions.
We also studied the characteristics of the thermoregulatory
response to PACAP38 and found that the hyperthermia started
to develop promptly: already 10min after drug administration,
we could detect the activation of thermoeffectors and a slight
increase of Tc. This is a novel finding of the study as in all of
the earlier studies investigating the thermal effect of
PACAP38, Tb was recorded hourly and the substance was
administered in a stressful manner, thus the developing
stress-induced hyperthermia, which was also present in the
vehicle-treated animals masked the early phase of the re-
sponse. We found that PACAP38 administration resulted in
the simultaneous activation of non-shivering thermogenesis
and cutaneous vasoconstriction, which are the two principal
autonomic cold-defense thermoeffectors (Romanovsky
2007a). It has to be noted that the measured increase in VO2
can theoretically originate from elevation of both shivering
and non-shivering thermogenesis; but in small rodents, non-
shivering thermogenesis is the primary source of heat produc-
tion (for review, see Cannon and Nedergaard 2004). The
initial skin vasoconstriction seems to contradict the reported
vasodilatory effect of PACAP38 (Absood et al. 1992;
Tsueshita et al. 2002), but this contradiction can be resolved
by considering that in the current study PACAP38 was deliv-
ered into the lateral ventricle of the brain, from where it can
broadly access the POA, where neurons of the thermoeffector
pathway for tail skin vasomotor tone are situated (Nakamura
and Morrison 2008a, b). Therefore, it is plausible that
PACAP38 acted on central thermoregulatory elements
resulting in skin vasoconstriction, but when the peptide spread
to more distant (non-thermoregulatory) areas, it caused
vasodilatory effect, which was also observed in the current
study ~40 min after PACAP38 injection (Fig. 1). Although the
later occurring cutaneous vasodilation lasted longer than the
initial skin vasonconstriction, from a thermoregulatory point
of view, the initial decrease of heat loss is equally important,
as it was present during the developmental phase of
PACAP38-induced hyperthermia, thus contributed to the rise
of deep Tb.
Since neurons of the thermoeffector loop for non-shivering
thermogenesis are also located in the POA (for review, see
Romanovsky et al. 2009), it is tempting to assume that the site
of the hyperthermic effect of PACAP38 is in the POA on
neurons, which belong to the common part of the
thermoeffector pathways for non-shivering thermogenesis
and cutaneous vasoconstriction. Supporting this hypothesis,
the PAC1 receptor, which has been shown to be involved in
mediation of the hyperthermic effect of PACAP38 (Tachibana
et al. 2007; Resch et al. 2013), is abundantly expressed in the
MnPO of the POA (Joo et al. 2004), where GABAergic
neurons controlling autonomic cold-defense thermoeffectors
can be found (Nakamura and Morrison 2008a). In recent
studies from Resch et al. (2011, 2013), it has been proposed
that the hyperthermic and hypermetabolic effects of
PACAP38 are mediated by neurons in the hypothalamic ven-
tromedial nucleus and possibly in the lateral parabrachial
nucleus. Our hypothesis is also in harmony with these results,
because in the cold-activated pathway glutamatergic neurons
from the lateral parabrachial nucleus project to GABAergic
neurons in the MnPO (Nakamura and Morrison 2008b),
which in turn, are connected to neurons of the hypothalamic
550 J Mol Neurosci (2014) 54:543–554
ventromedial nucleus (Imai-Matsumura et al. 1988; Thornhill
et al. 1994).
As an alternative approach to study the role of PACAP in
thermoregulation, we investigated deep Tb and locomotor
activity of Pacap−/− mice and found that these mice were
hyperactive throughout the day and hyperthermic during the
light phase as compared to controls. The hyperactivity of
Pacap−/− mice was also observed in an earlier study
(Hashimoto et al. 2001) and, although Adams et al. (2008)
reported no alteration in the locomotor activity of the Pacap−/−
mice compared to controls, in their study during the three
consecutive nights of the experiments the number of beam
breaks in case of the Pacap−/− mice exceeded by ~2,000 (i.e.,
by ~50 %) that of controls at certain time points. It is a novel
finding of the present study that in our experiments, the
increased activity of the Pacap−/− mice resulted in elevated
Tb during the light phase of the day, in which phase locomotor
activity correlates strongly with Tb (Weinert and Waterhouse
1998, 1999). In contrast to our findings, in the study by
Hashimoto et al. (2009) Pacap−/− mice had lower Tb during
the night than controls, but those experiments were conducted
at a Ta of 23 °C, which could be presumably below the
thermoneutral zone ofmice. As it has been repeatedly shown
that cold-defense responses of Pacap−/− mice are impaired
compared with controls (Gray et al. 2002; Adams et al.
2008; Cummings et al. 2008), it can be assumed that the
different influence of a chronic, mild cold exposure on the
Tb of Pacap
−/− and Pacap+/+ mice could contribute to the
observed lower Tb in the Pacap
−/− mice. Indeed, inadequate
heat production and lower Tb in Pacap
−/− mice were ob-
served in response to chronic, mild (21 °C) cold exposure
in the study by Gray et al. (2002). In an earlier study by
Cummings et al. (2008), the Tb of Pacap
−/− mice did not
significantly differ from that of controls, however, in that
study the authors measured rectal temperature in previously
decapitated mice, which method is not sensitive enough to
detect small (especially locomotion-induced) differences in
Tb. Locomotor activity is widely viewed as a thermoregu-
latory effector in mice (Kanizsai et al. 2009; Szentirmai
et al. 2010; Garami et al. 2011) and our findings suggest
that freely moving Pacap−/− mice utilize locomotor activity
as a thermoeffector to maintain an elevated Tb during the
light phase and normal Tb during the night phase of the
day. It has to be mentioned that the increased locomotor
activity of the Pacap−/− mice could possibly also originate
from distinct mechanisms, which are independent from
thermoregulation.
We then asked whether the basal daytime Tb of loosely
restrained Pacap−/− mice (i.e., those that can not use loco-
motion as a thermoeffector) also differs from their wild-
type littermates. In contrast to our results in freely moving
mice, when restrained, Pacap−/− mice were hypometabolic
and had lower Tb than controls. The decreased metabolic
rate and Tb in the absence of PACAP is in harmony with
our results demonstrating the hypermetabolic and hyper-
thermic effect of PACAP38 injection in rats. When we
measured the expression of c-Fos positive cells in the
POA of the mice, we found that the number of c-Fos
positive cells in the MPO was markedly higher in Pacap−/−
mice than in controls, suggesting that the absence of
PACAP results in an increased activation of MPO neurons.
Since GABAergic neurons in the MPO tonically suppress
thermogenesis (Osaka 2004), we propose that in Pacap−/−
mice inhibitory MPO neurons are more activated and this
results in an enhanced suppression of thermogenesis. This
hypothesis is also in harmony with the proposed action of
PACAP38 injection on GABAergic MnPO neurons (see
above), because activation of these neurons results in an
increased inhibition of the inhibitory MPO neurons, which
leads to elevated metabolic rate and hyperthermia. Al-
though alternate explanations are also plausible, it can be
assumed that the absence of PACAP38 results in a lower
resting metabolic rate (and Tb) and as a compensatory
mechanism for the hypometabolism, Pacap−/− mice become
hyperkinetic to maintain normal (or even higher) Tb. Inter-
estingly, a similarly altered thermoeffector pattern
(hypometabolism and hyperkinesis) was observed in our
recent study with mice lacking the TRPV1 channel
(Garami et al. 2011). The similar thermoregulatory conse-
quences of the absence of PACAP and TRPV1 can be
explained with the alteration of the same neural pathways
as PACAP38 is released from activated capsaicin-sensitive
(i.e., TRPV1-expressing) neural afferents into the systemic
circulation (Helyes et al. 2007). Although the exact molec-
ular and neuronal mechanisms involved in the development
of the observed thermoregulatory phenotype of Pacap−/−
mice need to be further investigated, an involvement of
altered biochemical processes in the CNS of Pacap−/− mice
can be suspected (Maasz et al. 2014).
In conclusion, we showed in a straightforward compar-
ative experiment that PACAP38 causes hyperthermia by
acting on targets within the CNS. The PACAP38-induced
hyperthermia is brought about through the simultaneous
activation of both autonomic cold-defense effectors: eleva-
tion of non-shivering thermogenesis and cutaneous vaso-
constriction. We hypothesize that GABAergic neurons
within the MnPO are involved in mediation of thermoreg-
ulatory response to PACAP38. The absence of PACAP
results in hyperkinesis and daytime hyperthermia in
freely-moving Pacap−/− mice through mechanisms which
need to be clarified, but an involvement of TRPV1 and
altered central biochemical processes can be suspected. The
increased locomotor activity is presumably a compensatory
mechanism for the hypometabolism and hypothermia,
which is present under resting conditions in the absence
of PACAP.
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Introduction
Systemic inflammatory response syndrome (SIRS) is the leading 
cause of death in hospitalized patients.1,2 SIRS is considered a 
disease of the aged: its incidence and mortality are substantially 
higher in the older population.3 SIRS can be either triggered by 
non-infectious insults, such as blunt trauma, or associated with 
an infection (in which case it is called sepsis). In the laboratory, 
systemic administration of lipopolysaccharide (LPS, a cell-wall 
constituent of Gram-negative bacteria) in mice and rats is often 
used to induce SIRS aseptically, whereas polymicrobial sepsis is 
often studied in rodents subjected to cecal ligation and puncture 
(CLP). In either model, shock and death can occur, largely as 
the result of the “cytokine storm,” an overt production of proin-
flammatory cytokines, including TNFα,4 and other mediators, 
cumulatively referred to as the “inflammatory soup.”5-7 In both 
Studies in young rodents have shown that the transient receptor potential vanilloid-1 (TRPV1) channel plays a suppressive 
role in the systemic inflammatory response syndrome (SIRS) by inhibiting production of tumor necrosis factor (TNF)α 
and possibly by other mechanisms. We asked whether the anti-inflammatory role of TRPV1 changes with age. First, we 
studied the effect of AMG517, a selective and potent TRPV1 antagonist, on aseptic, lipopolysaccharide (LPS)-induced 
SIRS in young (12 wk) mice. In agreement with previous studies, AMG517 increased LPS-induced mortality in the young. 
We then studied the effects of TRPV1 antagonism (AMG517 or genetic deletion of TRPV1) on SIRS in middle-aged (43–
44 wk) mice. Both types of TRPV1 antagonism delayed and decreased LPS-induced mortality, indicating a reversal of the 
anti-inflammatory role of TRPV1 with aging. In addition, deletion of TRPV1 decreased the serum TNFα response to LPS, 
suggesting that the suppressive control of TRPV1 on TNFα production is also reversed with aging. In contrast to aseptic 
SIRS, polymicrobial sepsis (induced by cecal ligation and puncture) caused accelerated mortality in aged TRPV1-deficient 
mice as compared with wild-type littermates. The recovery of TRPV1-deficient mice from hypothermia associated with 
the cecal ligation and puncture procedure was delayed. Hence, the reversal of the anti-inflammatory role of TRPV1 found 
in the aged and their decreased systemic inflammatory response are coupled with suppressed defense against microbial 
infection. These results caution that TRPV1 antagonists, widely viewed as new-generation painkillers, may decrease the 
resistance of older patients to infection and sepsis.
Aging reverses the role of the transient receptor 
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LPS-induced SIRS and CLP-induced sepsis, proinflammatory 
cytokine production and mortality rate are much lower in young 
animals.8-11 Furthermore, sepsis in young animals is much more 
responsive to treatment.11
Recent studies have brought attention to the role that the tran-
sient receptor potential vanilloid-1 (TRPV1) channel may play in 
SIRS. Abundant on small-diameter sensory nerve fibers, TRPV1 
is activated by diverse stimuli, including several ingredients of the 
inflammatory soup.12,13 Activation of TRPV1 on sensory nerves 
potently inhibits LPS-induced TNFα production.14 Studies using 
either knockout (Trpv1-/-) mice, a pharmacological blockade with 
capsazepine (TRPV1 antagonist) or desensitization with resin-
iferatoxin (TRPV1 agonist) have shown that TRPV1 plays an 
anti-inflammatory role in LPS-induced SIRS by, among other 
mechanisms, limiting the production of TNFα, possibly via sen-
sory nerves.15-17 However, all studies cited above were conducted 
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LPS-treated mice, both in this experiment and in other experi-
ments within the present study, developed profound hypother-
mia: deep (abdominal) body temperature (T
b
) decreased from 
~36°C to ~33°C at 10 h. However, no inter-treatment differences 
in the hypothermic response occurred during the short time 
period before mice started dying (data not shown). Similar to 
our previous studies in references 18 and 19, AMG517 caused a 
short-lasting increase in T
b
 compared with the vehicle (p < 0.01, 
Fig. 1B), thus confirming an effective systemic blockade of 
TRPV1 channels. Overall, the results of our experiment show 
that pharmacological blockade of TRPV1 increases mortality 
of young mice in LPS-induced SIRS. Similar observations have 
been made in adolescent (6–8 wk) mice and in rats treated with 
capsazepine.16,17 It should be noted, however, that capsazepine is 
not a highly selective TRPV1 antagonist and has a low potency 
of blocking the proton mode of TRPV1 activation in the rat and 
mouse.20 In fact, a non-TRPV1-mediated effect of capsazepine 
in young rodents. Whether TRPV1 channels play a similarly 
prominent anti-inflammatory role in the aged is unknown.
Results and Discussion
Effects of a TRPV1 antagonist on LPS-induced systemic 
inflammation in young mice. First, we verified whether pretreat-
ment with AMG517, a potent and selective TRPV1 antagonist,18,19 
decreases the mortality of young adult (12 wk) C57BL/6 mice 
in LPS-induced SIRS. Mice responded to LPS (40 mg/kg, ip) 
with a marked, rapidly progressing SIRS (Fig. 1A). Pretreatment 
with AMG517 (210 μg/kg, sc) profoundly decreased the sur-
vival rate at multiple time points (e.g., from 50% to 5% at 26 h, 
p < 0.001), overall (48 h) survival rate (from 15% to 5%, p < 
0.05) and increased the risk of mortality (hazard ratio of death 
of 0.9, p = 0.01, Table 1). AMG517 pretreatment also shortened 
the mean time to death from 26 ± 2 to 19 ± 1 h (p = 0.003). All 
Figure 1. Systemic pretreatment with AMG517 (dose indicated) decreases survival of young mice in LPS-induced SIRS (A). Confirming an effective 
blockade of TRPV1 channels, the AMG517 pretreatment increases deep T
b
 in young mice (B).
Table 1. Effects of age and TRPV1 antagonism on mortality in LPS-induced SIRS and CLP-induced sepsis
Model Variable Cox survival regression analysis Logrank test Time to death
Hazard ratio of 
death
95% confidence 
interval
p Score p Mean ± SE (h) p
LPS Aged vs. young 2.2 1.3 ÷ 3.1 <0.001 20.5 <0.001 16 ± 1 vs. 26 ± 2 <0.001
LPS in young AMG517 vs. vehicle 0.9 0.2 ÷ 1.6 <0.010 4.1 <0.05 19 ± 1 vs. 26 ± 2 0.003
LPS in aged AMG517 vs. vehicle -1.0 -1.8 ÷ -0.2 <0.015 5.4 <0.05 19 ± 1 vs. 16 ± 1 <0.040
LPS in aged Trpv1-/- vs. Trpv1+/+ -1.3 -2.4 ÷ -0.2 <0.020 5.4 <0.05 24 ± 3 vs. 19 ± 1 <0.100
CLP in aged Trpv1-/- vs. Trpv1+/+ 0.7 -0.5 ÷ 1.9 0.239 1.4 >0.05 20 ± 2 vs. 52 ± 11 <0.007
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vary from none to strong exaggeration of severity and mortal-
ity,15-17 whereas the effect of TRPV1 blockade on mortality in 
untreated sepsis is the opposite: attenuation.28
Effects of AMG517 on LPS-induced systemic inflammation 
in aged mice. To study whether the anti-inflammatory role of 
TRPV1 in SIRS is preserved with aging, we conducted experiments 
in middle-aged (44 wk) C57BL/6 mice (Fig. 2A). The outcome 
of LPS-induced SIRS in these older mice was more severe than in 
young mice (hazard ratio of 2.2, p < 0.001, Table 1). The mean 
time to death in vehicle-pretreated aged mice was 16 ± 1 h, and 
none of the vehicle-pretreated aged mouse survived for longer than 
24 h. Pretreatment of aged mice with AMG517 (210 μg/ kg, sc) 
increased the survival rate (p < 0.05), delayed the mean time to 
death (19 ± 1 h, p < 0.05) and decreased the risk of mortality 
(hazard ratio of -1.0, p < 0.05)—effects directly opposite of those 
observed in the young. Survival rate of AMG517-pretreated aged 
mice at 18 h was 10 times higher than that of vehicle-pretreated 
aged mice (60% vs. 6%, p < 0.001). Confirming a systemic block-
ade of TRPV1 channels in this experiment, AMG517 increased 
T
b
 as compared with the vehicle (p < 0.05, Fig. 2B). Hence, 
whereas the effect of AMG517 on LPS-induced systemic inflam-
mation in aged mice was the opposite to that found in young mice 
(Figs. 1A and 2A), the effect on T
b
 was qualitatively the same 
(Figs. 1B and 2B). It is possible that the role of TRPV1 in differ-
ent functions changes with age in a different way. In the regula-
tion of locomotor activity29,30 and inflammation (present results), 
the role of TRPV1 reverses with age. In the modulation of T
b
 (for 
mechanisms, review ref. 31), it does not. In the regulation of body 
mass, TRPV1 channels are either uninvolved29 or counteract obe-
sity32 in the young but promote obesity in the aged.29,30
on the outcome of systemic inflammation has been proposed 
recently in reference 17. The present results also agree with the 
exaggerated symptoms of LPS-induced shock found in young 
mature (13–20 wk) Trpv1-/- mice.15
As reviewed by Steiner et al.21 and Guptill et al.,17 many treat-
ments affect mortality in LPS-induced aseptic inflammation and 
CLP-induced sepsis in opposite ways, confirming that the sys-
temic inflammatory response per se can be harmful to the host, 
even though it is crucial for defending the host against infec-
tion.6,7 For example, mice with a dysfunctional toll-like receptor 
4 are resistant to LPS but are highly susceptible to Gram-negative 
bacterial infection.22-24 This susceptibility to infection can be 
reserved by pretreating the toll-like receptor 4-deficient mice 
with TNF and interleukin-1α.22 Interestingly, antibiotic treat-
ment makes sepsis less different from aseptic SIRS, as it eradicates 
the infectious agent. For example, acute nicotine administra-
tion increases survival of mice in LPS-induced SIRS21,25-27 and 
in antibiotic-treated CLP-induced sepsis,25,26 but it worsens the 
outcome of untreated CLP-induced sepsis in the same species.21 
From this point of view, two studies of the role of TRPV1 in 
CLP-induced sepsis in adolescent (5–8 wk) mice17,28 agree with 
the effects observed in LPS SIRS. The first study17 has found that 
antibiotic-treated CLP-induced sepsis causes a higher mortality 
when TRPV1 channels are absent (Trpv1-/- mice) or desensitized 
(with intrathecal resiniferatoxin). The second study28 has found 
that capsazepine increases survival in untreated CLP-induced 
sepsis. Overall, prior literature data obtained in young rodents 
(adolescents to mature adults) and our present experiment with 
AMG517 in young adult mice show that the effects of TRPV1 
blockade on both LPS-induced SIRS and antibiotic-treated sepsis 
Figure 2. Systemic pretreatment with AMG517 (dose indicated) increases survival of aged mice in LPS-induced SIRS (A). Confirming an effective block-
ade of TRPV1 channels, the AMG517 pretreatment increases deep T
b
 in aged mice (B).
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channels on sensory nerves.14 Loss of TRPV1-mediated suppres-
sion of TNFα production in aged animals may reflect reduced 
translation of the TRPV1 protein and its reduced transport to 
the periphery,41 possibly due to age-associated decline in neu-
rotrophic support to ganglionic neurons.42 Changes in TNFα 
production may be central to aging-related changes in the patho-
biology of sepsis: elderly patients respond to infection, including 
septic shock, with higher TNFα,43,44 and inflammatory cytokine 
production in intensive-care-unit patients with sepsis is affected 
by TNFα-related genetic polymorphisms.45
Effects of genetic deletion of TRPV1 channels on CLP-
induced sepsis in aged mice. Next, we tested whether the atten-
uation of aseptic SIRS (of LPS-induced TNFα response and 
mortality) observed in middle-aged Trpv1-/- mice would result in 
attenuation of the body’s defense against CLP-induced polymi-
crobial infection. CLP sepsis caused substantial mortality in aged 
mice of both genotypes (Fig. 4A). However, Trpv1-/- mice died 
significantly faster than their Trpv1+/+ littermates (Table 1). The 
mean time to death in Trpv1-/- mice was 20 ± 2 h, as compared 
with 52 ± 11 h in Trpv1+/+ mice (p < 0.01), and the 30 h survival 
rate in Trpv1+/+ mice was 3.9 times higher than in Trpv1-/- mice 
(86% vs. 22%, p < 0.001). Further confirming the higher severity 
of sepsis in Trpv1-/- mice, recovery of deep T
b
 after the CLP proce-
dure (and the related anesthesia) was delayed (p < 0.001, Fig. 4B).
Conclusions. The present study shows that the anti-inflam-
matory role firmly established for TRPV1 channels in young 
rodents15-17 is reversed with aging. Whereas pharmacological or 
genetic TRPV1 antagonism decreases the survival rate in aseptic 
SIRS and in antibiotic-treated sepsis in the young, both types 
of TRPV1 antagonism have the opposite effect on aseptic SIRS 
Effects of genetic deletion of TRPV1 channels on LPS-
induced systemic inflammation in aged mice. We then 
tested whether genetic deletion of TRPV1 would have the 
same effects on SIRS in middle-aged mice as a pharmacologi-
cal blockade. Experiments were conducted in 43–44 wk-old 
Trpv1-/- C57BL/6 x 129 mice of both sexes and in their age- and 
sex-matched Trpv1+/+ littermates. LPS caused death in all Trpv1+/+ 
mice but only in 80% of Trpv1-/- mice (p < 0.05, Fig. 3A). 
Survival rate of Trpv1-/- mice at 21 h was 3.5 times higher than of 
wild-type controls (70% vs. 20%, p < 0.001). Genetic deletion 
of TRPV1 channels decreased the risk of mortality (hazard ratio 
of -1.3, p < 0.05) and tended to delay death (p < 0.1, Table 1). 
Importantly, Trpv1-/- mice exhibited a 70% suppression of the 
TNFα response at 12 h post-LPS (p < 0.05, Fig. 3B). It should 
be noted that aged Trpv1-/- mice in this study (see Materials and 
Methods) and in our previous studies in references 29 and 30 
were overweight compared with their wild-type littermates. 
Obesity33-36 and hyperlipidemia37 associated with various muta-
tions in rats do not seem to affect the febrile response to low, 
non-shock-inducing doses of LPS, and obesity does not seem to 
increase the risk of sepsis even though it increases the risk of an 
infection.38 Nevertheless, systemic inflammation and obesity are 
intimately interconnected,39,40 and we cannot rule out that obe-
sity could have been a contributing factor to at least some of the 
effects found in aged Trpv1-/- mice.
Mechanisms of the age-associated reversal of the anti-inflam-
matory role of TRPV1 are unknown. Our TNFα data suggest 
that the reversal occurs at initial stages of the pathogenesis of 
SIRS—at or upstream of TNFα production. The TNFα response 
to LPS has been shown to be under suppressive control of TRPV1 
Figure 3. Compared with their age-matched wild-type littermates, middle-aged Trpv1-/- mice have a higher survival rate (A) and a lower serum TNFα 
concentration (B) during LPS-induced SIRS.
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middle-aged C57BL/6 mice were 44 wk-old, and their body 
mass was 32 ± 1 g (n = 46). The ages of C57BL/6 mice listed 
are approximate; the vendor filled orders for a specified age, but 
did not provide the date of birth for each mouse. Middle-aged 
Trpv1+/+ C57BL/6 x 129 mice were 43 ± 1 wk-old (n = 30), and 
their body mass was 40 ± 1 g. Middle-aged Trpv1- /- C57BL/6 x 
129 mice were 44 ± 1 wk-old (n = 37) and significantly heavier 
(46 ± 1 g; p < 0.001) than their wild-type littermates. The ages of 
C57BL/6 x 129 mice were calculated based on the dates of birth, 
which were known for all mice. Mice were maintained, surgi-
cally prepared and habituated to experimental setups as described 
in our earlier studies.21,29 All surgeries were performed under 
ketamine-xylazine-acepromazine (81.7, 9.3 and 1.2 mg/ kg, ip) 
anesthesia. Antibiotic protection (enrofloxacin, 1.1 mg/kg, sc) 
was provided, except for animals subjected to CLP. For deep T
b
 
measurements, all mice were implanted intraperitoneally with 
telemetry transmitters (G2 E-Mitter series, Mini Mitter). For 
CLP, under the same anesthesia, the cecum was pulled out of 
the abdominal cavity, filled with the intestinal content (by gently 
squeezing the content from the ascending colon) and ligated with 
3-0 silk just distal to the ileocecal junction. The cecal wall was 
punctured through at the antimesenteric side with a 26-gauge 
needle. All protocols were approved by the St. Joseph’s Hospital 
and Medical Center Animal Care and Use Committee.
During all experiments, mice were housed singly in their 
home cages and placed inside a climatic chamber (model 3940, 
Forma Scientific) with an ambient temperature maintained at 
28.0°C, i.e., within the thermoneutral zone for this experimental 
setup.29,51 Cages were kept on top of telemetry receivers (model 
ER-4000, Mini Mitter). In the experiments with LPS-induced 
in middle-aged mice. The age-dependent reversal of the anti-
inflammatory role of TRPV1 to proinflammatory is likely due, 
at least in part, to a reversal of the suppressive control of TRPV1 
on TNFα production. These pathobiological changes are highly 
important, as evident from the decreased ability of aged Trpv1-
/- mice to resist polymicrobial sepsis. The reversal of the anti-
inflammatory role of TRPV1 reported in this study is another 
example of profound effects of aging on the pathobiology of sys-
temic inflammation.11,46,47
Significance. Our findings may influence development of 
TRPV1 antagonists, widely viewed as new-generation painkill-
ers.18,20,48 If what we found for murine models applies to human 
sepsis, anti-TRPV1 therapy may suppress the systemic inflam-
matory response in the previously uninfected (untreated with 
antibiotics) elderly and, hence, decrease their resistance to bacte-
rial infection and sepsis. This potential side effect is especially 
serious, because recognition of infection is often complicated in 
older patients by a variety of factors, including the absence of 
fever, which often delays treatment.49,50
Materials and Methods
The study was conducted in 168 adult mice (either young or mid-
dle-aged) of both sexes, including 101 Trpv1+/+ C57BL/6 mice 
(Charles River Laboratories) and 67 Trpv1-/- or Trpv1+/+ C57BL/6 
x 129 mice (Amgen colony at Charles River Laboratories). 
Several phenotypic properties of Trpv1- /- mice from the Amgen 
colony have been characterized in our recent studies in references 
29 and 30. At the time of experiments, young adult C57BL/6 
mice were 12 wk-old, and their body mass was 25 ± 0 g (n = 55); 
Figure 4. Compared with their age-matched wild-type littermates, middle-aged Trpv1-/- mice have a shorter survival time (A) and a slower T
b
 recovery 
(B) during CLP-induced sepsis.
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Survival data were analyzed by the χ2 test for individual time 
points and by the logrank test52 for the entire observation period. 
The Cox proportional hazard survival regression model was used 
to determine hazard ratios of death.53 Unpaired student’s t-test 
was used to compare times to death and TNFα concentrations. 
Deep T
b
 values were compared across treatments and time points 
by two-way ANOVA; p-values for the entire duration of response 
are reported. A difference was considered significant at p < 0.05. 
Results are reported in the format mean ± SE.
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SIRS, the survival rate and T
b
 were monitored for 48 h. To this 
end, mice were periodically examined for the presence of sponta-
neous movements and cardiac and respiratory activities. Because 
deep T
b
 decreases steeply toward the ambient temperature when 
an animal dies, T
b
 curves were also examined to identify mor-
tality events. In the experiments with CLP-induced sepsis, the 
same parameters were monitored for 108 h. At the end of experi-
ments, any survivors were euthanized with sodium pentobarbital 
(200 mg/kg, ip).
In a separate series of experiments (under the same anesthesia 
as for surgery), blood (1 ml) was collected by cardiac puncture at 
12 h after LPS administration, and mice were euthanized with 
sodium pentobarbital. The 12 h time point for blood collection 
was chosen because aged mice in this model start dying shortly 
after this point (Fig. 3A). Serum concentration of TNFα was 
determined by ELISA according to the manufacturer’s instruc-
tions (SABiosciences, catalog number MEM-004A).
A suspension of E. coli 0111:B4 LPS (Sigma-Aldrich, L2630, 
2.5 mg/ml) in saline was prepared in advance and stored at 4°C. 
To induce SIRS, LPS (40 mg/kg ip) was injected as a bolus; con-
trols received saline.
AMG517 (gift from Amgen) was used to block TRPV1 
receptors pharmacologically. This is a highly potent and selec-
tive TRPV1 antagonist that had been tested in human patients.18 
Aliquots of an ethanolic solution of AMG517 (3 mg/ml) were 
stored at -80°C. This stock was diluted with ethanol and saline 
ex tempore to achieve a 21 μg/ml final concentration of AMG517 
in 3.3% ethanol. AMG517 (210 μg/kg sc) or its vehicle was 
administered as a bolus, 1 h before the administration of LPS 
(or saline).
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Thermoregulatory Phenotype of the Trpv1 Knockout Mouse:
Thermoeffector Dysbalance with Hyperkinesis
Andras Garami,1 Eszter Pakai,1 Daniela L. Oliveira,1 Alexandre A. Steiner,1 Samuel P. Wanner,1,2 M. Camila Almeida,1
Vladimir A. Lesnikov,3 Narender R. Gavva,4 and Andrej A. Romanovsky1
1Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona 85013, 2Department of Physiology
and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais 31270-901, Brazil, 3Fred Hutchinson Cancer Research Center, Seattle,
Washington 98109, and 4Department of Neuroscience, Amgen, Thousand Oaks, California 91320
This study aimed at determining the thermoregulatory phenotype of mice lacking transient receptor potential vanilloid-1 (TRPV1)
channels. We used Trpv1 knockout (KO) mice and their genetically unaltered littermates to study diurnal variations in deep body
temperature (Tb ) and thermoeffector activities under basal conditions, as well as thermoregulatory responses to severe heat and cold.
Only subtle alterations were found in the basal Tb of Trpv1 KO mice or in their Tb responses to thermal challenges. The main thermoreg-
ulatory abnormality of Trpv1 KO mice was a different pattern of thermoeffectors used to regulate Tb. On the autonomic side, Trpv1 KO
mice were hypometabolic (had a lower oxygen consumption) and hypervasoconstricted (had a lower tail skin temperature). In agreement
with the enhanced skin vasoconstriction, Trpv1 KO mice had a higher thermoneutral zone. On the behavioral side, Trpv1 KO mice
preferred a lower ambient temperature and expressed a higher locomotor activity. Experiments with pharmacological TRPV1 agonists
(resiniferatoxin and anandamide) and a TRPV1 antagonist (AMG0347) confirmed that TRPV1 channels located outside the brain toni-
cally inhibit locomotor activity. With age (observed for up to 14 months), the body mass of Trpv1 KO mice exceeded that of controls,
sometimes approaching 60 g. In summary, Trpv1 KO mice possess a distinct thermoregulatory phenotype, which is coupled with a
predisposition to age-associated overweight and includes hypometabolism, enhanced skin vasoconstriction, decreased thermoprefer-
endum, and hyperkinesis. The latter may be one of the primary deficiencies in Trpv1 KO mice. We propose that TRPV1-mediated signals
from the periphery tonically suppress the general locomotor activity.
Introduction
The development of new pharmacological and genetic tools to
work with the transient receptor potential vanilloid-1 (TRPV1)
channel has caused a surge of studies aimed at identifying the
roles of this channel in various functions, including the regula-
tion of body temperature (Tb). Studies using pharmacological
tools have revealed clear and highly reproducible effects on Tb:
TRPV1 agonists cause hypothermia, whereas TRPV1 antagonists
cause hyperthermia (for reviews, see Gavva, 2008; Romanovsky
et al., 2009). In contrast to the unequivocal results obtained with
pharmacological tools, studies in genetically modified animals
have failed to reveal a clear thermoregulatory phenotype (Szele´-
nyi et al., 2004; Iida et al., 2005; Christoph et al., 2008; Motter and
Ahern, 2008). Szele´nyi et al. (2004) have reported that Trpv1
knockout (KO) mice have an exaggerated magnitude of day–
night fluctuations in Tb, whereas Iida et al. (2005) have not seen such
an exaggeration. Motter and Ahern (2008) have found that Trpv1
KO mice have an enhanced capacity for cold-induced thermogene-
sis, whereas Iida et al. (2005) have not seen such an enhancement.
Knowing that thermoregulatory responses in mice are notori-
ously difficult to study (Rudaya et al., 2005), we reexamined
the ability of Trpv1 KO mice to regulate Tb. Because thermoef-
fectors are regulated independently (Romanovsky, 2007; Mor-
rison et al., 2008; McAllen et al., 2010), we studied several
autonomic and behavioral effector mechanisms. Because am-
bient temperature (Ta) affects many thermoregulatory re-
sponses and often determines the pattern of effectors used to
regulate deep Tb (Romanovsky et al., 2002), the present study
was conducted under tightly controlled thermal conditions.
Furthermore, it was verified in each experimental setup used
whether the thermal conditions were neutral [i.e., within the
thermoneutral zone (TNZ)], subneutral, or supraneutral.
Initially, the primary goal of this study was to determine a
thermoregulatory phenotype of the Trpv1 KO mouse. After we
found that the absence of the Trpv1 gene was accompanied by an
increased locomotor activity, which is considered to be a thermo-
regulatory effector in small rodents (Mount and Willmott, 1967;
Brown et al., 1991; Weinert and Waterhouse, 1998), we focused
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the second part of the study on this novel finding. In pharmaco-
logical experiments, we used TRPV1 agonists and a TRPV1 an-
tagonist to investigate the potential involvement of TRPV1
channels in the regulation of locomotor activity. Based on exper-
iments with Trpv1 KO mice and with pharmacological tools, we
propose that tonic activation of peripheral TRPV1 channels sup-
presses the general locomotor activity. Even though TRPV1
channels are unlikely to be those long-sought thermosensors that
respond to skin temperature (Tsk) or deep Tb signals to regulate
thermoeffector activity (Romanovsky et al., 2009), the tonic,
nonthermal activation of TRPV1 channels does modulate several
effector responses (Steiner et al., 2007), perhaps in a state-specific
manner (Kanizsai et al., 2009). It is likely, therefore, that new
mechanisms relevant to the TRPV1-dependent modulation of Tb
remain to be discovered.
Materials and Methods
Animals
Physiological experiments were conducted in 293 adult mice of both
sexes. Of these, 269 C57BL/6x129 mice were obtained from the Amgen
colony at Charles River Laboratories. These mice had the Trpv1 gene
either present (Trpv1/) or missing (Trpv1/) due to a targeted null
mutation (Caterina et al., 2000). They were produced by breeding
Trpv1/ males and females and genotyping their offspring; the breeding
and genotyping were performed by Charles River Laboratories at their
facilities. Twenty-four additional Trpv1/ mice of a different genotype,
C57BL/6, were purchased from Charles River Laboratories. Except for
the body mass comparison study, where the mice were observed for an
extended period of time (from the age of 4 weeks to the age of 56 weeks),
all experiments were performed in male mice with body mass of 30 g
(age of 17 weeks). The mice were housed in standard “shoebox” cages
kept in a Maxi-Miser ventilated rack (Thoren Caging Systems) at a Ta of
27°C. The room was on a 12 h light/dark cycle (lights on at 6:00 A.M.).
Tap water and standard (5.0% fat) rodent chow (Laboratory rodent diet
5001; Labdiet) were available ad libitum. The body mass of mice was
measured regularly with a portable digital scale (model VI-200; Acculab).
At the end of the study, we confirmed the absence or presence of func-
tional TRPV1 channels in the KO and control mice, respectively. For this,
24 Trpv1/ and 24 Trpv1/ C57BL/6x129 mice were randomly se-
lected from the study population, food deprived for 36 h, and then ex-
posed to an excessive amount of habanero chili (Capsicum chinense).
Habanero is one of the hottest chili peppers with a reported pungency of
100,000 –300,000 Scoville units (Berkley and Jacobson, 1992). For a 20
min period, eating events were counted by an observer blind to the mice’s
genotype. Trpv1 KO mice eagerly consumed the peppers, whereas the
controls did not ( p  0.0001) (Fig. 1).
For all experiments, the mice were extensively handled (8 daily ses-
sions, 5 min each) and then habituated to experimental setups as follows.
A mouse designated for an experiment in the telemetry, thermocouple,
or respirometry setup (see below, Experimental setups), was adapted to
staying in either a Plexiglas enclosure or a wire-mesh confiner (8 training
sessions, 1– 4 h each). The enclosure, which had a square (15  15 cm)
base and 25-cm-high walls, did not limit the animal’s movement; it was
used for experiments in the telemetry setup. The cylindrical confiner
(length, 10 cm; diameter, 3 cm) prevented the animal from turning
around but allowed for some back-and-forth movements; it was used in
the thermocouple and respirometry setups. A mouse designated for an
experiment in the thermogradient setup was adapted to staying in the
channels of the thermogradient apparatus (7 sessions, 3–24 h each). Dur-
ing long training sessions (12 h) the animal had unlimited access to
food and water. All protocols were approved by the St. Joseph’s Hospital
and Medical Center Animal Care and Use Committee.
Surgical preparations
Anesthesia and perioperative care. Surgeries were performed under
ketamine-xylazine-acepromazine (81.7, 9.3, and 1.2 mg/kg, i.p.) anesthe-
sia and antibiotic protection (enrofloxacin, 1.1 mg/kg, s.c.). During sur-
gery, a mouse was heated with a Deltaphase isothermal pad (Braintree
Scientific) and periodically (every 5 min) ventilated with oxygen through
a custom-made mask. The isothermal pad was placed either under a
surgery board (Plas-Labs) or on the base of a stereotaxic apparatus. For
immediate postoperative recovery, the mouse was placed in a climatic
chamber set to a Ta of 31.0°C. Experiments were performed 5–7 d after
surgery.
Implantation of temperature-measuring devices. If the mouse was des-
ignated for an experiment in the telemetry setup, it was implanted with a
miniature telemetry transmitter (G2 E-Mitter series; Mini Mitter) to
record abdominal temperature (Tab, a measure of deep Tb) and gross
locomotor activity. If the mouse was designated for an experiment in the
thermogradient setup, it was implanted with a miniature temperature
datalogger (Subcue Dataloggers) to record and store Tab data. Either
device was inserted into the peritoneal cavity via midline laparotomy and
fixed to the lateral abdominal wall (right side) with a suture. The surgical
wound was sutured in layers.
Intraperitoneal catheterization. For the intraperitoneal administra-
tion of drugs, a silicone catheter filled with pyrogen-free saline was
inserted into the peritoneal cavity through the same opening in the
abdominal wall that was used to insert a temperature-measuring de-
vice, and the internal end of the catheter was attached with a suture to
the lateral abdominal wall on the left side. The free end of the catheter
was knotted, tunneled under the skin to the nape, and exteriorized.
The catheter was flushed with saline on the day after surgery and every
other day thereafter.
Intracerebroventricular cannulation. For the intracerebroventricular
drug administration, a 22 ga steel guide cannula (Plastics One) was im-
Figure 1. Behavioral verification of TRPV1 deficiency in Trpv1 KO mice. Trpv1 KO mice are
insensitive to capsaicin and, when food deprived, eagerly consume habanero chili (A), including
the hottest parts, such as the septa and seeds (B). The mean number of pepper-eating events in
Trpv1/ versus Trpv1/ mice over a 20 min period is also shown (C). Here and in Figures 2,
3, and 5–10, numbers in parentheses are the numbers of animals in the corresponding groups.
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planted into the right lateral brain ventricle using the stereotaxic atlas by
Lesnikov and Tsvetkova (1985) and their original stereotaxic apparatus.
The head of a mouse was fixed in the stereotaxic apparatus; the scalp was
incised over the sagittal suture; the periosteum was excised; the bone
surface was cleaned; and three supporting microscrews were driven into
the skull. The position of the head of the mouse was then adjusted so that
bregma was located 0.5 mm higher than lambda, and a hole was drilled
0.5 mm posterior to bregma and 1.0 mm right of the sagittal suture. The
guide cannula with a 28 ga dummy injector inside was inserted into
the lateral ventricle by lowering the tip of the injector (which pro-
truded the cannula by 1.0 mm) 3.0 mm below the skull surface. The
cannula was affixed to the supporting microscrews with acrylic ce-
ment. At the end of the experiments, a correct placement of each
cannula was confirmed by anesthetizing the animal, infusing 3 l of
an aqueous solution of methylene blue (6 mg/ml) through the can-
nula, removing the brain, and examining coronal sections macro-
scopically for the presence of the dye in the ventricular system.
Experimental setups
Experiments were conducted in one of the following setups: the telemet-
ric thermometry (“telemetry”) setup, the thermocouple thermometry
(“thermocouple”) setup, the thermocouple thermometry with respirom-
etry (“respirometry”) setup, and the thermogradient setup (Table 1). All
experiments, unless specified otherwise, were conducted under thermo-
neutral conditions. Because the same animal has a different TNZ in each
setup (Romanovsky et al., 2002), the setups were used at different Tas
(Table 1). In these setups, we measured deep Tb [as either Tab or colonic
temperature (Tc)] and four thermoeffector activities, two autonomic and
two behavioral (Table 1). On the autonomic side, we measured tail skin
vasomotion (assessed by tail skin temperature, Tsk) and the rate of oxy-
gen consumption (VO2 ). On the behavioral side, we measured the pre-
ferred Ta and general locomotor activity. The latter has been shown
repeatedly to play an important thermoregulatory role in small rodents
such as rats and mice (Mount and Willmott, 1967; Brown et al., 1991;
Weinert and Waterhouse, 1998) and is now widely viewed as a thermo-
regulatory effector in these species (Kanizsai et al., 2009; Hunt et al.,
2010; Szentirmai et al., 2010). The locomotor activity was measured in
this study either as the velocity of longitudinal movement in the thermo-
gradient apparatus or as the frequency of changes of the position or
orientation of the implanted telemetry probe in the telemetry setup.
Telemetry setup. Telemetry receivers (model ER-4000; Mini Mitter)
were positioned inside a climatic chamber (model 3940; Forma Scien-
tific). The home cage of each mouse was placed on top of a receiver; a
Plexiglas enclosure was placed inside the cage; and the mouse was left in
the enclosure. The mouse was preimplanted with a telemetry transmitter
(to measure Tab and locomotor activity). In a subset of mice, the transmitter
was implanted in combination with either an intraperitoneal catheter or an
intracerebroventricular cannula for drug administration. If the mouse had
an intraperitoneal catheter, the catheter was extended with a length of
polyethylene-50 tubing filled with a drug of interest. This extension was
passed through a wall port of the climatic chamber and connected to a
syringe placed in an infusion pump (model KDS 220; KD Scientific).
Whereas most experiments in this setup were conducted at a neutral Ta of
31.0°C (Table 1), a subneutral Ta of 26.0°C was used when the expected
experimental outcome was a decrease in Tb, e.g., in experiments with admin-
istration of TRPV1 agonists (Hori, 1984; Romanovsky et al., 2009).
We had a concern that measuring locomotor activity with G2 teleme-
try probes might overestimate any meaningful locomotion, because this
method picks up changes not only in the position of the probe relative to
the receiver, but also in the probe orientation. Hence, there was a possi-
bility that breathing movements, intestinal peristalsis, yawning, cough-
ing, shivering, and similar activities may contaminate the results or even
mask any changes in true whole-body locomotion. To address this con-
cern, we conducted a separate series of experiments. We mounted a
motion sensor (Infrared Cage Top Motion Sensor; Mini Mitter), which
works with Mini Mitter hardware and software, on each Plexiglas enclo-
sure and simultaneously recorded locomotor activity with the implanted
G2 probes and with the external motion sensors. The external sensor-
based method is completely insensitive to any probe movement inside
the peritoneal cavity, and requires a true body movement to register an
activity event. Two groups of Trpv1/ C57BL/6x129 and two groups of
Trpv1/ C57BL/6 mice were injected intraperitoneally with either res-
iniferatoxin (RTX) or anandamide (AEA), or with their vehicle, as de-
scribed below. In all four groups, the activity curves obtained by the two
methods looked nearly identical (see Notes). When the obtained activity
curves were analyzed by two-way ANOVA (following a linear unit trans-
formation), no significant differences were found in any group. These
experiments confirm that the telemetric activity measure is a reliable
indicator of locomotor activity.
Thermocouple setup. A mouse equipped with copper-constantan ther-
mocouples (Omega Engineering) to measure Tc and Tsk was placed in a
confiner. The colonic thermocouple was inserted 2 cm beyond the anal
sphincter and fixed to the base of the tail with a loop of adhesive tape. The
skin thermocouple was positioned on the lateral surface of the tail (at
the boundary of the proximal and middle thirds) and insulated from the
environment with tape. The thermocouples were plugged into a data
logger (Cole-Parmer). The confiner with the mouse inside was trans-
ferred to a climatic chamber. Whereas most experiments in this setup
were conducted at a neutral Ta of 32.0°C (Table 1), this setup was also
used for heat-exposure experiments, in which Ta was raised from 31.0 to
39.0°C over 30 min and then maintained at 39.0°C.
In a separate series of experiments, thermocouples were not used, and
radiant Tsk was monitored by infrared thermography with a ThermoVi-
sion A20M camera (FLIR Systems) to assess the vasomotor tone of the
tail skin and to determine the TNZ (Romanovsky et al., 2002). The Ther-
moVision camera was positioned above a group of confined mice inside
the climatic chamber set to Ta randomly selected from the following list:
30.0, 30.5, 31.5, 32.0, 32.5, 33.0, 33.5, or 35.0°C. The mice were kept at
this Ta for 2 h, and infrared thermograms were taken. Thereafter, Ta
was changed in a stepwise fashion to another value from the same list and
maintained at this new level for 2 h. Infrared thermograms of the mice
were taken again, and a new Ta was chosen. Usually, three to four tem-
peratures were studied in the same experiment.
Respirometry setup. Each mouse was equipped with thermocouples as
for experiments in the thermocouple setup. Then each mouse in its con-
finer was placed inside a cylindrical Plexiglas chamber (Sable Systems),
which was sealed. The Plexiglas chambers with mice inside were kept in a
climatic chamber and continuously ventilated. The airflow was main-
tained at 600 ml/min with the help of a mass flow controller (Sierra
Instruments). The air leaving each chamber was automatically sampled,
dried, and passed through an oxygen analyzer (Sable Systems). The rate
Table 1. Experimental setups
Setup
Measures of deep body temperature (Tb ) and thermoeffector activities studied
Neutral ambient temperature (Ta , °C)
aTb Thermoeffector activities
Telemetry Abdominal (Tab) Gross locomotor activity (measured as frequency of probe movement) 31.0
Thermocouple Colonic (Tc)
Tail skin vasomotion (measured as tail skin temperature, Tsk, by thermocouple thermometry
or as radiant Tsk by infrared thermography) 32.0
b
Respirometry Tc Thermogenesis (measured as rate of oxygen consumption, VO2 ), tail skin vasomotion (Tsk ) 33.0
c
Thermogradient Tab Selection of preferred Ta , locomotor activity (measured as velocity of longitudinal locomotion) 27.0
d
aFor each setup, the table lists one Ta that has been shown to be within the TNZ for Trpv1
/ CB57BL/6 mice in that setup. bFor the lower and upper limits of the TNZ for Trpv1/ and Trpv1/ CB57BL/6x129 mice in the thermocouple
setup, see Results. cNote that Ta in the respirometry setup was measured inside the environmental chamber but outside the metabolic chamber.
dFor the values of preferred Ta for Trpv1
/ and Trpv1/ CB57BL/6x129 mice in the
thermogradient setup, see Results.
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of VO2 was calculated by comparing the oxygen fraction in the air exiting the
chamber occupied by a mouse to the oxygen fraction in the air exiting an
empty chamber (see below, Data processing and analysis). Whereas most
experiments in this setup were conducted at a neutral Ta of 33.0°C (Table 1),
this setup was also used for exposing mice to cold. Cooling was performed by
decreasing Ta in the climatic chamber from 33.0°C to 5.0°C over 150 min.
Thermogradient setup. The thermogradient apparatus used has been
described in detail previously (Almeida et al., 2006). The apparatus con-
sisted of six 200-cm-long aluminum channels. Each channel had a sec-
ond (inner) stainless-steel grid floor and an acrylic double-wall lid at the
top. At each end, all channels shared a common aluminum wall, which
separated the channels from a large tank. The tank at the “warm” end of
the channels was filled with water warmed with two electric heating units
(PolyScience) to maintain Ta inside the channels at this end at 30.0°C.
The tank at the “cold” end was constantly perfused with 10% ethylene
glycol by an external-circulation cooling/heating pump (PolyScience) to
maintain Ta inside the channels at this end at 20.0°C. In this setting, all
channels had a common, nearly linear longitudinal Ta gradient of 0.05°C/
cm. The position of a mouse in a channel of the thermogradient appara-
tus was monitored with 56 evenly spaced (3.5 cm) infrared emitter-
receiver pairs, which formed transversal infrared beams. This system also
allowed us to directly measure the longitudinal locomotor activity. By
knowing how the position of an animal changed in time (as the animal
crossed the beams), we knew the velocity of the longitudinal movement
(distance traveled divided by time).
Drugs and drug administration
RTX, a highly potent TRPV1 agonist, was purchased from Sigma-
Aldrich. An ethanolic stock solution of RTX (200 g/ml) was prepared,
aliquoted, and stored at 80°C. On the day of the experiment, the stock
was diluted with ethanol and saline to achieve a final concentration of
RTX of 6, 60, or 150 ng/ml and a final concentration of ethanol of 10%.
For the intraperitoneal administration, this working solution (or the
vehicle) was injected acutely, as a bolus (3.3 ml/kg), using a 26 ga needle.
For the intracerebroventricular administration, the same working solu-
tion of RTX (or the vehicle) was infused (1.5 l/min) over a 2 min period.
At these infusion volumes and rates, even much higher concentrations of
ethanol (50%) do not cause behavioral responses or changes in Tb (Steiner et
al., 2007). For the infusion, the dummy injector (mandrin) was removed
from the preimplanted guide cannula and replaced with a 28 ga injector needle
(Plastics One) connected to a 25 l Hamilton syringe by a polyethylene-50 ex-
tension. The injector needle protruded 1.0 mm beyond the tip of the guide
cannula.Attheendoftheinfusion,theinjectorwasheldinplaceforanadditional
1 min and then removed and replaced with the mandrin.
AEA (arachidonoyl N-ethanolamide), purchased from Tocris Bio-
science, was used in the present study as a TRPV1 agonist (Zygmunt et
al., 1999; Smart et al., 2000). An ethanolic solution of AEA (5 mg/ml) was
stored at 20°C. On the day of the experiment, the stock was diluted with
ethanol and saline to achieve a final concentration of AEA of 0.5 mg/ml in
10% ethanol. This working solution of AEA (15 mg/kg) or the vehicle
(10% ethanol) was injected intraperitoneally as a bolus at a total volume of 30
ml/kg. Because one of the expected outcomes of experiments with TRPV1
agonists was a decrease in the gross locomotor activity (Crawley et al., 1993;
Fride and Mechoulam, 1993; Smith et al., 1994; Di Marzo et al., 2001; Wiley
et al., 2006), RTX and AEA (or their vehicles) were administered acutely by
briefly restricting the animal, pricking it with a needle, bolus injecting the
drug, and then releasing the animal. In this paradigm, the handling and
needle pricking associated with drug administration elevate the low, near-
zero activity typical for habituated mice during the light (inactive) phase.
AMG0347, a highly potent and selective TRPV1 antagonist (Steiner et
al., 2007), was provided by Amgen. Aliquots of an ethanolic solution of
AMG0347 (3.5 mg/ml) were stored at 80°C. On the day of the experi-
ment, the stock solution was diluted with ethanol and saline to achieve a
final concentration of AMG0347 of 15 g/ml in 50% ethanol. AMG0347
(50 g/kg) or its vehicle was administered intraperitoneally as a bolus
(3.3 ml/kg) via a preimplanted catheter. The expected outcome in exper-
iments with AMG0347 was an increase in the locomotor activity. To avoid
stress hyperkinesis in these experiments, we used a nonstressful method of
intraperitoneal drug administration via a preimplanted cannula.
Data processing and analysis
The rate of VO2 was calculated by comparing the oxygen fraction in the air
exiting the chamber occupied by a mouse ( F) to the oxygen fraction in
the air exiting an empty chamber (F0):
VO2 
AF0  F
M  F0M1  Q
,
where A was air flow, Q was the respiratory quotient (considered to be
0.71), and M was the animal’s mass (Steiner et al., 2007).
All data collected as time series were compared across genotypes and
time points by two-way ANOVA with a Fisher LSD post hoc test, as
appropriate. These included the data on deep Tb (whether Tab or Tc),
measures of thermoeffector activities (i.e., tail Tsk, VO2 , preferred Ta, and
gross locomotor activity), and body mass. For a statistical analysis of the
tail images on the infrared thermograms obtained, the optical density
was determined for each image by using the VisionWorks 6.5.2 image
acquisition and analysis software (Ultra-Violet Products). The optical
density values were also compared by two-way ANOVA across genotypes
and Tas. All data collected as single-point measurements (chili pepper
eating events) or presented as a single number (light-phase mean, dark-
phase mean, and daily mean values of Tb measures and those of effector
activity measures) were compared between the genotypes by Student’s t
test. All analyses were performed using Statistica AXA 8.0 (Statsoft). The
data are reported as means 	 SE.
Results
Phase-specific changes in deep Tb of Trpv1 KO mice
To identify a thermoregulatory phenotype of the Trpv1 KO
mouse, we studied circadian fluctuations in deep Tb and ther-
moeffector activities of a large number of Trpv1/ and Trpv1/
mice in three experimental setups: thermogradient (Fig. 2A), te-
lemetry (Fig. 2B), and respirometry (Fig. 2C). In all three setups,
the light-phase mean deep Tb of Trpv1 KO mice was slightly (by
0.2– 0.7°C) but significantly lower than that of the controls (Fig.
2A–C). A similar difference in Tb between the KO and control
mice was found under basal conditions (before any drug admin-
istration) in several other experiments in this study (Table 2).
During the dark (active) phase, however, the intergenotype Tb
difference was attenuated (respirometry setup) (Fig. 2C) or com-
pletely disappeared (telemetry setup) (Fig. 2B). In the thermo-
gradient setup (Fig. 2A), this difference became reversed, that is,
the mean dark-phase Tab of the KO mice was 0.5°C higher than
that of the controls ( p  0.05). As the result of such biphasic
dynamics, the daily mean Tb of Trpv1 KO mice was either similar
to or slightly lower than that of the controls in all setups (Fig.
2A–C). The magnitude of day–night changes in Tb of the Trpv1
KO mice was increased compared to that of the controls in the
thermogradient setup (0.8 	 0.2 vs 0.2 	 0.1°C; p  0.05) and in
the telemetry setup (1.0 	 0.1 vs 0.5 	 0.1°C; p  0.01). It also
had a tendency to be increased in the respirometry setup (0.5 	
0.1 vs 0.2 	 0.2°C; p  0.1). In summary, our results agree with
studies by others (Szele´nyi et al., 2004; Iida et al., 2005) showing
that Trpv1 KO mice have only slight alterations in the level at
which their deep Tb is regulated throughout the day, as compared
to control mice. Furthermore, these alterations are phase specific
and, to some extent, depend on the experimental setup.
Trpv1 KO mice exhibit a distinct thermoeffector pattern
What differed drastically between the two genotypes in our study
was not the level of Tb, but the pattern of behavioral and auto-
nomic effectors used to regulate Tb. We studied two behavioral
and two autonomic effectors (Table 1). Behavioral effector activ-
ities included the “classic” selection of preferred Ta and the gross
locomotor activity (Fig. 3A). The autonomic effector activities
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included thermogenesis (measured as VO2 ) and tail skin vasomo-
tor tone (measured as Tsk) (Fig. 3B). All four effector activities
were reproducibly altered in the setups studied. On the behav-
ioral side, Trpv1 KO mice selected a lower Ta than their Trpv1
/
counterparts (daily means of 26.3 	 0.2 vs 27.2 	 0.2°C, respec-
tively; p  0.01), regardless of the phase. Trpv1 KO mice also
expressed a higher locomotor activity, especially during the light
phase. Although the mean velocities during the light phase, the
dark phase, or the entire day did not differ statistically between
the genotypes (Student’s t test), the 24 h activity curves were
significantly different (ANOVA, p  0.01). From the biological
point of view, the magnitude of the effect was remarkable: at one
time point during the inactive phase (3:00 P.M.), Trpv1 KO mice
were moving in the thermogradient with an average linear veloc-
Figure 2. During the inactive (light) phase, Trpv1 KO mice have a lower deep Tb than their genet-
ically unaltered counterparts in the thermogradient (A), telemetry (B), and respirometry (C) setups.
Table 2. Basal deep body temperature (30 min mean  SE) of Trpv1/ and
Trpv1/ mice in different experimental setups during the light phase
Experimental setup
Ambient
temperature (°C)
Basal body temperature (°C), n
Trpv1/ Trpv1/
Telemetry 31.0 36.7 	 0.1 36.3 	 0.1a
n 
 32 n 
 35
28.0 36.4 	 0.1 36.1 	 0.1b
n 
 14 n 
 14
Thermocouple 32.0 37.1 	 0.3 37.3 	 0.2
n 
 6 n 
 6
Respirometry 33.0 36.8 	 0.2 36.3 	 0.2a
n 
 13 n 
 12
Thermogradient 20.0 –30.0 35.8 	 0.3 35.0 	 0.2a
n 
 21 n 
 20
ap  0.05; bp  0.1.
Figure 3. Compared to genetically unaltered controls, Trpv1 KO mice regulate Tb by using a
different thermoeffector pattern. In the thermogradient setup (A), they prefer a lower Ta and
are hyperactive. In the respirometry setup (B), they are hypometabolic (have a lower VO2 ) and
vasoconstricted (have a lower tail Tsk).
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ity of 85 cm/min (1.2 km/d), which was 3 times higher than
the average speed of wild-type mice at the same time of day.
Furthermore, it was higher than the locomotion speed of wild-
type mice at any time, including the peak of their activity at night.
When we measured autonomic thermoeffector activity in the
respirometry setup, we found that Trpv1 KO mice maintained a
lower metabolic rate and exhibited a more pronounced cutane-
ous vasoconstriction than the controls, regardless of the phase.
The means for VO2 and Tsk for the KO versus control mice were
18.9 	 1.0 versus 26.3 	 1.3 ml/kg/min ( p  0.0001) and 35.0 	
0.2 versus 35.7 	 0.2°C ( p  0.05), respectively. The difference in
VO2 recorded was not contaminated by the tendency of the two
genotypes to have different levels of locomotor activity, as these
experiments were performed in restrained animals. In summary,
under basal conditions, Trpv1 KO mice have a thermoregulatory
phenotype that reveals itself in a distinct thermoeffector pattern.
These mice are prone to select a cooler environment; they are also
hyperactive, hypometabolic, and vasoconstricted.
Trpv1 KO mice have a higher TNZ
The TNZ can be defined as a Ta range in which regulation of
deep Tb is achieved primarily by changing the vasomotor tone in
specialized heat-exchange organs, such as the mouse or rat tail
(Romanovsky et al., 2002). Below the TNZ, rodent tails exhibit
continuous skin vasoconstriction. Above the TNZ, they show
continuous skin vasodilation. Within the TNZ, the tone of tail
skin vasculature changes between moderate constriction and
moderate dilation and exhibits a high intrasubject and intersub-
ject variation (Romanovsky et al., 2002; Rudaya et al., 2005;
Almeida et al., 2006). The fact that Trpv1 KO mice exhibited
stronger tail skin vasoconstriction at Ta of 33.0°C in the respi-
rometry setup (Fig. 3B), warranted further investigation. Hence,
we assessed the TNZ of Trpv1/ and Trpv1/ C57BL/6x129
mice in the thermocouple setup by measuring radiant tail Tsk by
infrared thermography. At a high Ta of 35.0°C (Fig. 4A), the tails
of all mice studied were strongly and uniformly vasodilated. Un-
der these conditions, Tsk was approaching deep Tb and was sub-
stantially higher than Ta, which made the tails readily visible on
the thermograms. In contrast, the tails of all mice were strongly
vasoconstricted at a low Ta of 30.0°C (Fig. 4H). Under these
conditions, Tsk was approaching Ta, which made the tails invisi-
ble on the thermograms. At all Tas between 30.0 and 35.0°C, the
extent of tail skin vasodilation/vasoconstriction varied between
the animals, and Trpv1/ mice always showed stronger vaso-
constriction than their Trpv1/ counterparts. At some Tas (e.g.,
32.0°C) (Fig. 4E), the tails of all Trpv1 KO mice were invisible (Tsk
close to Ta), whereas the tails of all controls were readily visible
(Tsk  Ta). In this case the intergenotype difference in Tsk ex-
ceeded 4°C, which cannot be explained by a small difference in
the deep Tb and indicates unequivocally a difference in the tail
skin vasomotor tone. All control mice showed profound tail skin
vasoconstriction at Ta  30.5°C and profound vasodilation at
Ta  32.0°C, thus suggesting that their TNZ in the setup studied
was somewhere between 30.5 and 32.0°C. In the same setup, all
Trpv1 KO mice showed profound tail skin vasoconstriction at
Ta  31.5°C and profound vasodilation at Ta  33.5°C, thus
suggesting that their TNZ in this setup was somewhere between
31.5 and 33.5°C. To assess the extent of vasodilation quantita-
tively, we determined the optical density value for each tail image
shown in Figure 4. An analysis of these values (two-way ANOVA)
showed that the effect of the genotype was highly significant ( p 

0.0001). Hence, Trpv1 KO mice have a higher TNZ than wild-
type mice.
The thermoregulatory response of Trpv1 KO mice to heat
is unaltered
After we found that tail skin vasomotor tone was altered in Trpv1
KO mice (Figs. 3B, 4), we studied the thermoregulatory response
of these mice to ambient heating. To reveal even a small defi-
ciency in heat defenses, we used a severe heat exposure model that
results in a 3°C rise in deep Tb. When exposed to heat, the mice
Figure 4. Trpv1 KO mice have a higher TNZ. Three Trpv1 KO and three control mice in their
confiners were situated in the thermocouple setup as slices of a pizza pie, so that their tails
pointed to the center of the “pizza.” In this setup, infrared thermograms were taken at different
Tas: 35.0 (A), 33.5 (B), 33.0 (C), 32.5 (D), 32.0 (E), 31.5 (F ), 30.5 (G), and 30.0°C (H ). It is known
(see Results) that tails of rats and mice exhibit continuous skin vasodilation above the TNZ and
continuous skin vasoconstriction below the TNZ. Note that all tails are clearly visible (vasodi-
lated) at the highest Ta (A) and completely invisible (vasoconstricted) at the lowest Ta (H ). As Ta
decreases (from B to G), Trpv1 KO mice become vasoconstricted faster than wild-type mice.
Because within the TNZ, the tone of tail skin vasculature constantly changes between moderate
constriction and moderate dilation and exhibits a high intrasubject and intersubject variation
(Romanovsky et al., 2002), we conclude that the TNZ in this setup is 31.5–33.5°C for Trpv1 KO
mice and 30.5–32.0°C for the controls.
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of both genotypes (Trpv1/ and Trpv1/) responded with
rapid, near-maximal tail skin vasodilation with Tsk approaching
40°C (Fig. 5A). Neither the Tsk response nor the Tc response
differed between the genotypes. Hence, despite the strong atten-
uation of heat-induced tail skin vasodilation reported in rats de-
sensitized pharmacologically with TRPV1 agonists (for reviews,
see Hori, 1984; Romanovsky et al., 2009), Trpv1 KO mice are fully
capable of increasing heat loss through their tails and defending their
deep Tb against heat. These results confirm the earlier observations
by Szele´nyi et al. (2004) and Iida et al. (2005) showing that auto-
nomic heat defenses of Trpv1 KO mice are not compromised.
Trpv1 KO mice can maintain cold-induced thermogenesis
longer than genetically unaltered controls
To reveal even a small deficiency in cold defenses, we used a
severe cold exposure model that results in a pronounced drop in
deep Tb. When exposed to cold in this model, the mice of both
genotypes responded with tail skin vasoconstriction (a decrease
in Tsk) and cold-induced thermogenesis (an increase in VO2 ), but
despite these cold-defense responses, their Tc decreased by
14°C (Fig. 5B). The response dynamics differed between the
two genotypes. Whereas VO2 of Trpv1 KO mice reached a plateau
at 60 min after the beginning of cold exposure and was then
maintained at this level until the end of the experiment (150
min), VO2 of the controls reached the same level, but then started
decreasing at 100 min ( p  0.0001) and caused a correspond-
ing decrease in Tc ( p  0.0001). These data show that even
though Trpv1 KO mice have a lower metabolic rate under basal
conditions, they can maintain cold-induced thermogenesis for a
somewhat longer period of time than genetically unaltered mice.
An earlier study by Iida et al. (2005) did not find a difference in
the thermoregulatory response of Trpv1 KO mice to cold, but the
authors used a much milder cold exposure. The combination of
physical factors affecting the heat exchange between an animal
and its environment (Ta, air humidity, air velocity, etc.) together
with the use of confinement in our experimental paradigm re-
sulted in a much greater decrease in deep Tb of the wild-type mice
than that observed in the study by Iida et al. (2005): 14.2 	 1.1
versus 1.2 	 0.5°C. On the other hand, our results agree with
those of Motter and Ahern (2008), who used stronger cooling (a
2.0 –3.4°C decrease in Tb of wild-type mice) than Iida et al. (2005)
and found that Trpv1 KO mice could defend their deep Tb against
environmental cold somewhat better than their wild-type coun-
terparts. Whether the slightly enhanced thermogenic capacity of
the Trpv1 KO mice observed in this experiment was due to non-
shivering or shivering thermogenesis, or both, is unknown.
Peripheral administration of an exogenous TRPV1 agonist
decreases stress-induced locomotion via an action on the
TRPV1 channel
After finding that Trpv1 KO mice were hyperactive (Fig. 3), we
tested whether RTX, an ultrapotent exogenous TRPV1 agonist,
decreases the gross locomotor activity. For this, we administered
RTX intraperitoneally to Trpv1/ mice with a C57BL/6x129
genetic background and to two strains of Trpv1/ mice, C57BL/
6x129 and C57BL/6. These experiments (and all experiments to
follow) were performed in the telemetry setup. Because the ex-
pected effect of RTX was a decrease in the gross locomotor activ-
ity, RTX or its vehicle was administered acutely by briefly
restricting the animal and pricking it with a needle (see Materials
and Methods, Drugs and drug administration). In this paradigm,
the handling and needle pricking associated with drug adminis-
tration elevate the low activity typical for habituated mice during
Figure 5. Thermoeffector and deep Tb responses of Trpv1 KO and genetically unaltered
confined mice to severe heat exposure (A) and severe cold exposure (B). During heat exposure,
Ta was first raised from 31.0°C to 39.0°C at a rate of 0.3°C/min and then maintained at 39.0°C
until the end of the experiment. Deep Tb (colonic) and tail skin vasodilation (Tsk) responses of the
two genotypes to heat exposure were identical. During cold exposure, Ta was decreased from
33.0°C to 5.0°C at a mean rate of 0.2°C/min. In response to cold exposure, Trpv1 KO mice
maintain an increased thermogenesis (VO2 ) longer, thus better defending their Tb against se-
vere cold.
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the light phase. The well known ability of
RTX to decrease Tb (for review, see Ro-
manovsky et al., 2009) was also evaluated,
and to allow the animals to readily de-
crease their Tb, the experiments were per-
formed at a slightly subneutral Ta of
26.0°C. The administration of the vehicle
caused moderate hyperactivity and typical
stress hyperthermia in all genotypes tested
(Fig. 6). RTX (200 ng/kg, i.p.) blocked
both the hyperactivity and hyperthermia
responses in Trpv1/ C57BL/6 and
C57BL/6x129 mice ( p  0.0001 for both
responses in both strains) (Fig. 6A,B),
even though the low dose of RTX used did
not cause hypothermia. These results agree
with studies showing that capsaicin, another
exogenous TRPV1 agonist, decreases loco-
motor activity in rats and mice (Di Marzo et
al., 2000, 2001; Proulx et al., 2005; Lee et al.,
2006), and that both RTX (at higher doses)
and capsaicin cause hypothermia in many
mammalian species [for review, see Ro-
manovsky et al. (2009)]. In the present
study, the same dose of RTX that caused the
anti-hyperkinetic and anti-hyperthermic ef-
fects in the control mice did not affect the
stress-induced changes in Tab or locomotor
activity in Trpv1 KO mice (Fig. 6C). These
results indicate that peripherally adminis-
tered RTX decreases stress-induced loco-
motor activity and hyperthermia in mice by
acting on TRPV1 channels. It was important
to demonstrate an involvement of TRPV1
channels, because some effects of exogenous
TRPV1 agonists (Lundbaek et al., 2005), in-
cluding thermoregulatory effects (Dogan et
al., 2004; Nikami et al., 2008), are not
TRPV1 mediated.
Peripheral administration of an endogenous TRPV1 agonist
decreases stress-induced locomotion via an action on the
TRPV1 channel
We then tested whether AEA, an endocannabinoid with a full
agonistic activity against TRPV1, affects Tab and stress-induced
locomotion in a way similar to RTX. In this experiment, the acute
intraperitoneal injection of the vehicle resulted in an increase in
the locomotor activity, similar to those shown in Figure 6, but did
not cause stress hyperthermia. The blunted effect of stress on Tab
was probably due to the fact that a large volume of a room-
temperature vehicle was used to deliver the high dose of AEA: 30
ml/kg (0.9 ml per mouse) in this experiment (Fig. 7) as com-
pared to 3.3 ml/kg (0.1 ml per mouse) in the RTX experiment
(Fig. 6). As compared to its vehicle, AEA (15 mg/kg, i.p.) signifi-
cantly decreased Tab and strongly attenuated locomotor activity
(suppressed stress hyperkinesis) in Trpv1/ mice of both
strains: C57BL/6 ( p  0.0001 for Tab; p  0.05 for locomotor
activity) (Fig. 7A) and C57BL/6x129 ( p  0.05 for Tab; p  0.01
for locomotor activity) (Fig. 7B). These results agree with the
reported hypothermic and hypokinetic effects of AEA, adminis-
tered to rats and mice at high doses (Crawley et al., 1993; Fride
and Mechoulam, 1993; Smith et al., 1994; Adams et al., 1998;
Watanabe et al., 1999; Wiley et al., 2006; Wise et al., 2007). How-
ever, none of these effects occurred when AEA was injected in
Trpv1/ C57BL/6x129 mice (Fig. 7C). Even though AEA also
acts as a full agonist at the cannabinoid-1 receptor (Vogel et al.,
1993) and as a partial agonist at the cannabinoid-2 receptor
(Gonsiorek et al., 2000), the complete absence of both Tb-
decreasing and activity-decreasing effects of AEA in Trpv1 KO
mice shows that cannabinoid receptors do not mediate the effects
studied. This is the first observation showing directly that AEA
suppresses deep Tb and locomotor activity by acting on the
TRPV1 channel.
Peripheral administration of a selective TRPV1 antagonist
produces hyperkinesis via an action on the TRPV1 channel
Next, we studied the effect of AMG0347, a TRPV1 antagonist, on
deep Tb and locomotor activity of Trpv1
/ and Trpv1/
C57BL/6x129 mice. Based on the results with TRPV1 agonists
(Figs. 6, 7), we expected the antagonist to cause an increase in the
locomotor activity. To study the expected increase, we avoided
inducing stress hyperkinesis and infused AMG0347 or its vehicle
in a nonstressful manner, through a preimplanted intraperito-
neal catheter, from outside of the climatic chamber. Because the
expected thermal effect was hyperthermia (Steiner et al., 2007;
Garami et al., 2010), these experiments were conducted at Ta of
Figure 6. Intraperitoneal RTX (200 ng/kg) attenuates the injection-induced hyperthermia and hyperkinesis in Trpv1/ mice
of two strains, C57BL/6 (A) and C57BL/6x129 (B), but not in Trpv1/ C57BL/6x129 mice (C). These experiments and those
presented in Figures 7 and 9 were performed in the telemetry setup at a subneutral Ta of 26.0°C.
Figure 7. Intraperitoneal AEA (15 mg/kg) causes hypothermia and attenuates the injection-induced hyperkinesis in Trpv1/
mice of two strains, C57BL/6 (A) and C57BL/6x129 (B), but not in Trpv1/ C57BL/6x129 mice (C).
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31.0°C, which is neutral for both Trpv1 KO and control mice in
the telemetry setup (Table 1). As compared to its vehicle,
AMG0347 (50 g/kg, i.p.) caused hyperthermia and hyperkinesis
in Trpv1/ mice ( p  0.0001 for both) (Fig. 8A). Whereas it is
well known that TRPV1 antagonists cause hyperthermia (for re-
views, see Gavva, 2008; Romanovsky et al., 2009), the observed
increase in the locomotor activity was an unexpected finding,
because earlier studies in rats with several TRPV1 antagonists
reported no changes in the locomotor activity (Gavva et al., 2005;
Cui et al., 2006; Drizin et al., 2006; Mills et al., 2008). However,
the TRPV1 antagonists in all these studies were administered in a
stressful way (often as intragastric gavage), and the resultant
stress-induced hyperkinesis could have masked the short-lived
and modest increase in the locomotor activity seen in the present
study. The same dose of AMG0347 that caused hyperthermia and
hyperkinesis in the control mice affected neither Tab nor gross
locomotor activity in Trpv1 KO mice (Fig. 8B). Whereas it has
been shown in our previous studies that TRPV1 antagonists cause
hyperthermia by acting on TRPV1 channels (Steiner et al., 2007;
Garami et al., 2010), the present study is the first to demonstrate
a hyperkinetic effect for AMG0347 and to show that this effect
occurs due to an action at the TRPV1 channel.
A TRPV1 agonist suppresses stress-induced locomotion by
acting outside the brain
We then attempted to determine whether the anti-hyperkinetic
response to intraperitoneal RTX (Fig. 6) occurs due to an action
inside or outside the brain. A very low dose of RTX, 20 ng/kg, was
used in this experiment and administered either intraperitoneally
or into the lateral brain ventricle. When administered intraperi-
toneally, this dose attenuated the injection-induced hyperther-
mia and the locomotor response ( p  0.0001 for both) (Fig. 9A).
However, the same dose of RTX administered intracerebroven-
tricularly affected neither parameter (Fig. 9B). These data suggest
that RTX affects locomotion by acting outside the blood– brain
barrier. It should be noted that the low doses of RTX used in the
present study, 20 ng/kg (Fig. 9) and 200 ng/kg (Fig. 6), did not
cause a typical hypothermic response, but did decrease the
injection-associated rise in Tb. Such an action on Tb is likely to be
secondary to the decrease in locomotor activity. At higher doses,
RTX readily causes marked hypothermia (de Vries and Blum-
berg, 1989; Romanovsky et al., 2009), and the marked hypother-
mic response to RTX is thought to be due to a central, rather than
peripheral, action [for review, see Romanovsky et al. (2009)].
Aged Trpv1 KO mice are heavier than genetically
unaltered controls
As a side finding, we noticed that, with age, Trpv1 KO mice of
both sexes became heavier than their Trpv1/ counterparts (Fig.
10). For example, at the age of 8 months, the body mass of the
male Trpv1 KO mice was 14% higher than that of the age-
matched male controls: 49 	 1 versus 43 	 1 g ( p  0.0001). The
two heaviest mice in our colony were Trpv1 KO males, who had a
body mass of 59 g (at the age of 8 months) and 58 g (at the age of
14 months). By the time we discovered that aged Trpv1 KO mice
were significantly heavier than their wild-type counterparts, Am-
gen had terminated its colony, which made obtaining any addi-
tional measures (the amount and distribution of fat, blood lipids)
impossible. Even though we did not measure the amount of fat,
the aged Trpv1 KO mice looked obese, rather than proportionally
large. They had larger bellies, a symptom consistent with accu-
mulation of visceral fat, a generally accepted hallmark of aging
(Huffman and Barzilai, 2009). We also noticed both a large
amount of visceral fat and a thick layer of subcutaneous fat while
performing surgeries on older Trpv1 KO mice for a different
study (S. P. Wanner and A. A. Romanovsky, unpublished obser-
vations). The observed association of hyperactivity (recorded at a
younger age) with overweight (recorded at an older age) seems
paradoxical, but a similar relationship was reported for a group of
healthy humans: those individuals who were more physically ac-
tive when they were young showed a higher mass gain with age
(Westerterp and Plasqui, 2009). Based on the present observa-
tion, it is tempting to speculate that TRPV1 channels protect
from aging-associated obesity. From the thermoregulatory point
of view, the increased body mass found in aged Trpv1 KO mice
may have an insulating role, similar to that played by subcutane-
ous fat in animals living in cold climates (Blix and Steen, 1979).
Discussion
In agreement with previous studies (Szele´nyi et al., 2004; Iida et
al., 2005), we have found no profound alterations in basal Tb in
Trpv1 KO mice (Fig. 2). We have also confirmed that, compared
to their Trpv1/ counterparts, Trpv1/ mice have a slightly
higher magnitude of circadian fluctuations in Tb. The main ther-
moregulatory abnormality of Trpv1 KO mice appears to be not an
Figure 8. Intraperitoneal AMG0347 (50 g/kg) causes hyperthermia and locomotor hyper-
activity in wild-type mice (A) but not in Trpv1 KO mice (B). These experiments were performed
in the telemetry setup at a neutral Ta of 31.0°C.
Figure 9. The intraperitoneal (A), but not intracerebroventricular (B), administration of RTX
at a dose of 20 ng/kg attenuates the injection-induced hyperthermia and hyperkinesis in
Trpv1/ C57BL/6 mice.
Garami et al. • Activation of Peripheral TRPV1 Inhibits Locomotion J. Neurosci., February 2, 2011 • 31(5):1721–1733 • 1729
altered level of Tb, but a different pattern of thermoeffectors used
to regulate Tb under various thermal, housing, and restraint con-
ditions. Trpv1 KO mice were consistently hypometabolic (had a
lower VO2 ) and preferred a lower Ta than controls (Fig. 3). These
thermoeffector changes tend to decrease Tb. At the same time, the
KO mice expressed two thermoeffector activities aimed at in-
creasing Tb. First, they had more pronounced tail skin vasocon-
striction (Fig. 3B) and, in agreement with this, had a higher TNZ
(Fig. 4). Second, they expressed strong hyperkinesis with the average
locomotion velocity during the second half of the inactive phase
exceeding that of wild-type mice during the active phase (Fig. 3A).
This finding of increased locomotor activity of Trpv1 KO mice
deserves a separate discussion, as it seems to contradict several
studies showing that the deletion of the Trpv1 gene causes no
changes in locomotion (Caterina et al., 2000; Davis et al., 2000;
Marsch et al., 2007). However, all these studies used much
shorter observation periods, sometimes as short as 15 min. Fur-
thermore, even though these studies found no statistically signif-
icant differences in the locomotor activity of Trpv1 KO mice,
some of them showed strong tendencies that were in agreement
with the present results. For example, Davis et al. (2000) found
that Trpv1 KO mice tended to have higher scores in several activ-
ity tests. In the hole board test for exploratory behavior, the ac-
tivity of Trpv1 KO mice exceeded that of wild-type mice by 92%
( p 
 0.12). An increased activity of Trpv1 KO mice was also
observed by Marsch et al. (2007) in several tests for anxiety-
related behaviors. In these tests, Trpv1 KO mice adapted to
experimental conditions faster and expressed exploratory behav-
iors associated with a higher locomotor activity. However, other
studies have found no involvement of TRPV1 channels in anxiety
behaviors (Bitencourt et al., 2008; Panlilio et al., 2009). The increased
spontaneous locomotion observed in our study is also unlikely to be
due to changes in anxiety or exploratory behavior, because the mice
were extensively adapted to experimental conditions and observed
over long periods of time. Whether the increased locomotion relates
to changes in the sleep pattern is unknown, but TRPV1 antagonists
do not seem to affect sleep (Takeda et al., 2008).
Because their autonomic thermoregulatory responses showed
no attenuation in our study and in studies by others (Szele´nyi et
al., 2004; Iida et al., 2005; Motter and Ahern, 2008), we directed
our attention to the behavioral responses: the selection of Ta,
which is the classic example of thermoregulatory behavior, and
the gross locomotor activity, which is viewed by many authors as
a thermoregulatory effector in small rodents. In the thermogra-
dient apparatus, we saw that Trpv1 KO mice preferred a lower Ta
and were hyperactive as compared to the controls (Fig. 3). Similar
to how humans prefer to exercise in a cooler environment, exper-
imental rodents select a lower Ta when their activity is higher.
Such an adjustment of the preferred Ta accompanies the increase
in the locomotor activity of rats (Gordon, 1994) and mice (Fig. 3)
at the transition from the inactive (light) phase to the active
(dark) phase. A similar adjustment accompanies the exploratory
behavior of rats in a thermogradient apparatus when the animals
are not adapted to the apparatus [for discussion, see Almeida et
al. (2006)]. Having excluded profound deficiencies in the two
major autonomic effectors directly (Fig. 5) and knowing that a
decrease in the thermopreferendum often occurs secondarily to
an increase in locomotor activity, we are tempted to speculate
that the increased locomotion may be one of the “primary”
symptoms of the Trpv1 KO phenotype. We then focused the
second part of the study on locomotor activity.
We asked whether pharmacological manipulations with the
activity of TRPV1 channels would affect the locomotor activity
(and also Tb). First, we showed that RTX (an exogenous TRPV1
agonist) and AEA (an endogenous TRPV1 agonist) both attenu-
ated stress-induced hyperactivity in Trpv1/ mice of two strains
(Figs. 6, 7). This effect agrees well with the reported hypokinetic
action of these and other TRPV1 agonists in several different tests
(Di Marzo et al., 2001; Proulx et al., 2005; Wiley et al., 2006; Wise
et al., 2007). Next, we studied the responses to RTX and AEA in
Trpv1 KO mice. By showing that the locomotor activity response
was unaffected by these TRPV1 agonists in Trpv1 KO mice, we
have confirmed that the anti-hyperkinetic effect of either agonist
occurs via an action on TRPV1. This is in agreement with the
finding that the AEA-induced decrease in locomotor activity of
rats is blocked by TRPV1 antagonists (de Lago et al., 2004; Lee et
al., 2006; Tzavara et al., 2006). In the next experiment, we used
AMG0347, a highly potent and selective TRPV1 antagonist. In
addition to causing the well characterized hyperthermic effect
(Steiner et al., 2007; Garami et al., 2010), a nonstressful intraperi-
toneal administration of AMG0347 also increased the locomotor
activity in Trpv1/ mice (Fig. 8). However, AMG0347 did not
increase locomotion in Trpv1 KO mice, thus indicating that the
hyperkinetic effect of AMG0347 occurs via an action on TRPV1.
Hence, our results with RTX, AEA, and AMG0347 support the
hypothesis that TRPV1 channels tonically suppress the general
locomotor activity.
We then asked whether the TRPV1 channels involved are lo-
cated inside or outside the brain. To answer this question, we
injected a very low dose of RTX (20 ng/kg) either intraperitone-
ally or into the lateral cerebral ventricle. The intraperitoneal ad-
Figure 10. With age, both male (A) and female (B) Trpv1 KO mice become heavier than their
age-matched controls.
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ministration was effective in decreasing the injection-associated
locomotion, whereas the intracerebroventricular administration
was not (Fig. 9), thus suggesting that RTX causes its anti-
hyperkinetic activity by acting outside the blood– brain barrier.
Such a peripheral action agrees with the predominant location of
TRPV1 channels on polymodal sensory neurons in the dorsal-
root and nodose ganglia (Szallasi et al., 1995; Caterina et al., 1997;
Tominaga et al., 1998). These neurons are activated by a variety of
stimuli and are thought to modulate a wide array of autonomic
and behavioral functions (Caterina and Julius, 2001; Inoue et al.,
2006; Nilius et al., 2007; Szallasi et al., 2007; Sharif-Naeini et al.,
2008; Romanovsky et al., 2009). Tonic activation of peripheral
TRPV1 channels has been shown to inhibit thermogenesis and
heat retention in the study by Steiner et al. (2007), to modulate
spinal locomotor networks in the study by Mandadi et al. (2009),
and to inhibit the general locomotor activity in the present work.
As a side observation, we have found that, with age, Trpv1 KO
mice of either sex (maintained on a regular diet) become heavier
than their wild-type counterparts (Fig. 10). This observation
seems to contradict studies by Davis et al. (2000), Rong et al.
(2004), and Zhang et al. (2007), who found no changes in the
body mass of Trpv1 KO mice compared to controls, when main-
tained on a regular or high-fat diet. It also contradicts the study by
Motter and Ahern (2008), in which Trpv1 KO mice were found
less prone than wild-type controls to become obese on a high-fat
diet. However, all abovementioned studies used young mice with
the body mass in a 10 –30 g range (on a regular diet). In this body
mass range, the intergenotype difference in our study was also
small, but with age (we observed the mice up to the age of 14
months), the difference increased (Fig. 10). Interestingly, the
obesity-protective role of TRPV1 channels has been proposed
(Zhang et al., 2007; Suri and Szallasi, 2008) and is supported by
two lines of evidence. First, Zhang et al. (2007) detected TRPV1
channels in preadipocytes, as well as in visceral adipose tissue
from mice and humans. These authors demonstrated TRPV1
downregulation during regular adipogenesis and a reduced
TRPV1 expression in visceral adipose tissue from obese mice and
humans. Second, a long-term administration of capsaicin or
capsinoids (nonpungent, capsaicin-related TRPV1 agonists) has
been repeatedly shown to suppress visceral fat accumulation, in-
duce thermogenesis, and prevent an increase in the body mass in
laboratory animals and humans (Kawabata et al., 2006; Zhang et
al., 2007; Snitker et al., 2009). Further studies of the role of the
TRPV1 channel in obesity seem warranted.
In conclusion, the first part of the present study shows that
Trpv1 KO mice possess a distinct thermoregulatory phenotype,
which includes hypometabolism, enhanced skin vasoconstric-
tion, preference for a lower Ta, and an increased locomotor ac-
tivity. The second part of our study shows that TRPV1 agonists
and antagonists decrease and increase, respectively, the locomo-
tor activity by acting on TRPV1 channels. For agonists, their
effect on locomotion is due to an action outside the brain. We
propose that TRPV1-mediated signals from the periphery toni-
cally suppress general locomotor activity. Whether such suppres-
sion occurs due to a direct action on the locomotor system or
indirectly (e.g., by affecting motivation or vigilance state) is a
topic for future studies. The nature of the TRPV1-mediated sig-
nals that suppress locomotion also remains to be elucidated.
Notes
The curves of gross locomotor activity measured simultaneously by
intraperitoneal telemetry probes and by external motion detectors in
mice treated with different drugs are presented in supplemental
Figure 1 posted at http://www.feverlab.net/pages/publicationpdfs/
supplementJN2011.pdf. This material has not been peer reviewed.
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